1.0 TITLE PAGENCT0338 NNN NN2639
TAKEDA PHARMACEUTICALS
PROTOCOL
A Phase 2, 12
-Week, Randomized, Double-Blind, Placebo-Controlled, Parallel Study to 
Evaluate Efficacy, Safety, Tolerability, and Pharmacokinetics of 3 Dose Levels of TAK
-831 
in Adjunctive Treatment of Adult Subjects With Negative Symptoms of Schizophrenia
A Study of 3 Doses of TAK-831 as an Adjunctive Treatment for Negative Symptoms of 
Schizophrenia
Sponsor: Millennium Pharmaceuticals, Inc, a who lly owned subsidiary o f [COMPANY_005] 
Pharmaceut ical Co mpany, Ltd
40 Landsdowne Str eet
Cambridge MA [ZIP_CODE]
[LOCATION_003]
Study Number: TAK -831-2002
IND Number: 135,[ADDRESS_1242648] Number: 2017-003471-54 
Compound: TAK -
831
Date: 08 June 2020 Amendment Number: 04
Amendment History: 
Date Amendment Number Amendment Type Region
30 October 2017 Initial Protocol Not applicable Global
26 June 2018 Amendment 01 Substantial Global
19 July  2018 Amendment 02 Substantial Local (Czech Republic)
[ADDRESS_1242649] #: NCT03382 [ADDRESS_1242650] Type/Role North America Contact [CONTACT_888049], Inc 
Fax: +1 -[PHONE_2671]
Email: [EMAIL_16894]
[COMPANY_005] Development Center Europe, Ltd
Fax: +44 - 207-242- 1820 
Email: [EMAIL_13866]
Medical Monitor
(medical advice on protocol 
and study drug) 
IQVIA
US: 
Mobile: 
Email: 
 
IQVIA
Mobile: 
Email: 
Responsible Medical Officer 
(carries overall responsibility 
for the conduct of the study) 
 
[COMPANY_005] Development Center Americas, Inc
Office: 
Mobile: 
Email:  
 
[COMPANY_005] Development Center Americas, Inc
Office: 
Mobile:
Email:

TAK -[ADDRESS_1242651] ance with the requirements of this study  protocol  and also in accordance wit h the 
following:
The ethical principles that have their origin in the Declaration of Helsinki.
International Council for Harmonisat ion E6 (R2) Good Clinical Pract ice: Consolidated 
Guideline.
All applicable laws and regulat ions, including, without limitat ion, data privacy laws, clinical 
trial discl osure l aws, and regul ations.
SIGNATURES
The signature [CONTACT_4233] (and other signatories, as applicable) can
be found on the signature [CONTACT_3264].
Electronic signatures are provided on the last page of this document.
Date Date
Date Date

TAK -[ADDRESS_1242652] igator’s Brochure, 
package insert and any  other product i nformat ion provi ded by [CONTACT_456]. I agree to conduct this 
study  in accordance with the requirements of this protocol  and also to protect the rights, safet y, 
privacy , and well -being o f study  subjects in accordance with the following:
The ethical principles that have their origin in the Declaration of Helsinki.
International Council for Harmonisat ion, E6 (R2) Good Cli nical  Practi ce: Consolidated 
Guideline.
All applicable laws and regulat ions, including, without limitat ion, data privacy laws and 
regul ations.
Regulatory  requi rements for reporting serious adverse events defined in Sect ion10.2 of this 
protocol .
Terms outlined in the study  site agreement.
Responsibilit ies o f the Invest igator (Appendix B).
I further authorize that my  personal informat ion may be processed and transferred in accordance 
with the uses contem plated in  Appendix Dof this protocol .
Signature [CONTACT_4235] (print or ty pe)
Invest igator’s Tit le
Locati on of  Facilit y (Ci ty, State/Provi nce)
Locati on of  Facilit y (Country )
TAK -[ADDRESS_1242653] ion describes the changes in reference to the protocol incorporating Amendment No. 04. 
The primary  reason for thi s amendment is to describe management of study  procedures (eg, 
alternat ive strategies for collect ing data, conducting study  visits and di stribut ing investigational 
product) during unexpected, unavo idable circumstances (eg, a widespread disease outbreak or 
natural  disaster) such as the coronavirus disease 2019 (COVID -19) pandemic.
Minor gra mmat ical, editorial, formatting, and administrative changes not affect ing the conduct of 
the study  are included for clarificat ion and administrative purposes only.
A history  of TAK -831-[ADDRESS_1242654] Version of the Approved Protocol
Description of Each Change and RationaleSection(s) 
Affected by 
[CONTACT_746748](s)
1.Updated medical monitor and responsible medical 
officer contact [CONTACT_888050].To update contact [CONTACT_888051], the responsible 
medical officer, and names and 
titles of signatories who will 
approve this protocol amendment.Sections:
1.1Contacts
1.2Approval
2.Added guidance regarding rescreening of 
potential subjects who discontinued during 
screening or the single -blind run -in due to 
COVID -[ADDRESS_1242655] (Reasons 
numb er 4 and 11)
TAK -[ADDRESS_1242656] Version of the Approved Protocol
Description of Each Change and RationaleSection(s) 
Affected by 
[CONTACT_746748](s)
4.Added guidance regarding supply of study drug to 
study subjects during unavoidable circumstances 
such as the COVID -19 pandemic.To provide flexibility for sites to 
provide subjects with drug supply in 
situatio ns where traveling to the site 
or pr esenting at the site may present 
a risk to health or well -being of 
subjects.8.2Study Drug 
Assignment and 
Dispensing 
Procedures
5.Added section with guidance on alternative 
approaches to executing study procedures and 
collecting study data due to COVID -19 or other 
unavoidable circumstances.To eliminate apparent hazards to 
participants by [CONTACT_888052] -
19 pandemic.Sections:
9.1.[ADDRESS_1242657] a typographical error. Section [IP_ADDRESS]
Definitio ns and 
Procedures for 
Contraception a nd 
Pregnancy 
Avoidance
7.Added COVID -19-related guidance for informed 
consent procedures.To ensure informed consent 
procedures are in accordance with 
all applicable laws and regulations.Section 9.1.2
Informed Consent 
Procedure
8.Added COVID -19-related guidance for 
documenta tion of screen and randomization 
failure.To ensure that reasons for screen 
failure or randomization failure due 
to COVID -19 related factors are 
documented.Sections:
9.1.20
Documentation of 
Screen Failure
9.1.21
Documentation of 
Randomization 
Failure .
9.Added clarification to text regarding 
documentation of pretreatment events 
(PTE)/adverse events (AEs).Original author of protocol 
inadvertently deleted the 
abbreviation PTE from this text 
which describes how PTE/AE data 
are to be collected in the database. 
This is a typographical error and 
does not indicate a change in 
process.Section [IP_ADDRESS]
PTE and AE 
Reporting
TAK -[ADDRESS_1242658] Version of the Approved Protocol
Description of Each Change and RationaleSection(s) 
Affected by 
[CONTACT_746748](s)
10.Added COVID -related terms to the table of 
[COMPANY_005] Medical ly Significant AEs.To comply with [COMPANY_005] Global 
Patient Safety Evaluation guidance 
on the medically significant AE list.Table 10.a[COMPANY_005] 
Medically 
Significant AEs
11.Updated serious adverse event (SAE) reporting 
guidance.Text was revised per a new [COMPANY_005] 
process for SAE reporting that 
includes an acknowledgment of 
receipt for information sent via fax 
or email.Section 10.2.[ADDRESS_1242659] results due to 
unavoidable ci rcumstances such as the COVID -19 
pandemicTo allow flexibility during
unavoidable circumstances such as 
the COVID -19 pandemic to extend 
the Visit 3 (randomization) window 
for a maximum of [ADDRESS_1242660] eligibility.Appendix A
Schedule of Study 
Procedures , 
footnote b
15.Extended visit window for final visit (Day 84/End 
of Treatment [ET]). To allow flexibility during 
unavoidable circumstances such as 
the COVID -[ADDRESS_1242661] Version of the Approved Protocol
Description of Each Change and RationaleSection(s) 
Affected by 
[CONTACT_746748](s)
16.Added clarification to footnote b in Schedule of 
Study Pro cedures regarding conduct of final visit 
(Day  84/ET) in unavoidable circumstances such 
as the COVID -19 pandemic.To emphasize the importance of 
performing the final visit 
(Day 84/ET) in person and the need 
to contact [CONTACT_888053] -[ADDRESS_1242662] of Abbreviat ions............................................................................................... 21
3.4 Corporate Identificat ion........................................................................................... 23
4.0 INTRODUCTION ......................................................................................................... 24
4.1 Background ............................................................................................................. 24
4.1.1 Study  Drug ...................................................................................................... 24
4.1.2 Schizophrenia .................................................................................................. 24
4.1.3 Clinical Background ........................................................................................ 25
4.2 Rationale for the Proposed Study ............................................................................. 27
4.3 Benefit/Risk Profile .................................................................................................[ADDRESS_1242663] ives...................................................................................... 29
5.1.3 .................................................................................... 29
5.2 Endpoints ................................................................................................................. 30
5.2.1 Primary Endpo int............................................................................................. 30
5.2.2 Seco ndary  Endpo ints....................................................................................... 30
5.2.3 Safety Endpo ints.............................................................................................. 31
5.2.4 ..................................................................................... 31
6.0 STUDY DESIGN AND DES CRIPTION ....................................................................... 32
6.1 Study  Design ........................................................................................................... 32
6.2 Justificatio n for Study  Desi gn, Dose, and Endpoints ................................................ 35
6.2.1 Study  Design ................................................................................................... 35
6.2.2 Dose ................................................................................................................ 35
6.2.3 Endpoints ........................................................................................................ 35
[IP_ADDRESS] Efficacy Endpo ints.................................................................................. 35

TAK -831
Study No. TAK -831-2002 Page 10of 111
Protocol Incorporating Amendment No. 04 08 June 2020
CONFIDENTIAL6.2.3.2 Safety Endpo ints...................................................................................... 37
6.3 Prem ature Terminat ion or Suspension o f Study  or Study  Site................................... 37
6.3.1 Criteria for Premature Terminat ion or Suspension of the Study ........................ 37
6.3.2 Criteria for Premature Terminat ion or Suspension of Study  Sites..................... 37
6.3.3 Procedures for Premature Termination or Suspension of the Study  or the 
Parti cipation of  Study  Sites.............................................................................. 37
7.0 SELECTION AND DISCONTINUATION/WITHDRAWAL OF SUBJECTS .............. 38
7.1 Inclusio n Cri teria..................................................................................................... 38
7.2 Exclusio n Cri teria.................................................................................................... 40
7.3 Randomization Criteria ............................................................................................ 43
7.4 Excluded/Allowed Medicat ions, Procedures, and Treatments ................................... [ADDRESS_1242664] ...................................... 47
8.0 CLINICAL STUDY MATER IAL MANAGEMENT ..................................................... 47
8.1 Study  Drug and Materials ........................................................................................ 48
8.1.1 Dosage Form, Manufacturing, Packaging, and Labeling .................................. 48
[IP_ADDRESS] Study  Drug (TAK -831 and Matching Placebo Tablets) ............................ 48
[IP_ADDRESS] Com panion Medicati on............................................................................ 48
[IP_ADDRESS] Rescue Medicat ion.................................................................................. 49
[IP_ADDRESS] Sponsor -Supplied Drug ............................................................................ [ADDRESS_1242665] Database Authorizat ion.................................................. 56
9.1.4 Dem ographics, Medi cal History , and Medicat ion History  Procedure ................ 56
TAK -831
Study No. TAK -831-2002 Page 11of 111
Protocol Incorporating Amendment No. 04 08 June 2020
CONFIDENTIAL9.1.5 Physical Examinat ion Procedure ...................................................................... 57
9.1.6 Weight, Height and BMI .................................................................................. 57
9.1.7 Vital Sign Procedure ........................................................................................ 57
9.1.8 Docum entati on of  Conco mitant Medi cation..................................................... 58
9.1.9 Docum entati on of  Concurrent Medi cal Condit ions........................................... 58
9.1.10 Efficacy Measurements .................................................................................... 58
[IP_ADDRESS] MINI ....................................................................................................... 59
[IP_ADDRESS] PANSS .................................................................................................... 59
[IP_ADDRESS] CGI-SCH Scal e....................................................................................... 59
[IP_ADDRESS] BACS ...................................................................................................... 60
[IP_ADDRESS] BNSS ...................................................................................................... 60
[IP_ADDRESS] SCoRS ..................................................................................................... 60
[IP_ADDRESS] CDSS ...................................................................................................... 60
[IP_ADDRESS] .................................................................................. 61
[IP_ADDRESS] ............................................................................................... 61
[IP_ADDRESS] .................................... 61
9.1.11 Addit ional Safet y Assessments ........................................................................ 62
[IP_ADDRESS] Modified SAS .......................................................................................... 62
[IP_ADDRESS] C-SSRS ................................................................................................... 62
9.1.12 Order of Psychiatric/Neurological Rat ing Scales/ Assessments ......................... 63
9.1.13 PK Measurements ............................................................................................ 63
[IP_ADDRESS] PK Sam ple Collect ion.............................................................................. 63
[IP_ADDRESS] Bioanaly tical Methods ............................................................................. 63
[IP_ADDRESS] Popul ation PK ......................................................................................... 63
9.1.14 ................................................................................ 63
[IP_ADDRESS] ction.................................................................. 64
[IP_ADDRESS] ................................................................................. 64
[IP_ADDRESS] .............................................................................. 64
9.1.15 .......................................................................................... 64
[IP_ADDRESS] ............................................................................ 65
9.1.16 Procedures for Clinical Laboratory  Samples .................................................... 65
[IP_ADDRESS] Antipsychotic Plasma Levels ................................................................... 68
9.1.17 Contraception and Pregnancy Avo idance Procedure ........................................ 68
[IP_ADDRESS] Male Subjects and Their Female Partners ................................................ 68
[IP_ADDRESS] Female Subjects and Their Male Partners ................................................ 69

TAK -831
Study No. TAK -831-2002 Page 12of 111
Protocol Incorporating Amendment No. 04 08 June 2020
CONFIDENTIAL9.1.17.3 Definit ions and Procedures for Contraception and Pregnancy 
Avoidance ............................................................................................... 69
9.1.18 Pregnancy ........................................................................................................ 71
9.1.19 ECG Procedure ................................................................................................ 71
9.1.20 Docum entati on of  Screen Failure ..................................................................... 72
9.1.21 Docum entati on of  Rando mization Failure ........................................................ 72
9.1.22 Rater Qualificat ion and Cert ification Process ................................................... 73
9.1.22 .1Rater Qualificat ions................................................................................. 73
[IP_ADDRESS] Submissio n of Experi ence Details ............................................................ 73
[IP_ADDRESS] Rater Training and Qualificat ion Program ................................................ 73
[IP_ADDRESS] Site Changes to Rater Personnel During the Study ................................... 73
[IP_ADDRESS] Rater Monitoring ..................................................................................... [ADDRESS_1242666] ion and Reporti ng of AEs ..................................................................... 81
[IP_ADDRESS] PTE and AE Collection Period .................................................................81
[IP_ADDRESS] PTE and AE Reporting ............................................................................ [ADDRESS_1242667] ics......................... 86
13.1.3 Efficacy Analysis ............................................................................................. 86
[IP_ADDRESS] Analysis of Primary Efficacy Endpoint .................................................... 86
[IP_ADDRESS] Analysis of Other Efficacy Endpo ints...................................................... 87
13.1.4 PK Analysis ..................................................................................................... 88
13.1.5 PD Analysis ..................................................................................................... 88
13.1.6 ................................................................................................... 88
13.1.7 Safety Analysis ................................................................................................ 88
[IP_ADDRESS] AEs......................................................................................................... 88
[IP_ADDRESS] Clinical Laboratory  Evaluat ion................................................................ 89
[IP_ADDRESS] Vital Signs............................................................................................... 89
[IP_ADDRESS] ECGs ....................................................................................................... 89
[IP_ADDRESS] C-SSRS ................................................................................................... [ADDRESS_1242668] ions................................ 90
15.0 ETHICAL ASPECTS OF T HE STUDY ........................................................................ 91
15.1 IRB and/or IEC Approval ........................................................................................ [ADDRESS_1242669] igator Consent to Use of Personal Information........................................ 108
Appendix E History  of Protocol  Amendments 01 through 03 ............................................... 109
TAK -831
Study No. TAK -831-2002 Page 15of 111
Protocol Incorporating Amendment No. 04 08 June 2020
CONFIDENTIAL2.0 STUDY SUMMARY
Name [CONTACT_790]:
Millennium Pharmaceuticals, Inc, a wholly owned 
subsidiary of [COMPANY_005] Pharmaceutical Company, Ltd
[ADDRESS_1242670]
Camb ridge MA [ZIP_CODE]
[LOCATION_003]Compound:
TAK -831
Title of Protocol: A Phase 2, 12 -Week, Randomized, 
Double -Blind, Placebo -Controlled, Parallel Study to 
Evaluate Efficacy, Safety, Tolerability, and 
Pharmacokinetics of 3 Dose Levels of TAK -831 in 
Adjunctive Treatment of Adult Subjects With Negative 
Symptoms of SchizophreniaIND No.:
135,176EudraCT No.: 
2017 -003471 -54
Study Number: TAK -831-2002 Phase: 2
Study Design:
This is a randomized, double -blind, parallel, placebo -controlled, phase 2 study to evaluate the efficacy, safety, 
tolerability, and pharmacokinetics (PK) of adjunctive treatment with TAK -831 when administered orally once daily 
(QD) in adult subjects with negative symptoms of schizophrenia. The study will consist of a screening period of up 
to 28 days, a 14- day single -blind placebo run -in period, a 12 -week dou ble-blind treatment period, and a safety 
follow -up visit.
Approximately 234 subjects will be enrolled at up to 48 sites in North America and Europe.
At the screening visit (Visit 1), subjects who provide informed consent will proceed with screening procedu res. 
Subjects who meet a current diagnosis of schizophrenia, as defined by [CONTACT_223151] (MINI), will then be administered additional psychiatric and neurological rating scale assessments, and 
undergo other screening ass essments. Subjects must be currently receiving stable treatment on antipsychotic 
medication at a total daily dose between 2 mg and 6 mg of risperidone equivalents (as outlined in an Antipsychotic 
Dose Equivalency reference supplied to the sites), with no c linically  meaningful change in psychotropic medications 
(no increase, ≤25% decrease in dose) for the preceding [ADDRESS_1242671] a Brief Negative Symptom Scale (BNSS) total score (12 -item, excluding item number 4) ≥28 
and limited Positive and Negative Syndrome Sca le (PANSS) symptoms as outlined in the study inclusion criteria, 
and must demonstrate stable BNSS total scores ( ≤20% change from the screening score) at the single -blind placebo 
run-in visit (Day -14; Visit 2) and baseline visit (Day 1; Visit 3). Subjects with extrapyramidal signs/symptoms or 
depressive symptoms based on study assessments, as outlined in the study entry criteria, will be excluded. 
Confirmation that the subject meets these and other selected entry criteria will be provided by [CONTACT_888054].
The 2 -week single -blind placebo run -in period will be used to evaluate compliance with study drug intake and 
stability of the BNSS assessment. At baseline (predose Day 1), subjects who continue to meet all eligibility criteria, 
including placebo run -in drug compliance requirements, will be randomized to 12 weeks of double -blind o ral 
treatment with TAK -831 (T2 tablet formulation) or matching placebo.
TAK -831
Study No. TAK -831-2002 Page 16of 111
Protocol Incorporating Amendment No. 04 08 June 2020
CONFIDENTIALSchematic of Study Design
Primary Objective:
The primary objective of this study is to determine whether add -on TAK -831 is superior to placebo on the Positive 
and Negative Syndrome Scale Negative Symptom Factor Score (PANSS NSFS).
Secondary Objectives:
To determine wheth er add -on TAK -831 is superior to placebo on the BNSS total score.
To determine whether add -on TAK -831 is superior to placebo on the Brief Assessment of Cognition in 
Schizophrenia (BACS) composite cognition score.
To determine whether add -on TAK -831 is supe rior to placebo on global severity as measured by [CONTACT_369011] -Schizophrenia -Severity (CGI -SCH -S) score.
To determine whether add -on TAK -831 is superior to placebo on global improvement as measured by [CONTACT_888055] -Schizo phrenia -Improvement (CGI -SCH -I) score.
To determine whether add -on TAK -831 is superior to placebo on the Schizophrenia Cognition Rating Scale 
(SCoRS) assessment of cognitive functional outcome.
To determine whether add -on TAK -831 is superior to placebo on the PANSS total score and additional 
subscales and factors.
To assess the safety and tolerability of TAK -831.
To assess the PK of TAK -831.
Subject Population: Male or female subjects, between 18 and 60 years of age, inclusive, with a diagnosis of 
schizophrenia with persistent negative symptoms of schizophrenia.
Number of Subjects:
Approximate number of subjects per treatment group:
TAK -831 50 mg QD: 52
TAK -831 125 mg QD: 52
TAK -831 500 mg QD: 52
Placebo QD: 78
Estimated total: 234 randomizedNumbe r of Sites: 
Approximately 48 sites in North America and Europe

TAK -831
Study No. TAK -831-2002 Page 17of 111
Protocol Incorporating Amendment No. 04 08 June 2020
CONFIDENTIALDose Levels:
TAK -831 50 mg QD
TAK -831 125 mg QD
TAK -831 500 mg QD
Placebo QDRoute of Administration:
Oral
Duration of Treatment:
12 weeksPeriod of Evaluation:
Approximately 20 weeks from screening visit to final 
visit (4 weeks of screening, a 14 -day single -blind 
placebo run -in period, 12 weeks of double -blind 
treatment, and 10 to 14 days of follow -up).
Main Criteria for Inclusion:
The subject has a current diagnosis of schizophrenia as de fined by [CONTACT_42145] 7.0.2 for Psychotic Disorders for 
the Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition (DSM -5) and the general psychiatric 
evaluation.
The subject’s initial diagnosis must be ≥1 year from screening.
The subject is male or female and aged 18 to 60 years, inclusive.
The subject is receiving primary background antipsychotic therapy (other than clozapi[INVESTIGATOR_050]) at a total daily dose 
between 2 mg and 6 mg of risperidone equivalents (as outlined in an Antipsychotic Reference docume nt). 
Concomitant treatment with a subtherapeutic dose of a second antipsychotic may be permitted with sponsor or 
designee approval if used to treat specific symptoms such as insomnia, but not if it is used for refractory 
positive psychosis symptoms. 
The s ubject is treated with a stable regimen of psychotropic medications with no clinically meaningful change 
(no increase in dose, ≤25% decrease in dose for tolerability) in the 2 months prior to the screening visit and no 
dose adjustment is anticipated throug hout study participation up to the Day 84/early termination visit.
The subject has a BNSS total score (12-item, excluding number 4) ≥28; stable single -blind placebo run -in and 
baseline BNSS total (12 -item, excluding number 4) scores ( ≤20% change from the s creening score).
The subject has no more than moderate -severe ( ≤5) rating on PANSS positive symptom items P1, P3, P4, P5, 
P6, or unusual thought content (G9), with a maximum of 2 of these items rated “5”; no more than moderate ( ≤4) 
rating o n conceptual dis organization (P2). 
There is evidence that the subject has stable symptomatology ≥3 months prior to the screening visit (eg, no 
hospi[INVESTIGATOR_888021], no emergency room admission due to symptoms of schizophrenia, no 
increase in level of psychi atric care due to worsening of symptoms of schizophrenia).
The subject must have an adult informant who will be able to provide input for completing the study rating 
scales including the PANSS and SCoRS (eg, family member, social worker, caseworker, reside ntial facility 
staff, or nurse who spends ≥4 hours/week with the subject) considered reliable by [CONTACT_093].
Main Criteria for Exclusion:
The subject has a lifetime diagnosis of schizoaffective disorder; a lifetime diagnosis of bipolar disorder; or a 
lifetime diagnosis of obsessive compulsive disorder based on the MINI combined with the general psychiatric 
evaluation. As an exception, subjects with a historical prior lifetime diagnosis of schizoaffective disorder may 
be enrolled in the study with spo nsor or designee approval provided that the principal investigator [INVESTIGATOR_888022]’s overall history and current clinical presentation and history is most consistent with schizophrenia, 
not schizoaffective disorder.
The subject has a recent (wi thin the last 6 months) occurrence of panic disorder, depressive epi[INVESTIGATOR_1865], or other 
comorbid psychiatric conditions currently requiring clinical attention based on the MINI for DSM -5 and the 
general psychiatric evaluation.
The subject has a diagnosis of sub stance use disorder (with the exception of nicotine dependence) within the 
preceding 6 months based on the MINI for DSM -5 and the general psychiatric evaluation.
The subject is participating in a formal structured nonpharmacological therapeutic treatment p rogram (cognitive 
TAK -831
Study No. TAK -831-2002 Page 18of 111
Protocol Incorporating Amendment No. 04 08 June 2020
CONFIDENTIALremediation, cognitive -behavioral therapy, intensive symptom/vocational rehabilitation) for <3 months prior to 
randomization. In addition, initiation of such nonpharmacological treatment programs is not permitted during 
study participatio n through the Day 84 visit.
The subject exhibits more than a minimal level of antipsychotic -induced parkinsonism symptoms, as 
documented by a score on the modified Simpson Angus Scale (SAS) (excluding item number 10, Akathisia) >6.
The subject has evidence of depression as measured by a Calgary Depression Scale Score (CDSS) >9.
The subject’s diagnosis of schizophrenia occurred prior to 12 years of age.
The subject has a history of developmental intellectual disability or mental retardation.
Antipsychotic pl asma levels for the subject’s primary background antipsychotic are below the minimum 
acceptable concentration criteria per the Antipsychotic Reference document at the screening or placebo run -in 
visits. This criterion is not applicable to subjects on a pri mary background antipsychotic for which a clinical 
assay  is unavailable (ie, not listed in the Antipsychotic Reference document).
The subject is taking concomitant treatment that can impact cognition as determined by [CONTACT_1961] [INVESTIGATOR_888023].
Main Randomization Criteria:
The subject must continue to meet all of the inclusion criteria and none of the exclusion criteria at the time of the 
baseline visit (Day 1; Visit 3). The subject has completed the single -blind placebo run -in period and has met the 
study drug compliance criteria (75% to 125%) as assessed using the digital compliance technology.
Main Criteria for Evaluation and Analyses:
Baseline is defined as the assessment prior to dosing on Day 1.
Primary  Endpoint:
Change f rom baseline on the PANSS NSFS at Day 84.
Secondary Endpoints:
Change f rom baseline on the PANSS NSFS at Days 28 and 56.
Change f rom baseline on the BNSS at Day 84.
Change f rom baseline on the BACS composite score at Day 84.
Change f rom baseline on the CGI -SCH -S score at Day 84.
CGI-SCH -I score at Day 84.
Change f rom baseline on the SCoRS at Day 84.
Change f rom baseline on the PANSS total score and additional subscales and factors at Day 84.
TAK -831 plasma concentrations.
Safety Endpoints:
Percentage of subjects who experience at least 1 treatment -emergent adverse event.
Percentage of subjects who meet the markedly abnormal criteria for safety laboratory tests at least once 
postdose.
Percentage of subjects who meet the markedly abnormal criteria for vital sign measurements at least once 
postdose.
Percentage of subjects who meet the markedly abnormal criteria for safety electrocardiogram parameters at least 
once postdose.
Percentage of subjects with treatment -emergent suicidal id eation or suicidal behavior as measured using the 
Columbia -Suicide Severity Rating Scale (C -SSRS).
Statistical Considerations:
Primary  Efficacy Analysis
The primary endpoint will be analyzed by [CONTACT_888056] -831 and placebo over all assessed time points using 
estimates from a mixed model for repeated measures (MMRM) with baseline value as a covariate; pooled site, visit, 
TAK -831
Study No. TAK -831-2002 Page 19of 111
Protocol Incorporating Amendment No. 04 08 June 2020
CONFIDENTIALtreatment, and categorical age (randomization factor) as fixed factors; and treatment -by-visit and baseline -by-visit 
interactions. Based on a Missing at Random Assumption, this analysis will be performed using observed case data 
only. The effect at each time point for each treatment is allowed to vary freely and an unstructured covariance 
matrix is assumed. If the model does not converge, other covariance structures (unstructured, compound symmetry, 
2-Toeplitz, etc) will be considered. Additional analyses to address sensitivity to missing data will be specified in the 
statistical analysis plan. 
Multiplicity will be controlled across dose -arms by  [CONTACT_888057] 125 mg QD and 500 mg QD dose -arms in 
parallel using Holm’s method to control the overall type I error at the 0.10 level (one -sided), then testing the [ADDRESS_1242672]. This analysis will be stratified by [CONTACT_888058].
Interim Analysis
An interim analysis for futility may be performed during the study, allowing for early study termination if the 
probability of success on the primary endpoint fails to meet a pre -specified criterion. The specifics of this analysis 
will be included in an interim analysis plan that will be finalized before interim unblinding .
Sample Size Justification: 
Assuming that the effect size is at least 0.[ADDRESS_1242673] 85% of the 
[ADDRESS_1242674] 82% power for at least 1 dose to be statisti cally -
significant at the 0.10 level with correction for multiple doses.
TAK -831
Study No. TAK -831-2002 Page 20of 111
Protocol Incorporating Amendment No. 04 08 June 2020
CONFIDENTIAL3.0 STUDY REFERENCE INFORMATION
3.1 Study -Related Responsibilities
The sponsor (or designee) will perform all study -related activit ies with the except ion of those 
ident ified in the Clinical Study  Supplier tem plate . The vendors ident ified in the template for 
specific study -related activit ies will perform  these activit ies in full or in partnership wi th the 
sponsor.
3.[ADDRESS_1242675] aspartate aminotransferase
AUC area under the plasma concentration -time curve
AUC t area under the plasma concentration -time curve from time 0 to time t
AUC ∞ area under the plasma concentration -time curve from time [ADDRESS_1242676] curve from time 0 to 24 hours
BACS Brief Assessment of Cognition in Schizophrenia
BMI body mass index
BNSS Brief Negative S ymptom Scale
CDSS Calgary  Depression Scale Score
CFR Code of Federal Regulations
CGI-SCH Clinical Global Impression -Schizophrenia
CGI-SCH -I Clinical Global Impression -Schizophrenia -Improvement
CGI-SCH -S Clinical Global Impression -Schizophrenia -Severity
CIAS cognitive impairment associated with schizophrenia
Cmax maximum observed plasma concentration
COVID -19 coronavirus disease 2019
CSF cerebrospi[INVESTIGATOR_872]
C-SSRS Columbia -Suicide Severity Rating Scale 
DAO D-amino acid oxidase
DMC Data Monitoring Committee
DNA deoxyribonucleic acid
DSM -5 Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition
ECG electrocardiogram
eCOA electronic clinical outcome assessment
eCRF electronic case report form
EDC electronic data capture
EIIB eosinophilic intranuclear inclusion body
FAS Full Analy sis Set
FDA Food and Drug Administration
FSH follicle -stimulating hormone 
GCP Good Clinical Practice
GGT -glutamy l transferase
GluR[ADDRESS_1242677] multiple -rising dose
NMDA N-methy l-D-aspartate
PANSS Positive and Negative Syndrome Scale
PANSS NSFS Positive and Negative Syndrome Scale Negative Symptom Factor Score
PD pharmacodynamic(s)
PET positron emission tomography
PK pharmacokinetic(s)
PT preferred term
PTE pretreatment event
QD once daily
QHS once daily  at bedtime
QTcF QT interval with Fridericia correction method
RNA ribonucleic acid
SAE serious adverse event
SAP statistical analysis plan
SAS Simpson Angus Scale
SCI-PANSS Structured Clinical Interview for the Positive and Negative Syndrome Scale
SCoRS Schizophrenia Cognition Rating Scale
SOC system organ class
SOP standard operating procedure
SRD single -rising dose

TAK -831
Study No. TAK -831-2002 Page 23of 111
Protocol Incorporating Amendment No. 04 08 June 2020
CONFIDENTIALS[LOCATION_003]R suspected unexpected serious adverse reaction
TEAE treatment -emergent adverse event
UGT uridine 5 ′-diphospho -glucuronosyltransferase
ULN upper limit of normal
3.4 Corporate Identification 
TDC [COMPANY_005] Development Center
[COMPANY_005] TDC Japan, TDC Asia, TDC Europe and/or TDC Americas, as applicable
TAK -831
Study No. TAK -831-2002 Page 24of 111
Protocol Incorporating Amendment No. 04 08 June 2020
CONFIDENTIAL4.0 INTRODUCTION
4.1 Background
4.1.1 Study Drug
TAK -831 i s a highly selective and potent inhibitor of D-amino acid oxidase (DAO), a 
peroxi somal enzyme act ive toward neutral D-amino acids, being developed by [CONTACT_11750]. DAO is 
involved in D-serine metabo lism in the brain and has been connected to the regulat ion of 
glutam atergi c neurotransmissio n [1]. D-serine is generated fro m its stereoiso mer, L-serine, by  
[CONTACT_888059], and is a potent N-methyl- D-aspartate (NMDA) –type gl utamate 
receptor co -agonist and an agonist for the δ2 glutamate receptor (GluR 2), which has been 
implicated in synaptic plasticit y and l ong-term depressio n [2]. The presence o f DAO has been 
ident ified in the cerebellum, brain stem, and other brain regio ns relevant to the pathophysio logy 
of schizoph renia, and numerous studies have verified that endogenous and exogenous D-serine 
potenti ate NMDA receptor funct ion in these regio ns [1,3,4 ]. TAK -831 inhibit ion of DAO in the 
liver, kidney , and cerebellum  leads to hi gher D-serine levels in the plasma and cerebellum in 
animal models. As such, TAK -831 has the potential to increase NMDA -dependent glutamatergic 
signaling via i ts impacts on D-serine –modulated neuronal  activit y.
4.1.2 Schizophrenia
Schizophrenia is a chronic and severe mental disorder that affects how a person t hinks, feels, and 
behaves. The onset of the disease is usually in late adolescence or early adulthood. Schizophrenia 
affects up to 1% of the populat ion and increases to 10% in individuals having a first -degree 
relative suffering fro m the disorder (40% to 65% for ident ical twins) [5-7] . Symptoms of 
schizophrenia can be subdivided into [ADDRESS_1242678] classes: posit ive, negative, and cognit ive symptoms 
[8]. Posit ive symptoms include hallucinat ions, delusions, and disordered thought and speech, and 
can be su mmarized as psychosis. Negative symptoms include reduced emotion, reduced abilit y 
to experience pleasure (anhedonia), lack o f motivati on, and reduced social interact ion. Finally , 
cogni tive symptom s include poor information processing, impaired abilit y to focus on obj ectives, 
and abnormalit ies of working memory  and l earning [8]. Deficits in glutamatergic transmissio n 
are hypothesized to play an important role in th e pathophysio logy of the disorder, parti cularly  in 
relation to the genesis of cognit ive impairment and negat ive symptoms, including anhedonia [9].
While current ly available antipsycho tics are broadly  effect ive for the treatm ent of posi tive 
symptoms, the treatment of persistent negat ive symptoms and cognit ive deficits of schizophrenia 
remains a maj or unmet m edical need. These symptom domains are associated with poor 
funct ional outcomes to a greater degree than posit ive symptoms wit h current ly available 
treatm ents [10,11] , and there are no approved therapi[INVESTIGATOR_014]. Thus, addressing these symptoms 
remains an important area of focus for the development of novel therapeut ics.
Inhibit ion of DAO is a promising target for the treatment of schizop hrenia. Hy pofunction of 
NMDA receptors is considered a poten tial mechanism in the pathophysio logy of schizophrenia, 
which coul d be mi tigated wi th increased D-serine levels in the brain [12]. Changes in the 
TAK -[ADDRESS_1242679] b een reported i n the plasma of pat ients with 
schizophrenia both naive to and undergoing drug treatment [13-16 ]. In addit ion, serine racemase 
(the D-serine generating enzyme) and the NMDA NR2A subunit are among the risk genes 
ident ified from the recent large -scale geno me-wide associ ation studies analysis, indicating the 
biological  relevance to schi zophrenia of the genet ic pathway  in which DAO is a component [17].
DAO is invo lved in D-serine metabo lism in the brain and has been connect ed to the regulat ion of 
glutam atergi c neurotransmissio n [1]. Inhibit ion of DAO elevates endogenous D-serine in the 
cerebellum, increasing Purkinje cell long -term depressio n via act ivation of GluR2 and/or 
NMDA receptors with subsequent α -amino -3-hydroxy -5-methyl-4- isoxazo le propi[INVESTIGATOR_149046] 
(AMPA) receptor internalizat ion [2].
Adding to the above evidence of a potential role o f DAO in the pathophysio logy of 
schizophrenia, a weak inhibitor of DAO, sodium benzoate, demonstrated efficacy in posit ive, 
negat ive, and cognit ive symptoms in a proof -of-concept study  in subjects wi th schizophrenia 
[18].
4.1.3 Clinical Background
The safet y evaluations performed in the TAK -831 early  clinical  devel opment program  
(Studi esTAK -831-1001 and TAK -831-1003) allo wed for the init ial characterization and 
quant ificat ion of the safet y profile of TAK -[ADDRESS_1242680] -in-human study  
TAK -831-1001 was designed to assess the pharmacokinet ics (PK) of an oral suspensio n of 
TAK -831 and plasma D-serine levels after single -rising dose (SRD) and m ultiple-rising dose 
(MRD) administration of TAK -831, as well as the relat ive bioavailabilit y and effect of food on 
the PK of the T1 tablet formulat ion of TAK -831. Study  TAK -831-1003 was designed to evaluate 
DAO target engagement in the brain, as measured by [CONTACT_87869] n tom ography  (PET), as 
well as assess plasma D-serine levels, TAK -831 plasma concentrations, and the safet y of 
TAK -831.
TAK -831 has been administered to a total of 103 healthy subjects in these 2 studies; 74 subjects 
received single doses ranging fro m 10 to 750 m g and 29 subjects received mul tiple doses ranging 
from 30 to 400 m g once daily (QD) for up to [ADDRESS_1242681] commo n treatm ent-emergent 
adverse event (TEAE) potentially related to study  drug. H eadaches were mild to moderate in 
intensity and generally self -limit ing. The rate of postural dizziness in TAK-831–treated subj ects 
did not m arkedly  differ from  that observed in placebo -treated subjects. No concerning trends in 
clinical laboratory , electro cardiogram (ECG), or vital sign data were observed. Addit ional detail 
on the safety  and tolerabilit y data f rom these studies m ay be found in the current TAK -[ADDRESS_1242682] igator’s Brochure.
After both single and mult iple dosing wit h TAK -831 (Study  TAK -831-1001 ), increases in the 
mean area under the effect curve from t ime 0 to 24 hours (AUEC 24) of D-serine were dose 
dependent; changes in D-serine were noticeably  higher after m ultiple QD doses of TAK -831 
400mg than after mult iple QD doses of TAK -831 30, 100, and 200 mg. Single oral doses of 
TAK -831
Study No. TAK -831-2002 Page 26of 111
Protocol Incorporating Amendment No. 04 08 June 2020
CONFIDENTIALTAK -831 tem porally increased D-serine plasma concentrations in the PET study  
(TAK -831-1003); the resu lts were similar to those obtained in Study  TAK -831-1001.
Since these studies were conducted, dosing in a single -dose PK and food -effect bioavailabilit y 
study  with the T2 tabl et formulation of  TAK -831 has been completed (Study  TAK -831- 1004). 
Also, a study  examining addit ional escalat ing multiple (QD) doses of TAK -831 higher than those 
achieved in Study  TAK -831-1001 was init iated and is ongoing (Study  TAK -831- 1005).
Study  TAK -831-[ADDRESS_1242683] of food on the bioavailabilit y of TAK -831 
400mg (administered as 4 × 100 mg oral T2 tablets) in [ADDRESS_1242684] met the criteria for orthostatic 
hypotension at a single t ime point without an accompanying report of a dizziness TEAE. No 
concerning trends in clinical laboratory , ECG, or vital sign data were observed. When the 
TAK -831 T2 tabl et formulation was coadministered with a nutrit ional drink (Ensure Plus), mean 
maximum observed plasma concentration (C max)and area under the plasma concentration -time 
curve fro m time 0 to infinit y (AUC ∞) values were increased by 35% and 21%, respectively . 
Treatment with a single oral dose of TAK- [ADDRESS_1242685] -blinded, sponsor -unblinded, 
placebo -controlled study  designed to cont inue evaluation of the safet y, tolerabili ty, PK, and 
pharmacodynamics (PD) of escalat ing multiple (QD) doses of TAK -[ADDRESS_1242686] to change upon finalizat ion 
following study  monitoring, source data verificat ion, and discrepancy query  management before
database lock. As of the cut -off date of 18 September 2017, 2 cohorts of 8 subjects each 
(6TAK -831:2 placebo) have completed dosing with TAK -831 600 m g QD (T2 tabl ets), 
TAK -831 800 m g QD (oral  suspensi on) or pl acebo, administered first as a single dose a nd then 
QD for up to [ADDRESS_1242687] safety  assessments, subjects underwent catheterized 
cerebrospi[INVESTIGATOR_872] (CSF) co llection for a [ADDRESS_1242688] commo nly reported TEAEs; nausea in the absence of 
postl umbar puncture syndrome was reported by  [ADDRESS_1242689] 1 assessment; none of these findings were associated with a 
TEAE of dizziness. No concerning trends in clinical laboratory , ECG, or vi tal sign data were 
observed for these cohorts.
Following QD dosing, mean plasma exposures of TAK -831 were higher (C max: 1.3-fold and area 
under the plasma concentration -time curve [AUC]: 1.8 -fold) when dosed as an oral suspensio n 
TAK -831
Study No. TAK -831-2002 Page 27of 111
Protocol Incorporating Amendment No. 04 08 June 2020
CONFIDENTIALthan as T2 tablets. Geometric mean C maxvalues were 1466 and 1976 ng/mL with 600 m g QD 
(T2tablets) and 800 mg QD (oral suspensio n), respectively. Mean steady -state exposures (area 
under the plasma concentration -time curve fro m time 0 to time t [AUC t]) over the 24 -hour 
dosing interval were 4993 and 8853 h*ng/mL for the 600 and 800 m g QD doses, respectively. 
The m ean 24 -hour PK profile o f TAK -831 in CSF was parallel to that in plasma, and observed 
TAK -831 CSF concentrations were well in agreement with the TAK- 831 unbound fraction in 
plasma. After both single and mult iple dosing with TAK -831 600 mg (T2 tablets) and 800 mg 
(oral suspensi on), the mean AUEC 24of D-serine in CSF increased notably co mpared with 
placebo; changes in CSF D-serine concentrations were noticeably higher after mult iple (QD) 
doses than after a single dose of T AK-831. The m agnitude of  the increase in AUEC 24of CSF 
D-serine was similar for both the 600 mg (T2 tablets) and 800 mg (oral suspensio n) doses, 
suggest ing that the maximal PD effect in the CSF was achieved at drug exposures attained with 
both doses.
Overa ll, the emerging safet y data fro m Studi es TAK -831- [ADDRESS_1242690] range of repeated doses in rodent behavioral models. As noted above, 
TAK -831 has been also demonstrated to increase D-serine levels in human CSF. TAK -831 i s 
under development for the treatment of the negat ive symptom s of schizophrenia, cognit ive 
impairment associated with schizophrenia (CIAS), and cerebellar ataxia. The current phase [ADDRESS_1242691] ive administration of 
TAK -831 in the treatment of negative sympto ms and cognit ion in symptomatically stable 
outpati ents wi th chronic schizophrenia on stable ant ipsychotic and other psychotropic 
medicat ions.
4.3 Benefit/Risk Profile
The current study  is desi gned to eval uate the efficacy , safet y, PD, and PK of [ADDRESS_1242692] been selected based on the available PK, brain 
target occupancy (PET), CSF D-serine, and safet y data for TAK -831 in healt hy subjects (see 
Secti on  6.2.2 ). The safet y data from  healthy subjects cannot be direct ly generalized to subjects 
with schizophrenia. However, no safet y signal has manifested that would prevent addit ional 
studi es in heal thy subjects or subjects with schizophrenia. A placebo -controlled study  is standard 
in the evaluat ion of novel therapeut ics for neuropsychiatric disorders; as TAK -[ADDRESS_1242693] ion of TAK -831, the 
available nonclinical data, the available phase 1 clinical data, and general considerat ions in the 
development of new chemical ent ities for central nervous system  disorders. Procedures may be 
added during the study  if necessary  based on evaluation of any addit ional clinical or nonclinical 
safet y data.
The exposures associated with the TAK -[ADDRESS_1242694] not resulted in a safet y signal that 
woul d prevent addi tional studi es.
Acute hypersensit ivity/anaphylact ic reactions to new chemical entit ies are al ways a possible 
risk in any clinical study . Appropri ate procedures should be used to manage such possible 
risks.
Subjects with a risk of suicide acco rding to the investigator’s clinical judgment (or as 
assessed by  [CONTACT_838583] -Suicide Severit y Rating Scale [C -SSRS]), or who have made a 
suicide attem pt in the previous 12 months, will be excluded from this study . The C -SSRS 
will be administered at prescr ibed intervals to m onitor em ergent sui cidali ty. Subjects shoul d 
be monitored for any  signs of  suicidal i deati on or behaviors, and appropriate psy chiatri c 
intervent ions or other precautions should be instituted, if warranted.
Eosinophilic intranuclear inclu sion bodi es (EIIBs) were observed in the proximal tubule 
epi[INVESTIGATOR_888024] ≥10 m g/kg/day  in rats. The EIIBs were not 
accompanied by [CONTACT_87807], inflammat ion, or impaired renal function and were not 
considered adverse. Similar fin dings have been reported in the literature and are considered 
to be species -specific to the rat [19]. Elevated creatinine levels were not reported in the 
TAK -831 clinical studies summarized above; creatinine will cont inue to be measured in the 
clinical studies.
Postural hypotensio n and dizziness were observed in prior TAK -831 studi es in heal thy 
subjects. However, the incidence o f dizziness in subjects treated with TAK -831 and placebo 
was similar. S ubjects will be informed of these findings and possible ways to mit igate thi s 
risk, and orthostatic vital sign assessments will be mo nitored peri odically  at study  visits.
Study  procedure –specific risks include issues relat ing to blood collection for safet y
assessment/PK monitoring (venipuncture may cause disco mfort at the si te of puncture; 
bruising and swelling; and rarely, infect ion or faint ness fro m the procedure), and the 
placement of ECG pads, which may  cause som e local redness and/or ery thema/i tching. The 
PD assessments planned for the study , aside from those requi ring a bl ood draw, are 
noninvasive and are associated with minimal risk.
TAK -[ADDRESS_1242695] ive of this study  is to determine whether add-on TAK -831 is superior to 
placebo on the Posit ive and Negat ive Syndro me Scale Negat ive Symptom Factor Score (PANSS 
NSFS).
5.1.2 Secondary Objectives 
To determine whether add -on TAK -[ADDRESS_1242696] acebo on the Bri ef Negative 
Symptom  Scal e (BNSS) total score.
To determine whether add -on TAK -[ADDRESS_1242697] acebo on the Bri ef Assessment of 
Cogni tion in Schizophrenia (BACS) composite cognit ion score.
To determine whether add -on TAK -[ADDRESS_1242698] acebo on gl obal severi ty as measured 
by [CONTACT_888060] n-Schizophrenia -Severit y (CGI -SCH- S) score.
To determine whether add -on TAK -[ADDRESS_1242699] acebo on gl obal improvem ent as 
measured by [CONTACT_888061] n-Schizophrenia -Improvement (CGI -SCH- I) 
score.
To determine whethe r add -on TAK -[ADDRESS_1242700] acebo on the Schizophrenia 
Cogni tion Rat ing Scale (SCoRS) assessment of cognit ive funct ional outcom e.
To determine whether add -on TAK -[ADDRESS_1242701] acebo on the Posit ive and Negative 
Syndrome Scale (PANSS) total score and addit ional subscales and factors.
To assess the safet y and tol erabilit y of TAK -831.
To assess the PK of TAK -831.
5.1.3
 
 
 
 
 

TAK -831
Study No. TAK -831-2002 Page 30of 111
Protocol Incorporating Amendment No. 04 08 June 2020
CONFIDENTIAL  
 
 
 
 
 
 
 
5.2 Endpoints
Baseline is defined as the assessment prior to dosing on Day  1 for all assessments other than the 
 where baseline is defined as the Day  -14 assessment.
5.2.1 Primary Endpoint 
Change from baseline on the PANSS NSFS at Day 84.
5.2.2 Secondary Endpoints
Change from baseline on the PANSS NSFS at Days 28 and 56.
Change from baseline on the BNSS at Day  84.
Change from baseline on the BACS composite score at Day  84.
Change from baseline on the CGI -SCH- S score at Day  84.
CGI-SCH- I score at Day  84.
Change from baseline on the SCoRS at Day  84.
Change from baseline on the PANSS total score and additional subscales and factors at 
Day 84.

TAK -831
Study No. TAK -831-2002 Page 31of 111
Protocol Incorporating Amendment No. 04 08 June 2020
CONFIDENTIALTAK -831 pl asma concentrations.
5.2.3 Safety Endpoints
Percentage of subjects who experience at least 1 TEAE.
Percentage of subjects who meet the markedly abnormal criteria for safet y laboratory  tests at 
least once postdose.
Percentage of subjects who meet the markedly abnormal criteria for vital sign measurements 
at least once postdose.
Percentage of subjects who meet the markedly abnorma l criteria f or safet y ECG param eters 
at least once postdose.
Percentage of subjects with treatment -emergent suicidal ideat ion or sui cidal  behavi or as 
measured using the C -SSRS.
5.2.[ADDRESS_1242702] of a 
screening period of up to 28 day s, a 14-day single -blind placebo run -in period, a 12 -week 
doubl e-blind treatment period, and a safet y follow-up visit.
Approximately  234 subjects will be enrolled at approximately  48 si tes in North Ameri ca and 
Europe.
At the screening visit (Visit 1), subjects who provide informed consent will proceed with 
screening procedures. Subjects who meet a current diagnosis o f schizophrenia, as defined by [CONTACT_888062] c Interview (MINI), will then be adm inistered additional 
psychiatric and neurological rating scale assessments as specified in Sect ion 9.1.[ADDRESS_1242703] be current ly receiving stable treatment on 1 
antipsychotic medicat ion at a total  daily dose between 2 mg and 6 mg of risperidone equivalents 
(as outlined in an Ant ipsychoti c Dose Equivalency referenc e supplied to the sites), with no 
clinically meaningful change in psychotropic medications (no increase, ≤25% decrease in dose) 
for the preceding 2 months before the screening visit and no dose adjustment is ant icipated 
throughout study  partici pation up to the Day  84/early  terminati on visi t. Concomi tant treatm ent 
with a subtherapeutic dose of a second antipsychotic may  be permitted wi th sponsor or designee 
approval  if used as a hypnoti c, but not if used for refractory  posi tive psychosis symptoms. 
Subjects must have a BNSS total score (12- item, excluding item number 4) ≥[ADDRESS_1242704] demonstrate stable BNSS 
total scores ( ≤20% change from the screening score) at the single -blind placebo run -in visit 
(Day -14; Visit 2) and baseline visit (Day  1; Visit 3). Subjects with extrapy ramidal  
signs/symptom s or depressive symptoms based on study  assessments, as outlined in the study  
entry  criteria, will  be excluded.
During the screening period (Day s -42 to -15), subjects will visit the clinic and receive full 
medical, neuro logical, and psychiatric examinat ions as well as be familiarized with study  
procedures. Addit ional screening procedures include diagnostic assessments, safet y assessments, 
and other c linical assessments, as outlined in
 Appendix A. An adul t informant capable of 
provi ding informat ion about the subject’s symptoms and funct ion for the PANSS and SCoRS 
must attend the screening or placebo run -in visit for evaluation by [CONTACT_888063]. Alternatively , a site staff member 

TAK -831
Study No. TAK -831-2002 Page 33of 111
Protocol Incorporating Amendment No. 04 08 June 2020
CONFIDENTIALmay also go to the informant’s locat ion to obtain i nform ed consent and, if a qualified rater, 
obtain the informant interview; or the informant interview may be conducted by [CONTACT_888064] a rater. If the informant is unavailable for an in -person interview at the screening
visit, the init ialinformed consent may be obtained in a telephone discussio n (as permitted by  
[CONTACT_888065]) so that the informant information may be included in the 
screening assessments requiring informant input.
Subject eligibilit y for the study  will be confirmed by a centralized vendor that will also provide 
rater qualificat ion, training, and ongo ing rater qualit y monitoring throughout the conduct of the 
study . For the screening visit, the centralized vendor will review documentation and recordings 
of the di agnosti c and selected symptom assessment interviews as well as collected informat ion 
addressing key  study  entry cri teria. The study  site must receive docum entati on of  approval  of 
subject eligibilit y before the subject can be enrolled into the sing le-blind run -in peri od.
The 2 -week single -blind placebo run -in period (Days -14 to -1) will be used to evaluate 
compliance wi th study  drug intake and stabilit y of BNSS scores. During this period, all subjects 
will receive placebo tablets that appear ident ical to the study  drug to be used during the 
rando mized double -blind treatment period. Note: If the scheduling of the Day  [ADDRESS_1242705] shoul d be instructed to continue treatment with run -in medicat ion 
until the Day 1 visit is rescheduled.
At baseline (predose Day  1; Visit 3), subjects who continue to meet all eligibilit y criteria, 
including placebo run -in drug compliance requirements, will be rando mized via an interactive 
response techno logy (IRT) sy stem  to 1 of  the fo llowing 4 treatm ents: TAK -[ADDRESS_1242706] acebo QD. Randomizat ion will be fo llowed 
by a 12-week double -blind treatm ent peri od (Days 1 to 84), during which subjects will undergo 
assessments as outlined in Appendix A. Efforts will be made to perform cognit ion testing at 
approximately  the same t ime of day throughout the double -blind treatment period (postbaseline 
assessmen ts must be administered ±2 hours fro m the time o f baseline assessment 
administration). A safety  follow-up visi t (between Days 94 and 98; Visit 11) will be scheduled 
for all subjects [ADDRESS_1242707] exceeded the 28 -day screening period may proceed to 
the placebo run -in visit after a discussio n with the sponsor/desi gnee to obtain approval and to 
determine whether any screenin g procedures should be repeated before that study  visit.

TAK -831
Study No. TAK -831-2002 Page 34of 111
Protocol Incorporating Amendment No. 04 08 June 2020
CONFIDENTIALSubjects who do not meet symptom or medicat ion stabilit y criteria (or other entry  criteria that 
may be met by  [CONTACT_37326] a future time) may be considered for rescreening with the approval 
of the sponsor or designee . Subjects who were in screening or the single -blind run -in period at 
the time that COVID -[ADDRESS_1242708] completes the safet y follow-up visi t 
(Visit 11).
A schemat ic of the study  design is included as  Figure 6.a. A schedule o f study  procedures i s 
provi ded in  Appendix A.
Figure 6.a Schematic of Study Design
DB: double -blind; F/U: follow -up; QD: once daily .
Sites shoul d see subjects at the study  site to conduct the study procedures. In unavoidable 
circumstances (eg, a widespr ead disease outbreak or natural disaster) that impact the study  site’s 
abilit y to conduct study  procedures according to the Schedule of Procedures (Appendix A), 
contingency measures may be implemented. Restrictions o f human act ivities or inst itution 
activit ies placed by [CONTACT_2360][INVESTIGATOR_600], local, state and nat ional governments may prevent conduct of 
study  procedures according to the Schedule of Procedures. Alternative a pproaches to study  
procedures and data collection for the current study  are described in Section  9.1.[ADDRESS_1242709] acebo will be ev aluated in the current study . The 
proposed doses of TAK -831 (50, 125, and 500 mg QD) have been selected based on the 
SRD/MRD PK data (Studies TAK -831- 1001 and TAK -831- 1005), food -effect PK data 
(Study TAK -831-1004), brain target occupancy  (PET) data (Study TAK -831- 1003), CSF 
D-serine data (Study TAK -831-1005), and safet y data f rom all clinical studi es after oral  
administration of TAK -831 in healt hy subjects. D-serine levels in CSF and plasma after 
administration of TAK -831 600 m g QD (oral  T2 tablets) and 80 0 mg QD (oral  suspensi on) 
increased similarly, suggest ing that 600 mg QD produced levels o f D-serine approaching 
maximal DAO inhibit ion in the brain. The planned 500 mg QD dose is expected to result in CSF 
D-serine level increases near the plateau that are maintained over 24 hours with QD dosing. 
Preliminary PK/PD modeling analyses showed that the high -dose regimen (500 mg QD) resulted 
in steady -state exposures associated with mean peak target occupancy  near the m aximum  
(>90%) and provided mean target occup ancy ≥50% over 16 hours, whereas the low -dose 
regimen (50 mg QD) produced daily  exposures associ ated wi th a peak target occupancy  of ≥50% 
of all subjects. The middle dose (125 mg QD) produced daily exposures associated with a peak 
target occupancy between 50% and the m aximum . All 3 doses selected for the current study  are 
predi cted to dem onstrate PD effects based on nonclinical efficacy models. The planned dose 
regimens are expected to deliver mean exposures within the range previously studied in Studies 
TAK-831- 1001 and TAK -831-1005 that were found to be well tolerated in healthy subjects.
6.2.3 Endpoints
[IP_ADDRESS] Efficacy Endpoints
Established, validated efficacy measures will be utilized to assess relevant schizophrenia 
symptom  domains (negative, posit ive, general symptom s, global improvement, cognit ive 
impairment, funct ional capacit y, and qualit y of life).
TAK -831
Study No. TAK -831-2002 Page 36of 111
Protocol Incorporating Amendment No. 04 08 June 2020
CONFIDENTIAL6.[IP_ADDRESS] PANSS
The PANSS is a reliable, validated comprehensive evaluat ion scale of the severit y of various 
symptoms of schizophrenia and is co mmo nly employ ed in clinical studi es invo lving 
antipsychotics [20,21 ]. The subscales of the PANSS and the [ADDRESS_1242710] ore different symptom domains of schizophrenia [22]. Change from 
baseline in the PANSS NSFS is the primary endpoint of the current study . In addi tion, the 
secondary  endpoints will  include the PANSS total  score and addit ional subscales and factors.
[IP_ADDRESS].2 Clinical Global Impression -Schizophrenia
The Clinical Glo bal Im pressi on-Schizophrenia (CGI -SCH) scale [23] is an adapted versio n of the 
CGI scale [24]that is designed to assess global severit y of illness and change in schizophrenia 
patients over time. The assessment consists of [ADDRESS_1242711] been shown to corroborate efficacy, as measured by  [CONTACT_226250] 
[21,24,25]. The CGI -I score and change from baseline in CGI -S score are included as secondary  
endpo ints in the current study .
[IP_ADDRESS].3 BNSS
The BNSS i s a 13 -item instrum ent desi gned for use in clinical trials and other studies that 
measures 5 domains o f negat ive symptoms: blunted affect, alogia, asocialit y, anhedonia, and 
avolition [26]. Examinat ion of the correlat ions between other instruments supports the 
discrimina nt validit y (ie, low correlati ons wi th other instrum ents m easuring posi tive symptom s) 
and convergent validit y (ie, high correl ations wi th other instruments measuring negat ive 
symptoms). The BNSS has been demo nstrated to have a [ADDRESS_1242712] ing of a diminished expressivit y subscale and a motivat ion and 
pleasure subscale [27]. Thi s feature will  support examinat ion of effects on these clinically 
important subsyndromes of negat ive symptoms. Change fro m baseline in BNSS total score is 
included as a secondary endpo int in the current study .
[IP_ADDRESS].4 BACS
Cogni tive symptom s of schizophrenia will be assessed as a secondary endpo int using the BACS, 
which is a reliable and sensit ive measure of cognit ive functi on in schizophrenia [28]. The BACS 
assesses [ADDRESS_1242713] ion found to be consistent ly impaired in schizop hrenia: 
verbal memory, working memory , motor speed, attent ion, executive funct ions, and verbal 
fluency . The BACS is specifically designed to measure treatment -related improvements in 
cogni tion and includes alternate forms. The BACS has high test- retest rel iabilit y and is sensit ive 
to cognit ive dysfunct ion in schizophrenia. The selection of the BACS was informed by [CONTACT_888066] a schizophrenia clinical trial with a weak DAO inhibitor, sodium benzoate [18], whi ch 
demonstrated beneficial effects on similar cognit ive tasks.
TAK -831
Study No. TAK -831-2002 Page 37of 111
Protocol Incorporating Amendment No. 04 08 June 2020
CONFIDENTIAL6.[IP_ADDRESS] SCoRS
The SCoRS is an interview -based measure of cognit ive funct ioning that was developed to 
specifically assess aspects of cognit ive funct ioning found in ea ch of the 7 cognit ive domains 
assessed by  [CONTACT_888067] m easure for clinical trials of new medicat ions to 
improve cognit ion in schizophrenia [29]. The psy chometrics and performance of the SCoR S 
were evaluated with a number of other cognit ion-focused funct ional endpo ints and found to have 
good test -retest reliabilit y and the highest feasibilit y of the interview -based assessments [30]. 
The SCoRS has also been found acceptable as a funct ional coprimary measure in a phase 3 
program by  [CONTACT_888068] o f an indicat ion for cognit ion in schizophrenia [31].
[IP_ADDRESS] Safety Endpoints
The secondary  endpoint of safet y will be evaluated by  [CONTACT_888069], clinical laboratory  
tests, phy sical examinat ions, ECGs, vital signs, and suicidalit y assessment with C-SSRS.
The C -SSRS is a well- established 3- part scal e that measures suicidal ideat ion (eg, subject 
endorses thoughts about a wish to be dead or has other thoughts of suicide), intensit y of ideation 
(frequency, duration, controllabilit y, deterrents, a nd reasons for ideat ion), and suicidal behavior 
(actual , interrupted, and aborted attempts at suicide) [32].
6.[ADDRESS_1242714] anned unless one or more of the fo llowing cri teria are satisfied 
that require temporary  suspensi on or early  terminati on of  the study .
New informat ion or other evaluat ion regarding the safet y or efficacy  of the st udy drug that 
indicates a change in the known risk/benefit profile for the compound, such that the 
risk/benefit is no longer acceptable for subjects participat ing in the study .
Significant vio lation of Good Clinical Practice (GCP) that compromises the abil ity to achieve 
the primary  study  objectives or compromises subject safet y.
6.3.2 Criteria for Premature Termination or Suspension of Study Sites 
A study  site may be terminated prem aturely or suspended if the site (including the invest igator) 
is found in significant vio lation of GCP, protocol, or contractual agreement, is unable to ensure 
adequate performance of the study ,or as otherwise permitted by  [CONTACT_39778].
6.3.[ADDRESS_1242715] (IRB)/independent ethics committee 
(IEC), or regulatory  authori ty elects to terminate or suspend the study  or the participati on of  an 
investigat ional site, a study -specific p rocedure for early  terminat ion or suspensio n will be 
provi ded by [CONTACT_456]; the procedure will be fo llowed by [CONTACT_888070].
TAK -831
Study No. TAK -831-2002 Page 38of 111
Protocol Incorporating Amendment No. 04 08 June 2020
CONFIDENTIAL7.0 SELECTION AND DISCONTINUATION/WITHDRAWAL OF SUBJECTS
All entry  criteria, including test results, need to be confirmed prior to the first dose of study  drug 
in the single -blind placebo run -in period.
7.[ADDRESS_1242716] eligibilit y is determined according to the following criteria prior to entry  into the study : 
1.In the opi[INVESTIGATOR_1649] o f the invest igator, the subject is capable of understanding and complying wit h 
protocol  requi rements.
2.The subject or, when applicable, the subject’s legally acceptable representative signs and 
dates a wri tten, informed consent form and any requi red privacy authorization prior to the 
initiation of any study  procedures.
3. The subject has a current diagnosis of schizophrenia as defined by [CONTACT_42145] 7.0.[ADDRESS_1242717] ical Manual o f Mental  Disorders, Fift h 
Edition (DSM -5)and the general psychiatric evaluation.
4.The subject is male or female and aged [ADDRESS_1242718] 45 kg and has a body  mass index (BMI) between 18 to 
40.5 kg/m2, inclusive. 
6.The subject’s init ial diagnosi s must be ≥[ADDRESS_1242719] is eligible to participate if she is of (a) nonchildbearing potential or 
(b)childbearing potential and, if sexually act ive with a nonsterilized* male partner, agrees to 
use an acceptable effect ive method of contracepti on* f rom signing o f informed consent 
throughout the duration of the study  and for [ADDRESS_1242720] at the screening, single -blind 
placebo run -in, and baseline visit s. Mal e subjects are not required to use barrier contraception 
in this study .
*Definit ions of acceptable effect ive methods of contraception are defined in 
Secti on  9.1.[ADDRESS_1242721] is receiving primary background a ntipsychoti c therapy  (other than clozapi[INVESTIGATOR_050]) at a 
total daily dose between 2 mg and 6 mg of risperidone equivalents (as outlined in an 
Antipsychotic Reference document supplied to the sites). Concomitant treatment with a 
subtherapeutic dose of a second ant ipsychoti c may be permitted with sponsor or designee 
approval  if used to treat specific symptoms, such as insomnia (for example, quetiapi[INVESTIGATOR_050] 100 
mg or i ts equivalent once daily  at bedt ime) or anxiety (for example, quetiapi[INVESTIGATOR_050] 25 -50 m g or 
its equivalent as nee ded for anxiet y), but not if it is used for refractory  posi tive psychosis 
symptoms. Under this except ion, the total  daily  dose of the second ant ipsychoti c will not 
have to be included in the calculat ion of the 6 mg/day  risperi done -equivalent limit. 
Recogni zing that som e prescribers use higher doses of quetiapi[INVESTIGATOR_53530] a hypnotic, subjects 
taking up to [ADDRESS_1242722] be included in the calculat ion of the 6 
mg/day  risperi done- equivalent limit.
9.The subject is treated with a stable regimen o f psychotropi c medicati ons wi th no clinically 
meaningful change (no increase in dose, <25% decrease in dose for tolerabilit y) in the 
prescribed dose for [ADDRESS_1242723] ment is ant icipated 
throughout study  partici pation up to the Day  84/early  terminati on visi t. As an except ion, 
prohibited medicat ions th at are used as hy pnoti cs or anxio lytics may be repl aced wi th 
permitted medicat ions as m edically appropriate with approval from the sponsor or designee. 
Recognizing that phy sicians outside of the study  may  be managing the subject’s background 
antipsychotic and other psychotropic medicat ions, changes in background medicat ion dosing 
that exceed this limit during the conduct of the study  shoul d be di scussed wi th the sponsor or 
designee to determine subject disposit ion (based on considerat ion of safet y and the s tudy 
scientific object ives).
10.The subject has a BNSS total score (12 -item, excl uding number 4) ≥28; stable single -blind 
placebo run -in and baseline BNSS total (12 -item, excluding number 4) scores ( ≤20% change 
from the screening score).
11.The subject has no mo re than moderate -severe ( ≤5) rating on PANSS posit ive symptom 
items P1, P3, P4, P5, P6, or unusual thought content (G9), with a maximum o f 2 of these 
items rated “5”; no more than moderate ( ≤4) rating on conceptual disorganizat ion (P2). 
12.There i s evidence that the subject has stable symptomatology  ≥3 m onths pri or to the 
screening visit (eg, no hospi[INVESTIGATOR_888021], no emergency  room  admissio n due 
to symptom s of schizophrenia, no increase in level of psychiatric care due to worsening of 
symptom s of schizophrenia).
13.The subject must have an adult informant who will be able to provide input for complet ing 
study  rating scales, including the PANSS and SCoRS (for example, a family  member, social 
worker, caseworker, residential facilit y staff, or nurse ) who spends ≥4 hours/week with the 
subject and is considered reliable by [CONTACT_093]. The informant must be able and willing 
to provi de wri tten inform ed consent and to participate in at least 1 in- person interview 
(during the screening period in the clinic, at Visit 2, or via site staff conduct ing informed 
consent at the informant’s location), then be able to provide cont inuing input by [CONTACT_888071] a telephone interview for other study  
visits that i nclude the PANSS or SCoRS endpoints. Informant participat ion at the screening 
visit is preferred, if possible. If the informant is unavailable for an in -person interview at the 
screening visit, the init ial informed consent may be obtained in a telephone di scussio n (as 
permitted by  [CONTACT_888072]) so that the informant informat ion may be 
included in the screening assessments requiring informant input .
TAK -[ADDRESS_1242724] who meets any  of the fo llowing cri teria will not qualify  for entry  into the study :
1.A female subject who is lactating or pregnant (positive prerando mizat ion serum pregnancy 
test) or pl ans to become pregnant during the study .
2.The subject has uncontrolled, clinically significant neuro logic, cardi ovascular, pulmo nary, 
hepat ic, renal, metabo lic, gastrointest inal, or endocrine disease or other abnormalit y (other 
than the disease being studied), which may impact the abilit y of the subject to participate or 
potenti ally confound the study  resul ts.
3.The subject has a lifet ime diagnosis of schizoaffective disorder; a lifet ime diagnosis of 
bipolar disorder; or a lifetime diagnosis of obsessive co mpulsive disorder based on the MINI 
combined wit h the general psychiatric evaluat ion. As an except ion, subjects with a historical 
prior lifet ime diagnosis of schizoaffective disorder may be enrolled in the study wit h sponsor 
or desi gnee approval provided that the principal investigator [INVESTIGATOR_888025]’s 
overall history  and current clinical presentation and history  is most co nsistent with 
schizophrenia, not schizoaffective disorder.
4.The subject has a recent (within the last 6 months) occurrence of panic disorder, depressive 
epi[INVESTIGATOR_1865], or other comorbid psychiatric condit ions currently requiring clinical attention based 
on the MI NI for DSM -[ADDRESS_1242725] has a diagnosis of substance use disorder (with the except ion of nicotine 
dependence) within the preceding [ADDRESS_1242726] is participat ing in a formal structured nonpharmaco logical psychosoc ial 
therapeuti c treatm ent program  (cogni tive remediat ion, cognit ive-behavioral therapy, 
intensive symptom /vocati onal rehabilitat ion) for a durati on of  <[ADDRESS_1242727]’s psychosocial treatment, changes to this 
type of treatm ent duri ng the conduct of the study  shoul d be di scussed with the sponsor (or 
designee) to determine subject disposit ion.
8.The subject has a posit ive drug screen for disallowed substances, including amphetamines, 
barbiturates, cocaine, marijuana, methadone, methamphetamine, 3,4 -
methylenedio xymethamphetamine (MDMA ), phency clidine, or nonprescribed 
benzodiazepi[INVESTIGATOR_260047].
Note: Subjects testing positive for marijuana at screening may be eligible for participat ion in 
the study  provi ded that the principal invest igator’s clinical assessment indicates that the 
subje ct is not a regul ar user of m arijuana, and after discussio n with and approval  from the 
sponsor or designee. Under this circumstance, a local urine dipst ick drug screen must be 
TAK -[ADDRESS_1242728]’s disposit ion.
9.The subject exhibit s more than a minimal level o f antipsychot ic-induced parkinsonism 
symptoms, as documented by  a score on the m odified SAS (excluding item number 10, 
Akathisia) >6.
10.The subject has evidence of depressio n as measured by  a Calgary  Depressi on Scale Score 
(CDSS) >9.
11.The subject is considered by [CONTACT_888073], others, or property , or the subject has attempted suicide wit hin the past y ear pri or to 
screening. Subjects who have posit ive answers on item number 4 or 5 on the C -SSRS (based 
on the past y ear)prior to randomizat ion are excluded.
12.The subject has a history  of brain trauma associated with loss of consciousness 
for >[ADDRESS_1242729]’s diagnosis of schizophrenia occurred prior to [ADDRESS_1242730] has received electroconvulsive th erapy within 6 months (180 days) before 
screening.
15.The subject has a history  of devel opmental  intellectual  disabili ty or m ental  retardati on.
16.Antipsychotic plasma levels for the subject’s primary background ant ipsychotic are below 
the minimum acceptable con centrati on cri teria per the Antipsychotic Reference document at 
the screening or placebo run -in visits. This criterion is not applicable to subjects on a primary 
background antipsychotic for which a clinical assay  is unavailable (i e,per the Ant ipsychotic 
Reference document). Screening ant ipsychoti c plasma l evels that do not meet the criteria 
listed in the Ant ipsychotic Reference document should be repeated as soon as possible if, in 
the judgment of the invest igator, the subject may actually be adherent to their medicati on 
regimen. Please see Section [IP_ADDRESS] and the Ant ipsychoti c Reference document for specific 
procedures to fo llow and for determinat ion of subject eligibilit yin this circumstance.
17.The subject is treatment resistant. Treatment resistance is defined as prior nonresponse of 
positive symptom s of schizophrenia to [ADDRESS_1242731] ive. 
18.Use of disallowed conco mitant m edicat ions as documented in Section  7.4that cannot be 
discontinued during the screening period (as medically  appropri ate). Note that disallowed 
psychotropic medicat ions may not be discont inued during screening because of the 
psychotropic medicat ion stabilit y requi rements for the study . Subjects taking disallo wed 
psychotropic medicat ions should not be considered for participat ion in the study  (except 
those explicit ly addressed in Secti ons  7.4and 8.1.1 ).
TAK -[ADDRESS_1242732] cognit ion as determined by [CONTACT_28824] [INVESTIGATOR_888026] h the sponsor or designee, including (but not limited 
to) the fo llowing: anticholinergics (except ion: up to 2 mg benztropi[INVESTIGATOR_050]/day or equivalent for 
treatm ent of extrapy ramidal  motor symptom s with sponsor or desi gnee approval; must not be 
taken wi thin 8 hours of any cogn ition assessment), stimulants, tricyclic ant idepressants, 
anticonvulsants (exception for pregabalin and gabapent in), and lit hium.
20. The subject has received TAK- 831 in a previous clinical study; or has previously  or is 
currently part icipating in this study ; has received treatment with other experimental therapi[INVESTIGATOR_888027] 60 days or <5 half -lives pri or to randomizat ion, whichever is lo nger; has 
participated in 2 or more clinical studies wit hin 12 months prior to screening; or has 
participated in a clinical study  for a psy chiatri c condit ion that i s exclusio nary per this 
protocol .
21.The subject is known by  [CONTACT_888074] (HIV).
22.The subject has a known hype rsensi tivity to any  component of the formulat ion of TAK -831 
or to the practice pi[INVESTIGATOR_3353] (ie, small candies) used during the compliance mo nitoring device 
training.
23.The subject has a history  of cancer. As an except ion, subjects may  be enrolled if they have a 
history  of treated basal cell carcino ma, stage I squamous cell skin cancer, or in situ cervical 
cancer that has been in remissio n for ≥[ADDRESS_1242733] dose of study  drug.
24.Subjects with evidence or history  of current clinically  significant cardi ovascul ar disease, 
including uncontrolled hy pertensi on (supi[INVESTIGATOR_119232] >95 mm Hg and/or 
supi[INVESTIGATOR_9219] >160 mm Hg, with or without treatment), symptomat ic 
ischemic heart disease, unco mpensated heart failure or recent (past 12 mont hs) acute 
myocardial  infarct ion or by [CONTACT_4897] . Controlled essent ial hypertensio n and nonclinically  
significant sinus bradycardia and sinus tachycardia will not be considered significant medical 
illnesses and would not exclude a subject from the study.
25.The subject has a QT interval with Fridericia correction method (QTcF) >450 msec (males) 
or >470 m sec (females), confirmed wit h [ADDRESS_1242734] 
has long QT syndrom e or is under the treatment with Class 1A (eg, quinid ine, procainamide) 
or Class 3 (eg, amiodarone, sotalo l) antiarrhyt hmic drugs.
26.The subject has ty pe 1 diabetes that requires insulin for their treatment; has t ype 2 diabetes 
that is poorly controlled; has had changes to their diabet ic treatment regimen with in 30 days 
before screening; or has had hospi[INVESTIGATOR_888028]/or diabetes -related condi tions 
in the past [ADDRESS_1242735] has any  of the f ollowing at the screening visit: a serum creatinine value >1.5 × 
upper limit of normal (ULN); a ser um total  bilirubin value >1.5 × ULN; a serum alanine 
aminotransferase (ALT) or aspartate aminotransferase (AST) value >2 × ULN. As an 
exception, subjects with Gilbert syndrome may be considered for enrollment after discussio n 
with the sponsor or designee i f the di rect bilirubin is wit hin the normal range. Subjects with a 
positive hepat itis B surface antigen (HBsAg) test result, or known or suspected active 
hepat itisC infecti on are also excluded.
29.The subject does not have a stable residence or is homeless.
7.[ADDRESS_1242736] continue to meet all o f the inclusion criteria and none o f the exclusio n 
criteria at the time of the baseline visit (Day  1; Visit 3). 
2.The subject has co mpleted the single -blind placebo run -in period and has met the study  drug 
compliance cri teria (75% to 125%) as assessed using the digital co mpliance techno logy. As 
an except ion, subjects who are in a resident ial setting that incorporates direct ly observed 
medicat ion administration who meet this criterion (but not via the digital com pliance 
techno logy) may be eligible for randomizat ion with site documentati on and approval o f the 
sponsor or designee.
NOTE: Before enrollment into the single -blind run- in period, the site must confirm that 
approval  has been received from th e study  sponsor or designee, and from the central 
eligibilit y vendor. The sponsor or designee approval will also serve as approval o f subject 
rando mizat ion provi ded that the subject meets the specified rando mizat ion criteria at the 
baseline visit.
7.4 Excluded/Allowed Medications , Procedures, and Treatments
Subjects m ust be instructed not to take any  medicati ons, including over- the-counter products, 
without fi rst consul ting wi th the investi gator.
Subjects who require treatment with one or more of the sp ecified medicat ions should be 
excluded or discontinued (as appropriate) fro m the study . If a subject is prescribed treatment 
with a prohibi ted m edicat ion during the conduct of the study , the invest igator should contact [CONTACT_888075] m edicati on treatm ent to 
determine subject disposit ion.
Excluded agents (prescript ion or nonprescription) or dietary  products are listed in  Table 7.a. 
Items with an ‘X’ indicate restrict ions on either chronic or epi[INVESTIGATOR_81532]. Drug classes wit hout an 
‘X’ in these co lumns indicate no restrictions. This table enco mpasses the most commonly used 
medicat ions; however, it is no t a com prehensive list. Addit ional detailed guidance on 
TAK -831
Study No. TAK -831-2002 Page 44of 111
Protocol Incorporating Amendment No. 04 08 June 2020
CONFIDENTIALexcluded/allowed medicat ions m ay be provi ded in separate reference documentation provided to 
study  sites.
Table 7.a Excluded Medications and Dietary Products
Drug ClassDisallowed (X) During the Study
(sections without [X] indicate no restriction unless noted in Comments )
Chronic Use Epi[INVESTIGATOR_882261] X X <60 days before screening or 5 half-lives –
whichever is longer
Narcotic analgesics X Epi[INVESTIGATOR_882262], must 
not be taken within 8 hours. of any study 
efficacy assessment.
Anorexiants (eg, phentermine, benzphetamine, 
phendimetrazine, methamphetamine, 
amphetamine, stimulants, sibutramine, Belviq 
(lorcaserin), Qsymia (phentermine/topi[INVESTIGATOR_052])X X Must be discontinued for ≥30 days prior to 
screening
Antiarrhythmics of 1C class, quinidine X X
Antibiotics X
Anticholinergics X X Exception: The maximum permitted dose of 
chronic anticholinergic treatment is 2 
mg/day benztropi[INVESTIGATOR_92652]; epi[INVESTIGATOR_888029] [IP_ADDRESS] .
Antithrombic agents and anticoagulants 
(excluding warfarin, which is excluded)X
Antidepressants (excluding tricyclic 
antidepressants, MAOIs, and reversible 
Inhibitors of MAO [RIMAs])X Tricyclic antidepressants, MAOIs, and 
RIMAs are excluded, and subjects taking 
them should not be considered for 
participation in the study, as their 
discontinuation could lead to symptom 
instability.
Chronic treatment with SSRIs, SNRIs, and 
other antidepressants no t listed above is 
permitted if they are prescribed at a stable 
dose for ≥2 months before screening and 
throughout study treatment.
Antihistamines X X Except nonsedating antihistamines including 
loratadine, desloratadine, cetirizine, 
levocetirizine, mizola stine, and 
fexofenadine, or country -specific equivalent. 
Note that antihistamines used for 
anticholinergic properties are addressed 
separately in the relevant section above.
Antihypertensives Clonidine NOT allowed.
Antipsoriatic agents X X Topi[INVESTIGATOR_276141].
TAK -831
Study No. TAK -831-2002 Page 45of 111
Protocol Incorporating Amendment No. 04 08 June 2020
CONFIDENTIALTable 7.a Excluded Medications and Dietary Products
Drug ClassDisallowed (X) During the Study
(sections without [X] indicate no restriction unless noted in Comments )
Chronic Use Epi[INVESTIGATOR_888030] X Clozapi[INVESTIGATOR_882264]; all other treatments 
must adhere to requirements outlined in the 
study  entry  criteria and Section  [IP_ADDRESS] .
Subjects being treated with low -dose 
clozapi[INVESTIGATOR_050] (up to 100 mg/day) for anxiety or 
insomnia before screening may be switched 
to a permitted medication during screening, 
as clinically appropria te, with sponsor or 
designee approval. 
Epi[INVESTIGATOR_81532]: As an exception, occasional 
use of an additional epi[INVESTIGATOR_888031] (see 
Section [IP_ADDRESS] ). 
Herbal remedies, which are psychoactive (eg, St 
John’s wort, kava, valerian, ginkgo biloba, 
melatonin)X X Must be discontinued ≥7 days prior to 
Visit 2.
Sedative hypnotics Barbiturates are excluded. Chronic treatment 
with BZs is allowed up to 3 mg/day 
lorazepam or equivalent (BZ equivalence 
standards will be provided in a site reference 
document). Epi[INVESTIGATOR_888032] [IP_ADDRESS] . 
Note that hypnotics are excluded from the [ADDRESS_1242737] 
consistently demonstrated the ability to 
adhere to their insulin and dietary regimens 
for an extended period of time in addition to 
demonstrating stable control of type 2 
diabetes mellitus for an extended p eriod of 
time may be considered for enrollment after 
discussion with the sponsor/designee.
Lithium X X
Steroids: Systemic oral or injectable X X As an exception, treatment with local 
steroid injections for orthopedic conditions 
may be permitted with sponsor or designee 
approval.
Topi[INVESTIGATOR_882267] X X Must be discontinued for ≥30 days prior to 
screening.
BZ: benzodiazepi[INVESTIGATOR_050]; MAOI: monoamine oxidase inhibitor; RIMA: reversible inhibitor of monoamine oxidase type A, SSRI: 
selective serotonin reuptake inhibitor; SNRI: serotonin -norepi[INVESTIGATOR_26331].
TAK -[ADDRESS_1242738] from  the study or study drug 
shoul d be recorded in the electronic case report form (eCRF) using the fo llowing categori es. For 
screen failure subjects, refer to Section 9.1.20 .
1. Pretreatment event (PTE) or AE. The subject has experienced a PTE or AE tha t requi res 
early  terminat ion because continued participation imposes an unacceptable risk to the
subject’s health or the subject is unwilling to continue because of the PTE or AE.
Liver Funct ion Test (LFT) Abnormalit ies:
Study  drug shoul d be discont inued i mmediately with appropriate clinical fo llow-up 
(including repeat laboratory  tests, until a subject’s laboratory  profile has returned to 
norm al/baseline status), if any  of the fo llowing ci rcumstances occur at any  time during 
study  drug treatm ent:
–ALT or AST >8 × ULN, or
– ALT or AST >5 × ULN and persists for >2 weeks, or
–ALT or AST >3 × ULN in conjunct ion with elevated total  bilirubin >2 × ULN or 
internat ional norm alized rati o (INR) >1.5.
2.Important protocol deviat ion. The discovery  post -rando mizat ion that the subject failed to 
meet protocol entry  criteria or di d not adhere to protocol requirements, and continued 
participat ion poses an unacceptable risk to the subject’s healt h.
3.Lost to follow -up. The subject did not return to the study  site and mul tiple attem ptsto con tact 
the subject were unsuccessful. Attempts to contact [CONTACT_45316].
4.Withdrawal by [CONTACT_1130]. The subject (or subject’s legally acceptable representative) wishes to 
withdraw from  the study . The reason for withdrawal, if provided, sh ould be recorded in the 
eCRF.
Note: All attempts should be made to determine the underlying reason for the withdrawal 
and, where possible, the primary  underlying reason shoul d be recorded (i e, wi thdrawal  due to 
an AE should not be recorded in the “vo luntary withdrawal” category ). If a subject chooses 
to wi thdraw from  study  parti cipat ion due to personal concerns related to the COVID -19 
pandemic (other than a COVID -19-related AE), this should be specified as the reason for 
subject withdrawal in the eCRF.
5.Study terminat ion. The sponsor, IRB/IEC, or regulatory  agency  terminates the study .
TAK -[ADDRESS_1242739] is found to be pregnant.
Note: If the subject is found to be pregnant, the subject must be withdrawn immediately. The 
procedure is described in Sect ion  9.1.[ADDRESS_1242740].
8.Noncom pliance wi th study  drug during the double -blind treatment period. Noncompliance 
with study  drug includes subjects who are <75% compliant between visits, as assessed via 
the digital co mpliance techno logy. As an except ion, thi s criterion may  be assessed via site -
recorded com pliance documentation for subjects who are in a resident ial setting that 
incorporates direct ly observed medicat ion administrati on wi th approval  of the sponsor or 
designee, as described for the placebo run -in period in Sect ion  7.3. If these criteria for 
nonco mpliance are met on more than [ADDRESS_1242741]’s continuat ion in the study  with the sponsor or designee. Based upon the assessment 
of the invest igator and sponsor or designee, an out -of-compliance subject m ay be wi thdrawn 
from the study .
9.Throughout the study , signs of suicidal risk will be assessed by C -SSRS and the 
investigator’s clinical judgment. If the subject has a significant risk of suicide according to 
the invest igator’s clinical judgment, the subject will be withdrawn fro m the study .
10.Symptom atic deteri oration: Any  subject from  the study  who experiences a clinically 
significant psy choti c epi[INVESTIGATOR_1865], rel apse in posi tive symptom s, or overall worsening of illness 
that poses an unaccepta ble ri sk to the subject based on the judgment of the invest igator 
shoul d be discont inued fro m study  parti cipat ion, and the event documented as an AE.
11.Other: The reason for discontinuation should be entered into the eCRF including unavo idable 
circumstances such as the COVID -[ADDRESS_1242742]’s study participat ion at any  time during the study  
when the subject meets the study  terminati on cri teria described in Sect ion 7.6. In addit ion, a 
subject may discont inue his or her participat ion without giving a reason at any  time during the 
study . Shoul d a subject’s par ticipat ion be discont inued, the primary criterion for terminat ion 
must be recorded by  [CONTACT_3170]. In addit ion, efforts should be made to perform all 
procedures scheduled for the early termination visit.
8.[ADDRESS_1242743] ioncontains informat ion regarding all medicat ions and materials provided directly by  
[CONTACT_456], and/or sourced by  [CONTACT_39785] m eans, that are required by  [CONTACT_23643] , including 
important sections describing the management of study  material.
TAK -831
Study No. TAK -831-2002 Page 48of 111
Protocol Incorporating Amendment No. 04 08 June 2020
CONFIDENTIAL8.1 Study Drug and Materials
8.1.1 Dosage Form, Manufacturing, Packaging, and Labeling
[IP_ADDRESS] Study Drug (TAK -831 and Matching Placebo Tablets)
TAK -[ADDRESS_1242744] acebo tablet s will be bottled in a 60 -count round high -
densit y polyethylene bottl e with a child -resistant cap.
[IP_ADDRESS] Companion Medication
Subjects m ust be on a stable ongoing oral or depot maintenance ant ipsychoti c (other than 
clozapi[INVESTIGATOR_050]) m onotherapy  regimen and on stable on going treatment with any nonprohibited 
concomitant psy chotropi c medicati ons f or ≥[ADDRESS_1242745] igators. Subjects may also be treated with other 
nonprohibited psycho tropi c medicat ions including ant idepressants, anxio lytics, and hypnotics 
with a stable treatm ent regimen for ≥2 months prior to the single -blind placebo run -in visit and 
throughout study  partici pation up to the Day  84/early  terminati on visi t.
All efforts s hould be made to m aintain background nonprohibited psychotropic medications at 
consistent doses throughout the double -blind treatment period . Allowable except ions to this rule 
include the fo llowing:
1.Primary background ant ipsychotic medicat ion: Minor adjust ments (no increase, ≤25% 
decrease) to manage drug -specific tolerabilit y issues with sponsor or designee approval if 
requi red to support the subject’s cont inued participation in the study. Recognizing that 
physicians outside of the study  may be m anaging the subject’s background antipsychotic and 
other psy chotropi c medicat ions, changes in background medicat ion dosing that exceed this 
limit should be discussed with the sponsor or designee to determine subject disposit ion. The 
evaluat ion will include assessment of whether the change in dosing poses a risk to clinical 
stabilit y of the subject’s condit ion as well as the potential for impact on subject safet y or the 
scientific object ives o f the study .
2.Other background psy chotropi c medicat ions: Mino r adjustments ( ≤25% increase or decrease) 
with sponsor or designee approval if required to support the subject’s cont inued participat ion 
in the study . Recognizing that phy sicians outsi de of the study  may be managing the subject’s 
background antipsychotic and other psy chotr opic medicat ions, changes in background 
medicat ion dosing that exceed this limit should be discussed with the sponsor or designee to 
determine subject disposit ion. The evaluation will include assessment of whether the change 
in dosing poses a risk to clini cal stabili ty of the subject’s condit ion as well as the potential for 
impact on subject safety  or the sci entific objectives of the study .
TAK -831
Study No. TAK -831-2002 Page 49of 111
Protocol Incorporating Amendment No. 04 08 June 2020
CONFIDENTIAL3.Concomitant treatment with a subtherapeutic dose of a second ant ipsychoti c may be 
permitted with sponsor or designee a pproval  if used as a hy pnoti c, but not if it is used for 
refractory  psychoti c symptom s. Under this except ion, if the total night ly dose of the second 
antipsychotic is ≤[ADDRESS_1242746] to be included in calculation of the 6 mg/day risperidone -
equivalent limit. If a subject is taking up to 200 mg quetiapi[INVESTIGATOR_888033] a hypnotic 
(the m aximum  allowed under this except ion), the dosage above [ADDRESS_1242747] be included in the calculat ion of the 6 m g/day  risperi done- equivalent limit.
4.Prohibited medicat ions that are used as hy pnoti cs or anxio lytics may be subst ituted with 
nonbenzodiazepi[INVESTIGATOR_82490] (eg, zolpi[INVESTIGATOR_610842] 10 mg/day, zaleplo n up to 20 mg/day , 
eszopi [INVESTIGATOR_217626] 3 mg/day, or zopi[INVESTIGATOR_323965] 7.5 m g/day ) within thei r respect ive reco mmended 
dose ranges.
[IP_ADDRESS] Rescue Medication
The gui delines below refer to use of medications that are not part of the subject’s routine 
ongoing background psy chotropi c com panion medication regimen.
1.Treatment of inso mnia as needed with benzodiazepi[INVESTIGATOR_888034] (eg, 
zolpi[INVESTIGATOR_610842] 10 mg/day, zaleplo n up to 20 mg/day , eszopi [INVESTIGATOR_217626] 3 m g/day , or 
zopi[INVESTIGATOR_11123] 7.5 m g/day ) is permi tted wi thin their respective rec ommended dose ranges.
2.Treatment of anxiet y or agi tation as needed with up to 2 mg/day lorazepam (or the equivalent 
dose of another benzodiazepi[INVESTIGATOR_050]) is permitted up to 3 times per week but cannot be taken 
within 8 hours of the administration of study  assessm ents.
3.Treatment of extrapy ramidal  motor sym ptoms as needed wi th up to 2 m g/day  benztropi[INVESTIGATOR_050] (or 
the equivalent dose of another anticho linergic) is permitted up to [ADDRESS_1242748] of care treatment, may  be permi tted wi th sponsor or designee 
approval .
[IP_ADDRESS] Sponsor -Supplied Drug
Sponsor -supplied drugs referenced in other section s of the protocol include the fo llowing :
TAK -831 10 m g T2 tabl ets.
TAK -831 25 m g T2 tabl ets.
TAK -831 100 m g T2 tabl ets.
Matching placebo tablets.
TAK -[ADDRESS_1242749] dose of study drug (placebo) will be 
administered to subjects by  [CONTACT_888076]’s designee in the clinic on Day -14 
(Visit 2) as subjects are familiarized wit h the compliance mo nitoring techno logy. Subjects will 
be instructed to take study  drug orally each morning during the remainder of this period.
For the double -blind treatm ent peri od, the fi rst dose of study  drug (TAK -831 or placebo) will be 
administered to subjects by  [CONTACT_888076]’s designee in the clinic on Day 1 
(Visit3) after com pletion the Day  1 study  procedures. Subj ects will also take study drug at the 
clinic on the morning of Day 28 (Visit 6). For all other dosing days during this period, subjects 
will be instructed to take study drug orally each morning. Note: While morning dosing is the 
preferred approach for subjects in this study , excep tions may  be granted wi th sponsor/desi gnee 
approval  based on individual subject contingencies and will not be considered protocol 
deviat ions.
Subjects should be advised to be consistent in the study  drug dosing time throughout the duration 
of the study .
The dose and tablet count that will be provided to each treatment group are described in 
Table 8.a.
Table 8.a Dose and Regimen
Treatment Group Dosage Treatment Description
Placebo Run -in Period Placebo QD 5 oral placebo tablets
A Placebo QD 5 oral placebo tablets
B TAK -831 50 mg QD 5 oral TAK -831 10 mg T2 tablets
C TAK -831 125 mg QD 5 oral TAK -831 25 mg T2 tablets
D TAK -831 500 mg QD 5 oral TAK -831 100 mg T2 tablets
QD: once daily.
8.1.[ADDRESS_1242750] according to the 
study  protocol .
TAK -831
Study No. TAK -831-2002 Page 51of 111
Protocol Incorporating Amendment No. 04 08 June 2020
CONFIDENTIALAll cases of overdose (with or without associated AEs) will be documented o n an Overdose page 
of the eCRF, in order to capture this important safety  information consistent ly in the database. 
Cases of overdose without manifested signs or symptoms are not considered AEs. AEs 
associ ated wi th an overdose will be documented on AE eCRF s according to Section 10.0.
Serious adverse events (SAEs) associated with overdose should be reported according to the 
procedure outlined in Sect ion 10.2.[ADDRESS_1242751]’s clinical status and addit ional clinical  monitoring shoul d be ini tiated.
8.[ADDRESS_1242752] identificat ion 
(ID) number (subject number) . The invest igator or designee will uti lize the IRT to init iate the 
Placebo Run -in treatment on Day -[ADDRESS_1242753] ID number assigned at screening. The m edicati on 
ID number of the study  drug to be dispensed will then be provided by  [CONTACT_6606]. If sponsor -
supplied drug (TAK -[ADDRESS_1242754] acebo) is l ost or damaged, the site can request a replacement from 
the IRT. (Refer to IRT m anual  provided separately).
At subsequent drug -dispensing visits, the invest igator or designee will again access IRT to 
request addit ional study  drug for the subject. The medicat ion ID number of the study  drug to be 
dispensed will be provided by  [CONTACT_6606].
On occasion, in unavoidable circumstances such as the COVID -[ADDRESS_1242755] the 
safet y of subjects, study  drug can be shipped directly  from study  sites to subj ects’ residences 
using the process known as Direct to Patient shipment. Addit ional drug supply may also be 
provi ded to subj ects (ei ther at an in -person visit or delivered to subject’s residence) to cover 
extended periods between on -site visi ts. Any  addi tional resupply  must be reviewed and approved 
in advance by  [CONTACT_36613]. 
8.3 Randomization Code Creation and Storage
All rando mizat ion informat ion will be stored in a secured area, accessible only by [CONTACT_85983].
The ra ndomizat ion will be stratified by [CONTACT_21406] (<35 and ≥35 years of age). The 
allocat ion rati o will be 2:2:2:[ADDRESS_1242756] not disclose the 
details o f study  drug (i e, placebo run -in) to subjects unt il the study has been co mpleted.
TAK -[ADDRESS_1242757] be recorded in the source documents and the same 
inform ation (except the time) must be recorded on the eCRF.
If any site personnel are unblinded during the double -blind treatment period, study  drug m ust be 
stopped immediately and the subject must be withdrawn fro m the study .
8.6 Accountability and Destruction of Sponsor- Supplied Drugs
Drug supplies will be counted an d reconciled at the site before being returned to the sponsor or 
designee. or before destruction at the site according to the site’s internal standard operating 
procedure (SOP).
The invest igator or designee must ensure that the sponsor -supplied drug is use d in accordance 
with the protocol  and is dispensed only to subjects enrolled in the study . To docum ent 
appropriate use of sponsor -supplied drug, the investigator or designee must maintain records of 
all sponsor -supplied drug delivery  to the si te, si te inve ntory, dispensat ion and use by [CONTACT_12072], and return to the sponsor or designee.
Upon recei pt of sponsor -supplied drug, the invest igator or designee must verify the contents of 
the shipments against the packing list. The verifier should ensure that the quant ity is correct, and 
the study  drug is in good condit ion. If quant ity and condi tions are acceptable, invest igator or 
designee should acknowledge the receipt of the shipment by  [CONTACT_117540]. If there are any  
discrepancies between the packing list ve rsus the actual  product received, [COMPANY_005] must be 
contact[CONTACT_45320]. The packing list should be filed in the investigator’s essent ial 
docum ent file.
The invest igator or designee must maintain 100% accountabilit y for all sponsor -supplied drugs 
received and dispensed during his or her entire participat ion in the study . Proper drug 
accountabilit y includes, but is not limit ed to the following:
Continuously mo nitoring expi[INVESTIGATOR_888035]. 
Frequent ly verifying that actual inventory  matches docum ented inventory .
Verifying that the log is completed with, at a minimum, the medication ID and lot number for 
each dose.
Verifying that all containers used are documented accurately on the log.
TAK -831
Study No. TAK -831-2002 Page 53of 111
Protocol Incorporating Amendment No. 04 08 June 2020
CONFIDENTIALVerifying that required fields are co mpleted accurately  and legibly .
If any dispensing errors or discrepancies are discovered, the sponsor must be notified 
immediately .
Current inventory  of all study  drug will  be recorded in the IRT. The following informat ion will 
be recorded at a minimum:
Protocol  number.
Subject ID number.
Nam e of investigator, site number.
Descript ion of sponsor -supplied drugs.
Date and am ount di spensed.
Date and am ount returned.
Nam e of the person making each IRT transact ion.
The IRT will include all required informat ion asa separate entry  for each subject to whom 
sponsor -supplied drug is dispensed.
All study  drug not returned to the site by a subject must be invest igated by [CONTACT_260228].
In the event of expi[INVESTIGATOR_888036], supplies m ay be 
relabeled wi th the new expi[INVESTIGATOR_57773]. In such cases, [COMPANY_005] or designee will prepare 
additional labels, certificates of analyses, and all necessary  docum entati on for com pletion of th e 
relabeling procedure at the sites.
At appropri ate intervals before site closure, a representative from the sponsor or designee will 
perform  clinical  study  material accountabili ty and reconciliat ion before clinical study  materials 
are returned to the spon sor or designee for destructio n. The investigator will retain a copy  of the 
docum entati on regarding clinical study  material accountabili ty, return, and/or destructi on, and 
originals will be sent to the sponsor or designee.
9.[ADDRESS_1242758] igator or site personnel 
whenever possible. The Schedule of Study  Procedures i s located in  Appendix A.
TAK -831
Study No. TAK -831-2002 Page 54of 111
Protocol Incorporating Amendment No. 04 08 June 2020
CONFIDENTIAL9.1.1 Alternative Approaches to Study Procedures and Data Collection Due to 
COVID -19 or Other Unavoidable Circumstances
In unavo idable circumstances (eg, a wi despread disease outbreak or natural disaster) that impact 
the study  site’s abili ty to conduct study  procedures according to the Schedule of Procedures 
(Appendix A), contingency measures may be implemented. In acknowledgement of study  site, 
hospi [INVESTIGATOR_307], local, state and nati onal restricti ons established in response to circumstances like 
COVID -19, the fo llowing m easures are being taken for the curr ent study :
For subjects impacted while in the double -blind peri od, all attempts should be made to 
perform  the assessments with the subject present at the site using the visit windows. 
Except ions may be granted for alternat ive approaches to study  procedures and data 
collect ion through approval by [CONTACT_36613]. Such instances must be 
docum ented in the study  records and m ay include the following:
– S ites must contact [CONTACT_888077] n approval for use of alternative approaches to study  
procedures and data collection due to COVID -19 or other unavoidable circumstances.
–Sites m ay seek approval  from the sponsor or designee to continue subjects in the 
study  despi [INVESTIGATOR_888037]. The principal invest igator 
is expected to evaluate the impact to the safet y of the study  parti cipants and site 
personnel for subjects to continue. In evaluat ing such requests, the sponsor or 
designee will give the highest priorit y to the safety and welfare of the subjects. 
Subjects m ust be willing and able to continue taking study  medicati on and remain 
compliant wi th the protocol . 
–Other than the final visit, alternative methods for conducting subject visits (eg, video 
conferencing, tele phone visits, or in -home study  visits conducted by  [CONTACT_888078], contingent upon local regulations) may be 
used per approval by  [CONTACT_858675]:
Under these circumstances, collect ion of certain study  assess ments may be 
omitted and visit windows may  be extended. 
When approval is given for a subject to miss an in -person study  visit, a study  site 
physician will speak directly wit h the subject by  [CONTACT_63195] (e.g. 
a com puter -based video communicat ion) during each visit window to assess 
subject safety  and overall clinical status. 
The study  site physician or other qualified site personnel should conduct the 
following assessments within specified -visit window timeframes: AE 
assessments, documentation of concomi tant m edicati on, administrati on of  
C-SSRS, and an assessment of clinical symptoms.
Other study  assessments may be co llected using an alternative method as feasible, 
and may  involve audio or video recording where allowed by  [CONTACT_211270]. In 
some cases, audio and/or video recording o f subject interviews may not be 
TAK -831
Study No. TAK -831-2002 Page 55of 111
Protocol Incorporating Amendment No. 04 08 June 2020
CONFIDENTIALpossible and thus will deviate from the planned rater monitoring plan. This will be 
docum ented in the study  records.
In some instances sites m ay need to split visits or sites may  only be able to 
perform  a few procedures on site and so me procedures may need to be performed 
remotely . Sites shoul d inform  sponsor or desi gnee when this occurs.
Sites m ay seek approval  to extend a visit window in order to conduct an on -site 
visit. Assessments that cannot be completed during the protocol -specified window 
or wi thin the visit window granted by  [CONTACT_743499]. 
There will be no interval lo nger than [ADDRESS_1242759].
–Study  site personnel  may dispense addit ional investigat ional medicinal product to 
subjects at a visit to allow for potentially lo nger intervals between visits than 
originally planned per protocol, or invest igational medicinal product may be supplied 
to subjects via delivery by  [CONTACT_888079].
–The final visit shoul d be performed in person. When it is not possible for the subject 
to com e to the study  site and the protocol  specified visit window c annot be extended 
further, the preferred alternat ive for the final visit is for qualified study  site personnel 
or desi gnated clinical personnel to go to the subject’s residence and conduct the 
protocol -specified procedures in that location. Assessments col lected at a subject’s 
residence shoul d com ply wi th applicable l ocal regul ations. If neit her option is 
available wit h sponsor or designee approval, sites may conduct final visit procedures 
remotely  as is f easible.
All subject discont inuat ions and alternat ive approaches to study  procedures (i e, procedures not 
conducted per the Schedule of Procedures) due to the COVID -[ADDRESS_1242760] be documented 
in the study  records as rel ated to COVID -19. Data collected using alternat ive methods m ay be 
handled different ly in the final data analyses. This will be documented in the 
statistical analysis 
plan(SAP) . 
9.1.[ADDRESS_1242761] Database Auth orization will be a component of the overall study  informed consent 
(see Section 9.1.3 ) in so me countries where this process is permitted by [CONTACT_5737] r egulat ions and 
ethics standards .
A unique subject ID number will be assigned to each subject at the time that informed consent is 
obtained/explained; this subject ID number will be used throughout the study.
In addit ion, as a requirement for entry  into this study , subjects are required to have an informant. 
Inform ants will  be requi red to si gn a separate Designated Study  Partner consent form.
When subjects have completed screening assessments prior to the study  under a generic 
screening consent form, the data from  this screening can be used in this study  for those subjects 
who were subsequent ly enrolled, as long as the screening procedures were performed wit hin the 
protocol -defined screening window.
9.1.[ADDRESS_1242762] identifiers on the registry  
website. An immediate report detailing matches is generated and should be printed for source 
docum entati on. The report will specify  either(1) no potential matches found, (2) a potential 
match was found with a subject participat ing in another study  within 30 days, and/or (3) the 
subject potentially matches wit h a subject who has prescreened/screened at another site. 
9.1.4 Demographics, Medical Hi story, and Medication History Procedure
Dem ographic informat ion to be obtained will include date of birth or age, sex, Hispanic ethnicit y 
([LOCATION_002] sites only), race as described by [CONTACT_423], education, work status, tobacco use, 
reproducti ve status , alcoho l consumpt ion, and caffeine consumpt ion of the subject at screening.
Medical and psychiatric history  to be obtained will include determining whether the subject has 
any significant condit ions or di seases rel evant to the condi tion/disease under stud y that stopped 
at or prior to informed consent, specifically  psychiatri c history , including number of previous 
hospi [INVESTIGATOR_36651] (lifet ime and in past y ear), durati on of  each hospi [INVESTIGATOR_3094] (in the past y ear), and 
date of init ial diagnosis of schizophrenia . Ongo ing medical or psy chiatri c condi tions are 
considered concurrent medical condit ions (see Section  9.1.9 ).
TAK -831
Study No. TAK -831-2002 Page 57of 111
Protocol Incorporating Amendment No. 04 08 June 2020
CONFIDENTIALMedicat ion history  informat ion to be obtained includes any medicat ion relevant to eligibilit y 
criteria stopped at or within 30 days prior to signing of informed consent.
9.1.5 Physical Examination Procedure
A baseline physical examinat ion (defined as the last assessment prior to first dose of study drug) 
will consist of the fo llowing body  systems: (1) eyes; (2) ears, nose, throat; (3) cardiovascular 
system; (4) respi[INVESTIGATOR_36517]; (5) gastrointest inal system; (6) dermatologic system; 
(7)extremit ies; (8) musculoskeletal system; (9) nervous system; ( 10)lymph nodes and 
(11) other.
All subsequent phy sical examinat ions shoul d assess clinically  significant changes from  baseline.
Any abnormal finding on a pretreatment physical examinat ion assessment must be assessed as 
not clinically significant or clinic ally significant by  [CONTACT_590027]. All clinically significant findings/changes will be recorded as a PTE or 
concurrent medical condit ion in the source document and on the appropriate eCRF as described 
in Sect ion 10.[ADDRESS_1242763]. For assessme nt of entry  criteria at screening, BMI 
shoul d be derived as follows:
Metri c: BMI = wei ght (kg)/height (m)2
Note that although height is reported in centimeters, the formula uses meters for height; meters 
can be determined fro m centimeters by [CONTACT_45322] 1 00. Thus, for example, if height=176 cm 
(1.76 meters) and weight=79.2 kg, then BMI=79.2/1.762=25.[ZIP_CODE] kg/m2.
The values should be reported to [ADDRESS_1242764] by [CONTACT_45323]. Thus, in the above example BMI 
woul d be reported as 25.6 kg/m2. If BMI is used as a study  entry  criterion, this determinat ion 
must be made after rounding.
9.1.7 Vital Sign Procedure
Vital signs will  include body  temperature, bl ood pressure (systolic and diastolic), and pulse 
(bpm ). Supi[INVESTIGATOR_888038], and pulse will be collected at a subset of study  visits as outlined in 
the Schedule of Study  Procedures (Appendix A). All other vital signs assessments will be 
collected in a sitting posit ion.
Body  temperature will be measured with an oral (temperature taken at floor of the mouth), 
tympanic, or infra -axillary  therm ometer. The same method (eg, oral, tympanic, or infra- axillary ) 
must be used for all subsequent measurements for each individual su bject and should be the 
same for all subjects.
TAK -[ADDRESS_1242765] 5 minutes prior to blood pressure and 
pulse measurements. The same method (eg, same size cuff, manual or automated) must be used 
for all measurements for each individual subject and should be the same for all subjects. It is also 
recommended that the same arm be used for all blo od pressure measurements for each individual 
subject.
Pulse shoul d be recorded separately and should not be derived from the E CG.
9.1.[ADDRESS_1242766]’s background antipsychotic medicat ion 
(which will be recorded on a specific ant ipsychotic medicat ion eCRF) as well as the other stable 
background medicat ions in the subject’s treatment regimen. At each study  visit, subjects will be
asked whether they  have taken any medicat ion other than the study  drug (used from signing of 
inform ed consent through the end of the study ), and all  medicat ions including vitamin 
supplements, over -the-counter m edicat ions, and oral herbal preparat ions, m ust be recorded in the 
eCRF.
9.1.[ADDRESS_1242767] igator. The condit ion (ie, diagnosis) should be described.
9.1.10 Efficacy Measurements 
All assessments will be performed per the Schedule of Study  Procedures (Appendix A). Clinical 
interviews will be video recorded for the MINI, PANSS, and BNSS and may  be recorded for 
other measures at the discret ion of the sponsor. The purpose of these recordings is to assess 
subject eligibilit y during the screening period and to provide feedback on interview technique 
and accuracy of rat ings to raters throughout the study for endpoint q uality assurance. To 
accommodate local cultural considerations in the schizophrenia populat ion with regard to vi deo 
recording versus audio recording, individual subject exceptions for video recording (record audio 
only instead) m ay be considered for sites that have al ready  dem onstrated hi gh-qualit y subject 
interviews and ratings. Except ions to proceed with only an audio recording will be made only 
after assessment of these factors, discussion o f the subject and clinical contingencies between the 
investigato r and the sponsor or designee, and receipt of documented approval fro m the sponsor 
or desi gnee. 
Note: i n unavo idable circumstances such as the COVID -19 pandemic, it may be necessary  to 
administer clinical interviews and assessments using alternat ive appro aches (please refer to 
Secti on  9.1.1 ). In some cases, audio/or video recording of subject interviews may not be possible
This will be documented in the study  records.
TAK -[ADDRESS_1242768] ic Interview. The results 
of these studi es showed that the MINI has acceptably  high validat ion and reliabilit y scores, but 
can be administered in a much shorter peri od of  time (m ean 18.7±11.6 minutes, median 
15minutes) than the above -referenced instruments [33-35] .
The assessment of the criterion for schizophrenia will be standardized using the MINI Version 
7.0.[ADDRESS_1242769] for inclusio n. Administration of the 
MINI will be video recorded (for exceptions, see Section 9.1.10 ) to facilitate review by [CONTACT_888080].
[IP_ADDRESS] PANSS
The PANSS is a reliable, validated comprehensive evaluat ion scale of the severit y of various 
symptoms of schizop hrenia and is co mmo nly employ ed in clinical studies involving 
antipsychotics [20,21 ]. The Structured Clinical Interview for the Posit ive and Negative 
Syndrome Scale (SCI -PANSS) m ust be used to support the rating of each item and in accordance 
with guidelines provi ded by  [CONTACT_456] (or desi gnee). The Informant Questionnaire for the 
Positive and Negat ive Syndro me Scale (IQ- PANSS) m ust be used to collect inform ation from 
the informant.
For all study  visit s, including the screening visit, administration of the PANSS will be recorded 
to facilitate review by [CONTACT_888081] (see Section  [IP_ADDRESS] ) and m ay be 
used for exploratory  analyses. Relevant data from  each recorded PANSS administration, 
including scores on each of the 30 PANSS Items, CGI scores for the visit, and supporting 
information (including corroborating informant data for the past week) may  be submi tted al ong 
with the recordi ng file to third party  clinicians. Addit ional instructi ons will  be provi ded during 
rater training and documented in the rater training manual.
The PA NSS total  score i s derived fro m the summati on of  each i tem. The total  time to administer 
the PANSS i s approximately [ADDRESS_1242770] suitable 
experience and training (as deemed by [CONTACT_36613]) to be eligible to rate subjects 
within the study .
[IP_ADDRESS] CGI-SCH Scale
The CGI -SCH scale is an adapted versio n of the CGI scale that is designed to assess global 
illness status in patients with schizophrenia [23]. The assessment consist of 2 subscales, the CGI -
TAK -831
Study No. TAK -831-2002 Page 60of 111
Protocol Incorporating Amendment No. 04 08 June 2020
CONFIDENTIALSCH- S and the CGI-SCH- I, which assess global severit y of illness and change in the clinical 
condi tion over time, respectively, on a 7 -point scale.
[IP_ADDRESS] BACS
The BACS is a cognit ion assessment battery  that assesses [ADDRESS_1242771] ion found 
to be consistent ly impa ired in schizophrenia: verbal memory , working m emory, motor speed, 
attenti on, execut ive funct ions, and verbal fluency [28]. It takes approximately 30 minutes to 
complete and is devised for easy  administrati on and scoring by [CONTACT_888082]. It is 
specifically designed to measure treatment -related improvements in cognit ion and includes 
alternate form s.
[IP_ADDRESS] BNSS
The BNSS i s a13- item instrum ent desi gned for use in clinical trials and other studies that 
measures 5 domains o f negat ive symptoms: blunted affect, alogia, asocialit y, anhedonia, and 
avolition [26]. Examinat ion of the correlat ions between other instruments supports the 
discriminant validit y (ie, low correlati ons wi th other instrum ents m easuring posi tive symptom s) 
and convergent validit y (ie, high correl ations wi th other instruments measuring negat ive 
symptoms). Similar to the procedures for the PANSS assessment noted in Sect ion  [IP_ADDRESS] , 
administration of the BNSS will be video recorded (for exceptions, see Section 9.1.10 ) for all 
study  visits including the screening visit to facilitate review by [CONTACT_888083].
[IP_ADDRESS] SCoRS
The SCoRS is an interview -based measure of cognit ive funct ioning that was developed to 
specifically assess aspects of cognit ive funct ioning found in each of the 7 cognit ive do mains 
assessed by  [CONTACT_888067] m easure for clinical trials of new medicat ions to 
improve cognit ion in schizophrenia [29]. The scale is intende d to incorporate informat ion 
obtained fro m an inform ant who bases his/her responses on interaction with and knowledge of 
the pati ent. The SCoRS includes 20 items focusing on cognit ive impairment and the degree to 
which it affects day -to-day functioning, as well as a gl obal functioning scale; at fo llow-up visits 
there is also a global scale reflecting change fro m the beginning of the subject’s treatment rated 
by [CONTACT_91519], the informant, and the subject.
[IP_ADDRESS] CDSS
The CDSS was developed to assess symptoms of major depressive disorder in patients with 
schizophrenia, and specifically  designed to assess comorbid depressive symptoms [ 36]. The 
CDSS consists of 9 items: depressed mood, hopelessness, self -deprecat ion, guilt y ideas of 
reference, pathological guilt, depressio n worse in the morning, early  wakening, sui cide, and 
observed depressio n. The items on the CDSS are all t ypi[INVESTIGATOR_888039]. The tool is administered via an 
interview wi th the subject.
TAK -831
Study No. TAK -831-2002 Page 61of 111
Protocol Incorporating Amendment No. 04 08 June 2020
CONFIDENTIAL9.1.10.8
 
 
 
 
 
 
 
 
 
[IP_ADDRESS]
 
 
[IP_ADDRESS]
 
 
 
 
 
 
 
[IP_ADDRESS].[ADDRESS_1242772]’s smartphone. The application will c ollect data from the 
smartphone fro m Day -14 through Day  84/early  terminat ion. These data will be collected during 
the typi[INVESTIGATOR_888040]’s part. 
The subject can at any  time choose to disco ntinue participat ing in the passive data collect ion 
assessments; in this case, the applicat ion will be deactivated or uninstalled. The data captured by 
[CONTACT_888084] a secure channel to a secure data storage site. All data 
captur ed by  [CONTACT_888085]. The data collected 

TAK -831
Study No. TAK -831-2002 Page 62of 111
Protocol Incorporating Amendment No. 04 08 June 2020
CONFIDENTIALfrom the smartphone will include the number and time of certain activit ies during phone use such 
as texts, emails, and phone calls (but not any  content from  these acti vities); keyboard input 
activit ies and gestures (without collect ing the specific keyboard characters); location informat ion 
(from the Global Posi tioning System  [GPS]); and mo vement and orientation (posit ion) of the 
smartphone. No absolute GPS data will be captured; GPS data will be measured relat ive to a 
rando m location, m asking the user’s true location. These data will be used to develop a digital 
phenoty pe of subjects with schizophrenia and will be analyzed for any  correl ations wit h clinical 
endpo ints. Th e data collect ion applicat ion does not collect informat ion on who or what phone 
numbers are called, nor similar informat ion from received calls. The data collect ion application 
does not capture the content of text messages that are sent or received. No per sonally ident ifiable 
inform ation is captured, and all other data is encrypted on the smartphone before transmissio n to 
the secure database.
[IP_ADDRESS].2 Optional Smartphone Visual/Audio/Electronic Clinical Assessments and Patient -
Reported Outcome Assessments
These asse ssments will co mbine act ive and passive data collect ion via the smartphone that is 
used for study  drug com pliance m onitoring. Act ive data collection assessments will include 
(1)standard schizophrenia symptom assessments and self -report questi onnai res admi nistered at 
regul ar intervals during the study , and (2) presentation of images from a standard set developed 
to elicit moderate emotional responses of posit ive valence (eg, duckling) or negative valence 
(eg,trash) and asking the subject to describe the im age in a few sentences. The subject’s facial 
expressio n, head posture, and properties o f speech are analyzed after each image presentation. 
Passive data collection will be conducted during use of the device’s co mpliance monitoring 
funct ion and will include (1) analyzing the subject’s facial expressio ns, head movements, and 
gestures, and (2) passive co llection of smartphone use and mo vement/l ocati on data, as described 
above.
9.1.11 Additional Safety Assessments
[IP_ADDRESS] Modified SAS
The SAS is a clinician -administered ratin g scale that has been widely  used to assess 
antipsychotic -induced parkinsonism in clinical practice and research settings [42]. The present 
study  uses a m odified 10 -item versio n of the SAS (for the screening and Day  1 assessment of 
eligibilit y) in which “Leg Pendulousness” and “Head Droppi[INVESTIGATOR_007]” items included in the original 
versio n have been replaced with “Head Rotation” and “Akathisia,” which has been used 
frequently in schizophrenia cl inical  trials [43]. Each item is rated using a 5 -point scale (0 -4); the 
modified SAS scores can range from 0 to 40.
[IP_ADDRESS] C-SSRS
The C -SSRS was developed by  [CONTACT_888086] y as a tool  to help 
system atically assess suicidal ideat ion and behavio r in subjects during participat ion in a clinical 
study  of centrally -acting drugs [32]. The C -SSRS is composed of [ADDRESS_1242773].
Two versions of the C- SSRS will be used in this study : the Screening/Baseline C -SSRS Lifet ime 
(assessing lifet ime and the past year separat ely) and the Since -Last-Visit C -SSRS.
9.1.12 Order of Psychiatric/Neurological Rating Scales/ Assessments
At screening, it is recommended to administer the BNSS first, fo llowed by [CONTACT_941] C -SSRS. These 
assessments should precede all other psy chiatri c and neurol ogical assessments at screening. After 
these assessments, the PANSS and then the MINI should be administered. At all other visits, the 
PANSS should take precedence over all other psychiatric assessments, and the BNSS should be 
administered after the PANSS. Therea fter, the order of assessments is not defined, except for the 
requi rement that the CGI -SCH- I and CGI -SCH- S are completed after complet ion of all other 
psychiatric assessments (with an except ion for the BACS, which does not contribute to the CGI 
assessments). Efforts should be made to perform the BACS cognit ion testi ng at approximately 
the sam e time of day  throughout the study  (postbaseline assessments must be administered 
±2hours fro m the time of baseline assessment administration).
9.1.13 PK Measurements
[IP_ADDRESS] PK Samp le Collection
Serial blood sam ples (one 4 m L sample per scheduled time po int) for measurement of TAK -831 
plasma concentrations will be collected into chilled Vacutainers containing the ant icoagulant 
dipotassi um ethylenediaminetetraacetic acid (K 2EDTA), acc ording to the Schedule of Study  
Procedures ( Appendix A).
The actual  date and time of each PK blood sample collect ion, time since last dose was 
administered, and time since last meal will be recorded on the source document and eCRF.
Instructi ons f or sam ple collect ion, processing, and shipment are provided in the laboratory  
manual.
[IP_ADDRESS] Bioanalytical Methods
Plasma concentrations o f TAK -831 will be measured by  a validated hi gh-performance liquid 
chromatography  (HPLC) wi th tandem  mass spectrom etry method.
[IP_ADDRESS] Population PK
PK will be assessed via populat ion PK analysis (see Section 13.1.4 ) .
9.1.14

TAK -831
Study No. TAK -831-2002 Page 64of 111
Protocol Incorporating Amendment No. 04 08 June 2020
CONFIDENTIAL 
 
[IP_ADDRESS]
 
 
 
 
 
 
 
 
 
 
 
[IP_ADDRESS]
 
[IP_ADDRESS]
 
9.1.15
 
 
 

TAK -831
Study No. TAK -831-2002 Page 65of 111
Protocol Incorporating Amendment No. 04 08 June 2020
CONFIDENTIAL 
 
 
[IP_ADDRESS]  
 
 
 
 
 
 
 
 
 
9.1.16 Procedures for Clinical Laboratory Samples
All samples will be co llected in accordance with acceptabl e laboratory  procedures. The 
maximum vo lume of blood at any  single visit i s approximately  39 mL (Visi t 3), and the 
approximate total vo lume of blood for the study  is 182 mL. Details of these procedures and 
requi red safety  monitoring will be given in the la boratory  manual.

TAK -831
Study No. TAK -831-2002 Page 66of 111
Protocol Incorporating Amendment No. 04 08 June 2020
CONFIDENTIALTable 9.a Approximate Blood Volume
SampleVolume
per
Sample
(mL)Number of Samples Per Subject
Total
Volume
(mL)Screening
(Days -28
to -15)Placebo
Run-in
(Day -14)Baseline
(Predose
Day 1) Day 28 Day 42 Day 56 Day 70 Day 84/ETSafety
Follow -up
(Days 94 to 98)
(Visit 1) (Visit 2) (Visit 3) (Visit 6) (Visit 7) (Visit 8) (Visit 9) (Visit 10) (Visit 11)
HBsAg, anti -HCV 4 1 4
Hb1Ac 2 1 2
Serum chemistry a6 1 1 1 1 1 1 b36
Hematology 2 1 1 1 1 1 1 c12
Antipsychotic 
medications e 4 1 1 1 1 16
PK (TAK -831) 4 1 2 1 1 1 24
PD ( D-and L-serine) 6 1 1 2 1 1 1 42
Total 182
Anti-HCV: antibody to hepatitis C virus; HBsAg: hepatitis B surface antigen; Hb1Ac: glycosylated hemoglobin; ET: early termination; PD: pharmacodynamics; : 
; PK: pharmacokinetics.
aIncludes serum pregnancy test at the screening and safety follow -up visits and follicle -stimulating hormone (FSH) test at screening.
bSerum chemistry tests will be performed at this visit only if clinically significant test results were reported at Day 8 4/ET. However, a serum pregnancy test must be performed for 
women of childbearing potential at this visit (blood sample volume will be reduced to 2 mL if other serum chemistry tests are not required).
cHematology will be performed at this visit only if clinically significant test results were reported at Day 84/ET.
eLevels may be retested at investigator’s reque st.

TAK -831
Study No. TAK -831-2002 Page 67of 111
Protocol Incorporating Amendment No. 04 08 June 2020
CONFIDENTIALThe tests that will be performed for each clinical laboratory sample are listed in Table 9.b. 
Table 9.b Clinical Laboratory Tests
Hematology Serum Chemistry Urinalysis
Hematocrit 
Hemoglobin 
RBC 
Mean cell volume 
Mean cell hemoglobin 
Mean cell hemoglobin concentration 
WBC with differential % and absolute
(neutrophils, lymphocytes, monocytes, 
eosinophils, basophils)
Platelets Sodium 
Potassium
Bicarbonate
Chloride
Calcium
Magnes ium
Phospho rus
Glucose 
Blood urea nitrogen 
Uric acid 
Total cholesterol
Triglycerides
High -density lipoprotein cholesterol
Low-density  lipoprotein cholesterol
Total protein 
Albumin 
Total bilirubin 
Direct bilirubin 
Alkaline phosphatase 
ALT 
AST 
GGT 
Creatine kinase 
Amylase 
Prolactin
Lactate dehydrogenase
Creatinine
Thyroid-stimulating hormoneSpecific gravity
pH 
Glucose 
Protein 
Occult blood 
Microscopic battery (WBC, 
RBC, epi[INVESTIGATOR_1663], casts) 
Other
Serum Urine
HbA1c
HBsAg and anti -HCV
hCG (for pregnancy) a
FSH b
Antipsychotic medications cDrug screen including: amphetamine, barbiturates, benzodiazepi[INVESTIGATOR_1651], 
cocaine, marijuana, methadone, methamphetamine, MDMA, opi[INVESTIGATOR_858] 
(including oxycodone) and phencyclidine
hCG (for pregnancy) a
ALT: alanine aminotransferase; anti -HCV: antibody to hepatitis C virus; AST: aspartate aminotransferase; FSH: 
follicle -stimulating hormone; GGT: -glutamyl transferase; HbA1c: glycosylated hemoglobin; HBsAg: hepatitis B 
surface antigen; MDMA: 3,4 -methy lenedioxy methamphetamine; hCG: human chorionic gonadotropin; RBC: red 
blood cells; WBC: white blood cells.
aWomen of childbearing potential only. Serum hCG test to be performed at the screening and safety follow -up 
visits, and urine hCG test to be performed a t all other scheduled time points. The hCG test can be repeated at any 
time at the investigator’s discretion.
bPostmenopausal females only. 
cFor all antipsychotics for which an assay is available at the central laboratory.
TAK -[ADDRESS_1242774] >3× ULN, follow -up laboratory tests (at a minimum, serum 
alkaline phosphatase, ALT, AST, total bilirubin, GGT, and INR) should be performed wit hin a 
maximum o f 7 day s and preferably within 48 to 72 hours after the abnormalit y was noted. (Refer 
to Section 7.6and Section 10.2.3 for the appropriate g uidance on reporti ng abnorm al LFTs.)
If ALT or AST remains elevated >3× ULN on these [ADDRESS_1242775] details, and possible 
alternat ive etio logies. The abnorm ality should be recorded as an AE (please refer to 
Secti on10.2.3 ). 
[IP_ADDRESS] Antipsychotic Plasma Levels
Experi ence wi th therapeut ic blood monitoring of ant ipsychotic medicat ions in clinical settings 
has demonstrated that a single ant ipsychotic plasma assessment may not be reliably 
representative of adherence to antipsychotic medications, so repeat testing may be warranted to 
confirm an init ial finding of a lower than adequate plasma level. 
Screening antipsychotic plasma levels that do not meet the criteria listed in the Ant ipsychotic 
Reference document should be repeated as soon as possible if, in the judgment of the 
investigator, the subject may  actually be adherent to their medicat ion regimen. Importantly, if the 
investigator’s init ial assessment results in a determinat ion that the subject is most likely not 
being adherent with their ant ipsychotic medicat ion regimen, the plasma level should not be 
repeated and the subject should be a screen failure. 
If it is uncertain whether the subject is being adherent with treatment, it is recommended that 
antipsychotic pl asma l evels be urgent ly co llected and sent to the central laboratory while the 
investigator collects addit ional inform ation. If the investigator subsequent ly determines that the 
subject is not adherent to their medicat ion regimen, the subject should be a s creen failure. 
It is important to note that Visit 2 should not be conducted before receipt of the ant ipsychoti c 
plasma l evel indicat ing an acceptable value (in addit ion to the sponsor or designee and 
centralized eligibilit y vendor approvals). The Ant ipsyc hotic Reference document should be 
consulted for addit ional guidance in the management and interpretation of ant ipsychotic plasma 
level assays.
9.1.17 Contraception and Pregnancy Avoidance Procedure
[IP_ADDRESS] Male Subjects and Their Female Partners
Male subjects are not re quired to use barrier contraception in this study .
TAK -[ADDRESS_1242776] 
dose of study  drug, female subjects of childbearing potential* wh o are sexually  active wi th a 
nonsterilized male partner** must use an acceptable effective method of contraception (fro m the 
list below). In addition, they  must be advised not to donate ova during this period.
[IP_ADDRESS] Definitions and Procedures for Contraception a nd Pregnancy Avoidance
The follow ing definitions apply for contraception and pregnancy avoidance procedures.
*A wo man is considered a woman of childbearing potential, ie, fertile, fo llowing m enarche and 
until becoming postmenopausal unless permanent ly sterile. Permanent sterilizat ion methods 
include hysterectomy and bilateral oophorectomy. A postmenopausal state is defined as no 
menses for 12 months wit hout an alternative medical cause. A high FSH level in the 
postm enopausal range (FSH >40 IU/L) may be used to confirm a postmenopausal state in 
younger wom en (eg, <45 years of age) or women who are not using hormonal contraception or 
horm onal replacement therapy . However, in the absence of 12 months o f amenorrhea, a single 
FSH m easurement is insufficient.
**Sterilized males should be at least [ADDRESS_1242777] had bilateral 
orchi dectomy .
The follow ing procedures apply for contraception and pregnancy avoidance.
1.In thi s study , where medicat ions and devices containing hormones are included, the only 
acceptable methods of contraception are as fo llows:
Nonhorm onal Methods:
–Intrauterine device.
–Bilateral tubal occlusio n.
–Vasectomized partner (provided that partner is the sole sexual partner of the study 
subject and that the vasectomized partner has received medical assessment of the 
surgi cal success).
–True sexual abstinence, only if this is in line wit h the preferred and usual lifest yle of 
the subj ect. True abstinence is defined as refraining from heterosexual intercourse 
during the ent ire peri od of  the study , from [ADDRESS_1242778] dose.
–Cervical cap (PLUS spermicidal cream or jelly) PLUS male condo m.
–Diaphrag m (PLUS spermicide cream or jelly) PLUS male condom.
Horm onal Methods:
–Combined (estrogen and progestogen) hormonal contraception associated with 
inhibit ion of ovulation initiated at least [ADDRESS_1242779] dose of study  drug 
TAK -831
Study No. TAK -831-2002 Page 70of 111
Protocol Incorporating Amendment No. 04 08 June 2020
CONFIDENTIALOR combined with a b arrier method (male condom, female condom or diaphragm) if 
for shorter durati on unt il she has been on contraceptive for 3 months. 
Oral.
Intravaginal (eg, ring). 
Transdermal. 
–Progestogen -only hormonal contracepti on associ ated wi th inhibit ion of ovulation 
initiated at least [ADDRESS_1242780] dose of study  drug OR combined with a 
barrier m ethod (m ale condom , female condo m or diaphragm) if shorter until she has 
been on con tracepti ve for 3 m onths. 
Progestogen -only hormonal contracepti on, where inhibit ion of ovulat ion is not the 
primary  mode of  action, PLUS condom with or without spermicide.
Oral. 
Injectable. 
Implantable.
2.Unacceptable methods of contraception are as follows:
Periodic abst inence (eg, calendar, ovulat ion, symptothermal, postovulat ion methods).
Spermicides only .
Withdrawal.
No m ethod at all.
Use of female and male condoms together.
Cap/di aphragm/sponge wi thout spermicide and wit hout condom .
3.Subjects will be provided with information on acceptable effective methods of contraception 
as part of the subject informed consent process and will be asked to sign a consent form 
stating that they  understand the requirements for avoidance of pregnancy and donati on of ova 
during the course of the study .
4.During the course of the study , regular urine hCG pregnancy tests will be performed only  for 
wom en of childbearing potential, and all female subjects will receive continued guidance 
with respect to the avoidance of preg nancy  as part of the study  procedures. Such guidance 
shoul d include a reminder of the fo llowing:
a)Contraceptive requirements of the study . 
b)Assessment of subject compliance through questions such as the fo llowing:
i. Have you used the contraception consistent ly and correctly  since the l ast visit ?
ii. Have y ou forgotten to use contraception since the last visit ?
TAK -831
Study No. TAK -831-2002 Page 71of 111
Protocol Incorporating Amendment No. 04 08 June 2020
CONFIDENTIALiii. Are y our menses l ate? (Even in wo men wit h irregular or infrequent menstrual cycles 
a pregnancy  test m ust be perform ed if the answer is “yes.”)
iv. Is there a ch ance y ou coul d be pregnant ?
5.In addit ion to a negative serum hCG pregnancy test at screening, female subjects of 
childbearing potential must also have confirmed menses in the mo nth before first dosing (no 
delayed menses). At the single- blind placebo run -in visit (Day  -14) and the 
baseline/randomization visit (Day  1), a negative urine hCG pregnancy  test m ust be 
established prior to the subject receiving any dose of study  drug.
9.1.[ADDRESS_1242781] is found to be pregnant during the study , she shoul d be wi thdrawn and any  
sponsor -supplied drug (TAK -[ADDRESS_1242782] acebo) should be immediately  discontinued. 
If the pregnancy  occurs during administration of active study  drug, eg, after Visit 3 
(baseline/rando mizat ion visit) or within [ADDRESS_1242783] received (blinded 
or unblinded, as applicable).
All pregnancies in subjects on acti ve study  drug will  be followed up to final outcome, using the 
pregnancy form. Pregnancies will remain blinded to the study  team . The outcom e, including any  
prem ature terminat ion, must be reported to the sponsor. An evaluat ion after the birth of the child 
will also be conducted.
9.1.[ADDRESS_1242784]’s ECG trace: heart rate, RR interval, PR 
interval , QT interval , QRS interval and QTc F. The central reader will interpret the ECG using 1 
of the fo llowing categori es: wi thin normal limits or abnormal. If interpreted as abnormal, the 
investigator will assess the findings as eit her abnormal clinically significant, or abnormal not 
clinically significant. The interpretation of the ECG will be recorded in the source documents 
and in the eCRF. ECG traces recorded on thermal paper will be photocopi[INVESTIGATOR_888041]. Requirements for the ECG equipment and procedure for 
collect ing and transferring informat ion to the central reader will be provided in the study 
reference manual.
TAK -[ADDRESS_1242785] igator should co mplete the eCRF. The IRT should 
be contact[CONTACT_39804] a notificat ion of screen failure.
The primary  reason for screen failure is recorded in the eCRF using the following categories:
PTE/AE.
Did not m eet incl usion criteria or di d meet exclusion criteria (specify  reason).
Important protocol deviat ion.
Lost to follow -up.
Voluntary  withdrawal (specify  reason).
Study  terminat ion.
Other (specify reason including unavo idable circumstances such as the COVID -19 
pandemic) .
Subject ID numbers assigned to subjects who fail screening should not be reused .
9.1.[ADDRESS_1242786] as a 
rando mizat ion failure in the IRT.
In addit ion, the primary  reason for randomizat ion failure will be recorded in the eCRF using the 
following categori es:
PTE/AE.
Did not m eet incl usion criteria or di d meet exclusion criteria (specify  reason).
Did not m eet study  drug compliance cri teria.
Important protocol deviat ion.
Lost to follow -up.
Voluntary  withdrawal (specify  reason).
Study  terminat ion.
Other (specify reason including unavo idable circumstances such as the COVID -19 
pandemic) .
TAK -[ADDRESS_1242787] ion of qualit y data f rom scales administered by  [CONTACT_216117], raters assi gned to this 
study  will be requi red to fulfill qualificati on and/or training requirements. The process for 
qualifying and training raters will be described in manuals provided by [CONTACT_888087]. Furthermore, the study  will include addi tional steps related to m onitoring 
the qualit y of rater activit y, which will be described in the manuals provided by [CONTACT_216119].
All raters will be required to successfully  fulfill  the f ull scope of rater training requirements for 
any scale they  will be administering prior to rating any subjects in this study . The si tes will be 
responsible for ensuring that they  have qualified raters who can conduct assessments in the study  
prior to enrollment of study  subjects.
The training materials and requirements may be adjusted or modified as needed throughout the 
course of the study .
[IP_ADDRESS] Rater Qualifications 
Each site will be required to ident ify and provide skilled raters who meet appropriate 
prespecified qualifications. [COMPANY_005] and/or designee will make the final decisio n regarding 
whether the site -assigned raters are acceptable to participate in the study .
[IP_ADDRESS] Submission of Experience Details
Raters will be required to complete and submit experience details and curriculum vitae (if 
applicable) to the rater vendor in a timely  manner. Once the rater’s experience level is re viewed 
and deemed adequate, then study -assigned raters will be approved to participate in the rater 
certification process.
[IP_ADDRESS] Rater Training and Qualification Program
Formal rater training and qualification will be conducted at the Invest igator’s Meeting and via 
web portals. For those raters who need to be trained outside of the Invest igator’s Meeting, the 
training will be conducted via web portals and/or on- site or rem ote training. Specific elements of 
the rater training and qualificat ion program  will be desc ribed further in the rater training and 
assessment vendor manuals.
Raters who receive an unacceptable rating will be required to complete addit ional training in 
conjunction with the [COMPANY_005] -designated rater training vendor.
[IP_ADDRESS] Site Changes to Rater Personnel D uring the Study
If a site rater changes during the course of the study , the newly  appointed rater m ust be approved 
by [CONTACT_888088] -related activit ies.
[IP_ADDRESS] Rater Monitoring
This study  will use electronic clinical outcome assessments (eCOAs) to capture questionnaire 
data. The data will be transmitted electronically  to a centralized database at the eCOA vendor. 
TAK -[ADDRESS_1242788]  that i s 
compliant wi th regulati ons f or electroni c records.
Appropriateness of the MINI, PANS S, and BNSS assessment administration and the scoring of 
responses will be mo nitored through video recordings (for except ions, see Section  9.1.10 ) and 
electroni c workbooks at predefined intervals (see Sections  [IP_ADDRESS] , [IP_ADDRESS] , and [IP_ADDRESS] ) 
located in the rati ngs vendor manual .
Addit ional scale data will be monitored for consistency and quali ty control  throughout the study . 
Further instructional act ivities or advisement will occur and may be requested for certain sites, if 
necessary .
BACS and SCoRS ratings may be reviewed by [CONTACT_888089] a 
frequency  determined by [CONTACT_456]. Copi[INVESTIGATOR_888042]’s data revi ew specialists for errors in scoring and administration. Errors 
will be noted by  [CONTACT_95137], and feedback delivered to raters so that corrected scores can b e 
entered into the study  database.
9.[ADDRESS_1242789] 
source records.
Noncom pliance wi th study  drug includes subjects who are <75% compliant between visits 
(including nonco mpliance as assessed via the digit al com pliance techno logy). If these cri teria for 
nonco mpliance are met on more than [ADDRESS_1242790]’s 
continuat ion in the study  with the sponsor (or designee). Based upon the assessment of the 
investigator and sponsor (or designee), an out -of-compliance subject m ay be wi thdrawn from  the 
study . As an excepti on, subjects who are living in a resident ial setting that incorporates direct ly 
observed medicat ion administration demo nstrate ≥75% compliance (but not via the digital 
compliance techno logy) may be considered to be within these compliance requirements with 
study  site docum entati on and approval  of the sponsor or designee.
9.3 Schedule of Observations and Procedures
The Schedule o f Study  Procedures i s provi ded in Appendix A. Assessments should be completed 
at the desi gnated visit/time po int(s).
TAK -[ADDRESS_1242791]’s part icipation in the study. 
Since suitable subjects for this study  will be symptom atically stable and on a stable ant ipsychotic 
treatm ent regimen, i t is recogni zed that they  will be under the care of the invest igator or another 
treating physician before entry  into the study  and during study  conduct. The subject should be 
returned to the care of a physician and standard therapi[INVESTIGATOR_888043].
9.4 Biological Sample Retention and Destruction 
In thi s study , specimens for genome/gene analysis will be co llected as described in 
Secti on9.1.[ADDRESS_1242792] the subjects’ personal informat ion to ensure optimal 
confident iality and defined standard processes for sample and data collect ion, storage, analysis, 
and destruction.
The sponsor and researchers working with the sponsor will have access to the samples collected 
and any  test resul ts. All  samples collected during the study  will be stored secure ly wit h limited 
access and the sponsor will require anyo ne who works with the samples to agree to hold the 
research informat ion and any results in confidence.
The sample will be labeled with a unique sample ident ifier similar to labeling in the main study 
but using a code that is different fro m the code attached to the healt h informat ion and other 
clinical test results collected in the study . The sampl e and data are linked to personal health 
inform ation with code numbers. This link means that the subject ma y be identified but only  
indirect ly. The code numbers will be kept secure by [CONTACT_82298].
 
. Notify sponsor of consent 
withdrawal .
10.[ADDRESS_1242793] who has 
signed inform ed consent to participate in a study  but pri or to administration of any study  drug; i t 
does not necessarily  have to have a causal relat ionship wit h study  parti cipat ion. Placebo 
administered during the single -blind placebo run -in period is not considered study drug for this 
definit ion.

TAK -[ADDRESS_1242794] 
administered a drug; it does not necessarily have to have a causal relat ionship with this 
treatm ent.
An AE can therefore be any unfavorable and unint ended sign (eg, a clinically significant 
abnorm al laboratory  value), symptom, or disease temporally  associated wi th the use of a drug 
whether or not it is considered related to the drug.
10.1.[ADDRESS_1242795] finding generally may:
Indicate a new diagnosis or unexpected worsening of a pre -exist ing condit ion. (Intermittent 
events for pre -exist ing condit ions or underlying disease should not be considered PTEs or 
AEs.)
Necessitate therapeutic intervent ion.
Requi re an invasive diagnostic procedure.
Require discont inuat ion or a change in dose of study  drug or a concomitant medicat ion.
Be considered unfavorable by [CONTACT_4168].
PTEs/AEs caused by a study  procedure (eg, a bruise after blood draw) should be recorded as 
a PTE/AE.
Diagnoses versus signs and symptoms:
Each event should be recorded to represent a single diagnosis. Acco mpanying signs 
(including abnormal laboratory  values or ECG findings) or symptoms should NOT be 
recorded as additional AEs. If a diagnosis is unknown, sign(s) or symptom(s) should be 
recorded appropriately as a PTE(s) or AE(s).
Laboratory  values and ECG findings:
Changes in laboratory  values or ECG findings are only  considered to be PTEs or AEs if they 
are judged to be clinically significant (ie, if some action or intervent ion is required or if the 
investigator judges the change to be bey ond the range of normal physio logic fluctuati on). A 
laboratory  or ECG retest and/or continued monitoring of an abnormal value or finding are not 
considered an intervention. In addi tion, repeated or addi tional noninvasive testing for 
verification, evaluat ion, or m onitoring of an abnormalit y is not consi dered an intervent ion.
If abnorm al laboratory  values or ECG findings are the result of pathology  for which there is 
an overall diagno sis (eg, increased creatinine in renal failure), the diagnosis only should be 
reported appropriately  as a PTE or AE.
TAK -[ADDRESS_1242796] ing condit ions:
Pre-exist ing condit ions (present at the time o f signing of informed consent) are considered 
concurrent medical con ditions and shoul d NOT be recorded as PTEs or AEs. Baseline 
evaluat ions (eg, l aboratory  tests, ECG, X -rays) should NOT be recorded as PTEs unless 
related to study  procedures. However, if the subject experiences a worsening or complication 
of such a concurr ent medical condit ion, the worsening or complicat ion should be recorded 
appropriately  as a PTE (worsening or complicat ion occurs before start of study  drug) or an 
AE (worsening or complicat ion occurs after start of study  drug). Investi gators shoul d ensure 
that the event term recorded captures the change in the condit ion (eg, “worsening of…”).
If a subject has a pre -exist ing epi[INVESTIGATOR_39747] (eg, asthma, epi[INVESTIGATOR_002]), 
any occurrence of an epi[INVESTIGATOR_45284] a PTE or AE if th e condi tion 
beco mes more frequent, seri ous, or severe in nature. Invest igators should ensure that the AE 
term recorded captures the change in the condit ion fro m baseline (eg, “worsening of…”).
If a subject has a degenerat ive concurrent medical condit ion (eg, cataracts, rheumatoid 
arthri tis), worsening of the condition should only  be recorded as a PTE or AE if occurring to 
a greater extent to that which would be expected. Investigators should ensure that the AE 
term recorded captures the change in the condit ion (eg, “worsening of…”).
Worsening of PTEs or AEs:
If the subject experiences a worsening or complication of a PTE after the start of study  drug, 
the worsening or complication should be recorded as an AE. Invest igators should ensure that 
the AE term reco rded captures the change in the PTE (eg, “worsening of…”).
If the subject experiences a worsening or complication of an AE after the first administration 
of study  drug or any change in study  drug, the worsening or complicat ion shoul d be recorded 
as a new A E. Investi gators shoul d ensure that the AE term recorded captures the change in 
the condi tion (eg, “worsening of…”).
Changes in severit y of AEs/seri ous PTEs:
If the subject experiences changes in intensit y of an AE/seri ous PTE, the event should be 
captured once with the maximum severit y recorded.
Prepl anned procedures (surgeries or intervent ions):
Prepl anned procedures (surgeries or therapi[INVESTIGATOR_014]) that were scheduled prior to signing of 
inform ed consent are not considered PTEs or AEs. However, if a preplanned p rocedure is 
perform ed early  (eg, as an emergency) due to a worsening of the pre -exist ing condit ion, the 
worsening of the condit ion shoul d be recorded as a PTE or AE. Complicat ions result ing from 
any planned surgery  shoul d be reported as AEs.
TAK -[ADDRESS_1242797] ive surge ries or procedures:
Elect ive procedures performed where there is no change in the subject’s medical condit ion 
shoul d not be recorded as PTEs or AEs, but should be documented in the subject’s source 
docum ents. Com plicat ions result ing from an elect ive surger y shoul d be reported as AEs.
Insufficient clinical response (lack of efficacy):
Insufficient clinical response, efficacy, or pharmacologic act ion, should NOT be recorded as 
an AE. The invest igator must make the dist inction between exacerbation o f pre-exist ing 
illness and lack of therapeut ic efficacy.
Overdose:
Cases of overdose with any  medicati on wi thout m anifested si de effects are NOT considered 
PTEs or AEs, but instead will be documented on an Overdose page of the eCRF. Any 
manifested side effects will be considered PTEs or AEs and will be recorded on the AE page 
of the eCRF.
10.1.[ADDRESS_1242798] medical occurrence that at any  dose:
1.Results in DEATH.
2.Is LIFE THREATENING.
The term  “life threatening” refers to an event in which the subject was at risk of death at 
the time o f the event; it does not refer to an event that hypothetically  might have caused 
death if it were more severe.
3.Requi res inpat ient HOSPI[INVESTIGATOR_39749].
4.Results in persistent or signi ficant DISABILITY/INCAPACITY.
5.Is a CONGENITAL ANOMALY/BIRTH DEFECT.
6.Is an IMPORTANT MEDICAL EVENT that satisfies any of the fo llowing:
May require intervent ion to prevent items 1 through 5 above.
May expose the subject to danger, even though the event is n ot immediately life 
threatening or fatal or does not result in hospi[INVESTIGATOR_059].
Includes any event or synonym described in the [COMPANY_005] Medically  Significant AE List 
(Table 10.a).
TAK -831
Study No. TAK -831-2002 Page 79of 111
Protocol Incorporating Amendment No. 04 08 June 2020
CONFIDENTIALTable 10.a [COMPANY_005] Medically Significant AEs
Term
Acute respi[INVESTIGATOR_1399]/acute respi[INVESTIGATOR_39750]/ventricular fibrillation / 
ventricular tachycardiaAcute liver failure
Anaphy lactic shock
Malignant hypertension Acute renal failure
Convulsive seizure Pulmonary hypertension
Agranulocytosis Pulmonary fibrosis 
Aplastic anemia Confirmed or suspected endotoxin shock
Toxic epi[INVESTIGATOR_194]/Stevens -Johnson 
syndromeConfirmed or suspected transmission of infectious agent by a 
medicinal product
COVID -19-related disease Neuroleptic malignant syndrome/malignant hyperthermia
COVID -19 pneumonia Spontaneous abortion/stillbirth and fetal death
AE: adverse event; COVID -19: coronavirus disease 2019 ; SAE: serious adverse event.
Terms identified on the Medically Significant AE List represent the broad medical concepts to be considered as 
“Important Medical Events” satisfying SAE re porting requirements.
AEs that fulfill 1 or more of the serious criteria above are also to be considered SAEs and should 
be reported and fo llowed up in the same manner (see Sections  10.2.2 and 10.3).
10.1.[ADDRESS_1242799] been ident ified for TAK -831.
10.1.6 Intensity of PTEs and AEs
The different categories o f intensit y (severit y) are characteri zed as follows:
Mild: The event is transient and easily tolerated by [CONTACT_423]. The event does not generally interfere 
with usual activities of daily living.
Modera te: An AE that is usually alleviated with additional specific therapeutic intervention. The event 
interferes with usual activities of daily living, causing discomfort but poses no significant or 
permanent risk of harm to the research participant.
Severe: An AE that interrupts usual activities of daily living, or significantly affects clinical status, or 
may require intensive therapeutic intervention.
TAK -831
Study No. TAK -831-2002 Page 80of 111
Protocol Incorporating Amendment No. 04 08 June 2020
CONFIDENTIAL10.1.7 Assigning Causality of AEs
The rel ationship of each AE to study  drug(s) will be assessed using the fo llowing categori es:
Related: An AE that follows a reasonable temporal sequence from administration of a drug (including 
the course after withdrawal of the drug), or for which possible involvement of the drug cannot 
be ruled out, although factors other than the drug, such as underlying diseases, complications, 
concomitant medications, and concurrent treatments, may also be responsible.
Not Related: An AE that does not follow a reasonable temporal sequence from administration of a drug 
and/o r that can reasonably be explained by [CONTACT_1604], such as underlying diseases, 
complications, concomitant medications, and concurrent treatments.
10.1.8 Relationship to Study Procedures
Relationship (causalit y) to study  procedures should be determined for all AEs.
The rel ationship shoul d be assessed as Related if the invest igator considers that there is 
reasonable possibilit y that an event i s due to a study  procedure. Otherwise, the relat ionship 
shoul d be assessed as Not Related.
10.1.9 Start Date
The start date of the AE/PTE is the date that the first signs/symptoms were noted by  [CONTACT_14426]/or invest igator.
10.1.10 Stop Date 
The stop date of the AE/PTE is the date at which the subject recovered, the event resolved but 
with sequelae, or the subject died.
10.1.11 Frequency 
Epi[INVESTIGATOR_39751] c AEs/PTEs (eg, vom iting) or those which occur repeatedly  over a peri od of  consecutive 
days are intermittent. All other events are continuous or once.
10.1.12 Action Concerning Study Drug
Drug withdrawn –a study  drug i s stopped due to the particular AE.
Dose not changed –the particular AE did not require stoppi[INVESTIGATOR_007] a study drug.
Unknown –only to be used if it has not been possible to determine what action has been 
taken.
Not Applicable –a study  drug was stopped for a reason other than the particular AE, eg, the 
study  has been terminated, the subject died, dosing with study  drug was al ready stopped 
before the onset of the AE.
Dose Interrupted –the dose was interrupted due to the particular AE.
TAK -831
Study No. TAK -831-2002 Page 81of 111
Protocol Incorporating Amendment No. 04 08 June 2020
CONFIDENTIAL10.1.13 Outcome
Recovered/reso lved –subject returned to first assessment status with respect to the AE/PTE.
Recovering/resolving –the intensit y is lowered by  1 or m ore stages; the diagnosis or 
signs/symptom s have alm ost disappeared; the abnormal laboratory  value improved, but has 
not returned to the normal range or baseline; the subject died fro m a cause other than the 
particular AE/PTE with the condit ion rem aining “recovering/reso lving”.
Not recovered/not resolved –there is no change in the diagnosis, signs, or symptoms; the 
intensity of the di agnosis, signs/symptoms, or laboratory  value on the last day of the 
observed study  period has got worse than when it started; is an irreversible congenital 
anomaly; the subject died fro m another cause with the particular AE/PTE state remaining 
“not recovered/not resolved”.
Reso lved with sequelae –the subj ect recovered from an acute AE/PTE but was left with 
perm anent/si gnificant impairment (eg, recovered from a cardiovascular accident but with 
some persisting paresis).
Fatal  –the AEs/PTEs are considered as the cause of death.
Unknown –the course of the AE /PTE cannot be followed up due to hospi[INVESTIGATOR_1670]’s participation in the study .
10.2 Procedures
10.2.1 Collection and Reporting of AEs
[IP_ADDRESS] PTE and AE Collection Period
Collect ion of PTEs will commence from the time the subject signs the inform ed consent to 
participate in the study  and cont inue until the subject is first administered double -blind study  
drug (Day  1; Visit 3) or until screen failure. For subjects who discont inue prior to double -blind 
study  drug administrati on, PTE s are collected unt il the subject discontinues study  parti cipat ion.
Collect ion of AEs will co mmence fro m the time that the subject is first administered double -
blind study  drug (Day  1; Vi sit 3). Routine collecti on of  AEs will continue unt il the Safet y 
follow-up visit (between Days 94 and 98; Visit 11).
[IP_ADDRESS] PTE and AE Reporting
At each study  visit, the investi gator will assess whether any  subjective AEs have occurred. A 
neutral  quest ion, such as “How have you been feeling since your last visit ?” may be asked. 
Subjects m ay report AEs occurri ng at any  other time during the study . Subjects experi encing a 
SAE m ust be m onitored until  the symptoms subside and any  clinically rel evant changes in 
laboratory  values have returned to baseline or there is a sat isfactory  expla nation for the change. 
Nonserious AEs, related or unrelated to the study  procedure, need not be fo llowed-up for the 
purposes of the protocol.
TAK -[ADDRESS_1242800] returned to baseline or until there is a sat isfactory  explanat ion for the 
changes observed. All PTEs/ AEs will be documented in the AE page of the eCRF, whether or 
not the invest igator concludes that the event is related to the drug treatment. The fo llowing 
inform ation will be documented for each event:
1.Event term .
2.Start and stop date and time.
3.Pattern of AE (Frequency).
4.Intensit y.
5.Invest igator’s opi[INVESTIGATOR_3078] n of the causal relationship between the event and administration of 
study  drug(s) (rel ated or not rel ated) (not com pleted for PTEs).
6.Invest igator’s opi[INVESTIGATOR_3078] n of the causal relationship to study  procedure(s), including the details 
of the suspected procedure.
7.Action concerning study  drug (not com pleted for PTEs).
8.Outcom e of event.
9.Seriousness.
10.2.2 Collection and Reporting of SAEs
When an SAE occurs through the AE collection period it should be reported according to the 
following procedure:
A short descript ion of the event and the reason why the event is categorized as serious.
-Subject ID number.
-Invest igator’s name.
-Nam e of the study  drug(s).
-Causalit y assessment.
SAEs shoul d be reported vi a the SAE eCRF page in electronic data capture 
([EDC]/RAVE), which is the preferred m ethod of reporting SAEs.
If access to EDC/RAVE is not feasible wit hin 24 hours of receiving the event, the paper 
SAE forms should be submitted via fax (please see fax numbers below). 
–In case of fax, site personnel need to confirm successful transmissio n of all pages and 
include an email address on the fax cover sheet so that an acknowledgment of receipt 
can be returned via email wit hin 1 business day.
Email submissio n of SAE forms with a PDF attachment should only be used in the case 
where fax is not possi ble and EDC is not feasible within 24 hours of receiving the event. 
TAK -831
Study No. TAK -831-2002 Page 83of 111
Protocol Incorporating Amendment No. 04 08 June 2020
CONFIDENTIAL–In case of email, site personnel need to confirm successful transmissio n by [CONTACT_888090] 1 business day. 
If SAEs are reported via fax or by  [CONTACT_6968], EDC/RAVE must be updated as soon as 
possible with the appropriate information.
Fax Numbers: 
–[LOCATION_002] and Canada: +1 -224 554 -1052
–Rest of World: +1- 224 554 -1052
Email Addresses:
–[LOCATION_002] and Canada: PVSafet [EMAIL_13865] m
–Rest of World: [EMAIL_13866] .
Any SAE spontaneously  reported to the investigator following the AE collect ion peri od shoul d 
be reported to the sponsor if considered related to study  parti cipat ion.
10.2.[ADDRESS_1242801] elevated >3× ULN on [ADDRESS_1242802] >3 × ULN and total bilirubin >2 × ULN for which an 
alternat ive etio logy has not been i dentified, the event should be recorded as an SAE and reported 
as per Secti on 10.2.[ADDRESS_1242803] be completed and transmitted with the [COMPANY_005] SAE form (as per Section 
10.2.2 ).
10.[ADDRESS_1242804] report becomes available at a later date, the 
investigator should complete a fo llow-up entry  inthe EDC by [CONTACT_701006] a SAE eCRF per 
Secti on 10.2.2 immediately  or wi thin 24 hours of receipt. Follow up SAE forms (if EDC is 
unavailable) or other written documentation must be faxed immediately or within 24 hours of 
recei pt. Copi [INVESTIGATOR_726284] (eg, ECGs, laboratory  tests, di scharge 
summary, postmortem results) should be sent to the addressee, if requested.
All SAEs should be fo llowed up unt il reso lution or permanent outcome of the event. The 
timelines and procedure for fo llow-up reports are the same as those for the init ial report.
TAK -[ADDRESS_1242805] ions 
(S[LOCATION_003]Rs) and any othe r applicable SAEs to regulatory  authori ties, including the European 
Medicines Agency, invest igators, and IRBs or IECs, as applicable, in accordance wit h nat ional 
regul ations in the countries where the study  is conducted. Relat ive to the first awareness of the 
event by/or further provisio n to the sponsor or designee, S[LOCATION_003]Rs will be submitted to the 
regul atory  authori ties as expedited report within 7 days for fatal and life -threatening events and 
15days for other seri ous events, unless otherwise required by [CONTACT_57802]. The sponsor 
will also prepare an expedited report for other safety  issues where these might materially  alter 
the current benefit -risk assessment of a study  drug/sponsor -supplied drug or that would be 
sufficient to consider changes in the study  drug/sponsor -supplied drug administration or in the 
overall conduct of the trial. The study  site also will forward a copy  of all expedi ted reports to hi s 
or her IRB or IEC in accordance with local regulatio ns.
11.[ADDRESS_1242806] not been any safet y findings that indicate the need for an independent Data Monitoring 
Committee (DMC).
However, in addit ion to the ongoing review of blinded safet y data by  [CONTACT_87839] , the sponsor will establish an internal DMC that is independent 
of the study  and proj ect team s to peri odically  review unblinded safety  data during conduct of the 
study  to com plement the routine safet y monitoring approach for drugs at this stage of 
development. If there is an interim analysis for fut ility, this committee will also be engaged to 
review the interim analysis results and make recommendat ions per the interim analysis plan. The 
funct ions and procedures of the committee will be outlined in a DMC Charter prior to the first 
DMC review meet ing.
12.[ADDRESS_1242807] ionary for Regulatory  Activities (MedDRA). Drugs will be coded using the World 
Health Organizat ion Drug Dictionary .
12.[ADDRESS_1242808] ly onto 
eCRFs. 
After complet ion of the data entry  process, com puter l ogic checks will be run to iden tify items, 
such as inconsistent dates, missing data, and questionable values. Queries may  be issued by 
[CONTACT_769367] (or designees) and will be answered by [CONTACT_779].
Correcti ons to eCRFs are recorded in an audit trail that captures the old information, the new 
inform ation, identificat ion of the person making the correction, the date the correction was made, 
and the reason for change.
The principal invest igator must review the eCRFs for completeness and accuracy and must e -
sign the appropri ate eCRFs as i ndicated. Furthermore, the invest igator must retain full 
responsibilit y for the accuracy  and authent icity of all data entered on the eCRFs.
After the lock of  the study database, any  change of, m odificati on of , or addi tion to the data on 
the eCRFs should be made by [CONTACT_354138]. The principal invest igator must review the data change for completeness and accuracy, 
and must e -sign and date.
eCRFs will be reviewed for completeness and acceptabilit y atthe study  site during peri odic visi ts 
by [CONTACT_36613]. The sponsor or designee will be permitted to review the subject’s 
medical and hospi[INVESTIGATOR_45289]. The 
completed eCRFs are the sole prope rty of the sponsor and should not be made available in any 
form to thi rd parti es, except for authorized representatives o f appropri ate governmental healt h or 
regul atory  authori ties, wi thout wri tten permissio n of the sponsor.
12.[ADDRESS_1242809] igator agrees to keep the records stipulated in Section 12.1 and those documents that 
include (but are not limited to) the study -specific documents, the ident ificat ion log of all 
participat ing subjects, medical records, temporary media such as thermal sensit ive paper, source 
worksheets, all original signed and dated informed consent forms, subject authorizat ion forms 
regarding the use of personal healt h information (if separate from  the inform ed consent forms), 
copi[INVESTIGATOR_888044]/electroni c copy  of eCRFs, including the audit trail, 
and detailed records of drug disposit ion to enable evaluat ions or audits from regulatory  
authori ties or from the sponsor or designees. Any  source docum entati on printed on degradable 
thermal sensi tive paper should be photocopi[INVESTIGATOR_395484]’s chart to ensure long -term legibilit y. Furthermore, International Council for 
Harm onisat ion (ICH) E6 (R2) Section 4.9.[ADDRESS_1242810] igator to retain essent ial 
docum ents specified in ICH E6 (R2) (Section 8) unt il at least [ADDRESS_1242811] igation is discont inued and regulatory 
authori ties are notified. In addit ion, ICH E6 (R2) Section 4.9.5 states that the study  records 
TAK -831
Study No. TAK -831-2002 Page 86of 111
Protocol Incorporating Amendment No. 04 08 June 2020
CONFIDENTIALshoul d be retained unt il an amount of time specified by  [CONTACT_87841] 
a time specified in the study  site agreement between the investigator and sponsor.
Refer to the study  site agreement for the sponsor’s requirements on record retention. The 
investigator should contact [CONTACT_63228].
13.[ADDRESS_1242812] ical methods.
13.1.1 Analysis Sets
The Full Analysis Set (FAS) will include all subjects who were randomized and received at least 
1dose of the study  drug during the double -blind treatment period. In FAS summaries, subjects 
will be analyzed by [CONTACT_87842].
The Safet y Analysis Set will include all rando mized subjects who received at least [ADDRESS_1242813] 1 postdose PD (plasma D-serine and L-serine) measurement.
13.1.2 Analysis of Demographics and Other Baseline Characteristics
Demographics and other baseline characteristics including age, gender, race, BMI, and medical 
history  will be listed and summarized by  [CONTACT_888091].
Baseline values for efficacy  assessments will also be summarized by [CONTACT_22058] t group and overall 
based on the FAS.
13.1.3 Efficacy Analysis
[IP_ADDRESS] Analysis of Primary Efficacy Endpoint 
The primary  endpoint will be analyzed by [CONTACT_888056] -[ADDRESS_1242814] acebo over all assessed 
time points using estimates fro m a mixed model for repeated measures (MM RM) wi th baseline 
value as a covariate; pooled site, visit, treatment, and categorical age (randomizat ion factor) as 
TAK -831
Study No. TAK -831-2002 Page 87of 111
Protocol Incorporating Amendment No. 04 08 June 2020
CONFIDENTIALfixed factors; and treatment -by-visit and baseline -by-visit interactions. Based on a Mi ssing at 
Random Assumpt ion, this analysis will be pe rformed using observed case data only .The effect 
at each time po int for each treatm ent is allowed to vary  freely  and an unstructured covariance 
matri x is assumed. If the model does not converge, other covariance structures (unstructured, 
compound symmetry , 2-Toeplitz, etc) will be considered.
Addit ional analyses to address sensit ivity to missing data will be specified in the SAP.
Multiplicity will be controlled across dose -arms by [CONTACT_888057] 125 mg QD and 500 mg QD 
dose-arms in parallel using Ho lm’s method to control the overall t ype I error rate at the 0.10 
level (one -sided), then testing the [ADDRESS_1242815] acebo.
In order to provide addit ional insight about dose-response, the primary endpoint may be analyzed 
using a Mult iple Comparison Procedure -Modeling (MCP -Mod) approach. Addit ional details of 
the MCP -Mod analysis will be specified in the SAP.
Before unblinding the data, the team will assess the degree of impact from COVID -[ADDRESS_1242816] i s deemed minimal, which 
is defined as less than 5% of the enrolled subjects having remote or missing final assessments 
due to COVID -19, then the original analysis plan will be fo llowed. If there i s more than a 
minimal impact, then a more thorough blinded review will be performed. After the blinded 
assessment, if substant ial changes to the statist ical analyses a re needed to address the impact, the 
SAP will be amended before study  unblinding. Minor changes may  be docum ented in the clinical 
study  report .
[IP_ADDRESS] Analysis of Other Efficacy Endpoints 
Other change fro m baseline endpoints will be analyzed in the same manner as the primary 
endpo int, but without control for mult iple doses. 
The change from baseline on the CGI -SCH- S at Day 84, and the CGI-SCH- I score at Day  [ADDRESS_1242817] on an endpoint is deemed 
minimal, which is defined as less than 5% of the enro lled subjects having remote or missing final 
assessments due to COVID -19, then the original an alysis plan will be fo llowed. If there i s more 
than a minimal impact, then a more thorough blinded review will be performed. After the 
blinded assessment, if substantial changes to the statist ical analyses are needed to address the 
impact, the SAP will be amended before study  unblinding. Minor changes may  be docum ented in 
the clinical study  report.
TAK -[ADDRESS_1242818] and summarized by [CONTACT_888092] -831 treatm ent group. Of note, the sparse PK sampling approach in this study  
will not support generation of t ypi[INVESTIGATOR_307154].
Individual concentration -time data will be pooled to describe the populat ion PK of TAK -831. As 
data permit, a nonlinear mixed effects modeling approach (NONMEM software) will be used to 
assess TAK -[ADDRESS_1242819] asma 
concentrations and drug response ( D-or L-serine plasma levels and/or selected measures of 
efficacy) will be explored. As appropriate, h istorical data may be used in this analysis to increase 
the robustness of the model and precisio n of estimated parameters. Details o f the modeling 
approach will be provided in a separate analysis plan, and the results of these analyses will be 
reported separately.
13.1.[ADDRESS_1242820] regimens 
(TAK -831 doses and placebo) will be made and the CIs for the difference in the LS means will 
be constructed for sel ected time points. Addit ional details and further analyses will be specified 
in the SAP (also see Section 13.1.4 ).
 
 
13.1.6
 
 
 
 
13.1.7 Safety Analysis
[IP_ADDRESS] AEs
All AEs will be coded by  [CONTACT_2942] (SOC) and preferred term (PT) using MedDRA. 
TEAEs wi th onset occurring within 30 days (onset date –last date of dose +1≤30) after study  

TAK -831
Study No. TAK -831-2002 Page 89of 111
Protocol Incorporating Amendment No. 04 08 June 2020
CONFIDENTIALdrug administration will be included in the summary  tables. TEAEs will be summarized by [CONTACT_16430]. The fo llowing summary tables will be generated: summary  of TEAEs and drug- related 
TEAEs, relat ionship of TEAEs to study  drug (rel ated vs not rel ated), severi ty of TEAEs, and 
related TEAEs. Data list ings will be provided for all AEs, including TEAEs, TEAEs leading t o 
study  drug di scont inuat ion, and SAEs.
[IP_ADDRESS] Clinical Laboratory Evaluation
Individual result s of clinical laboratory  tests from  hematol ogy, chemistry , and urinalysis that 
meet [COMPANY_005]’s markedly abnormal criteria will be summarized and provided in the data list ings. 
baseline, postdose, and change fro m baseline to postdose laboratory  data will be summarized. All 
clinical laboratory  data will be provi ded in the data list ings.
[IP_ADDRESS] Vital Signs
Individual result s of vital signs that meet [COMPANY_005]’s markedly abnormal criter ia will be 
summarized and provided in the data list ings. Baseline, postdose, and changes from baseline in 
vital sign m easurements will be summarized. All vital sign data will be provided in the data 
listings.
[IP_ADDRESS] ECGs
Individual result s of quant itative ECG par ameters fro m the 12-lead safet y ECGs that m eet 
[COMPANY_005]’s markedly abnormal criteria will be summarized and provided in the data list ings. 
baseline, postdose, and changes fro m baseline in quant itative ECG parameters will be 
summarized. Shift tables will be generated to show the investigator’s ECG interpretations at each 
postdose collect ion by [CONTACT_888093]. All ECG data will be provided in the data 
listings.
[IP_ADDRESS] C-SSRS
C-SSRS will be summarized at all t ime points for each treatment group using de scriptive 
statist ics.
13.[ADDRESS_1242821] 85% of the [ADDRESS_1242822] 82% power 
for at least [ADDRESS_1242823] to review by [CONTACT_98634] (as long as blinding is not jeopardized), includ ing but not limited to the Investigator’s 
Binder, study  drug, subject m edical records, informed consent documentation, documentation of 
subject authorizat ion to use personal healt h information (if separate fro m the inform ed consent 
forms), and eCRFs and as sociated source documents. It is important that the investigator and 
other study  personnel are available during the monitoring visits and that sufficient time is 
devoted to the process.
14.[ADDRESS_1242824] to study  subjects. Should other unexpected circumstances arise that will 
requi re deviat ion from protocol -specified procedures, such as the COVID -19 pandemic , the 
investigator should consult with the sponsor or designee (and IRB or IEC, as required) to 
determine the appropriate course of action. There will be no exemptions (a prospectively 
approved deviat ion) fro m the inclusio n or excl usion cri teria.
The site should document all protocol deviat ions in the subject’s source documents. In th e event 
of an important protocol deviat ion, the si te shoul d notify the sponsor or designee (and IRB or 
IEC, as required). Important deviat ions include, but are not limited to, those that invo lve fraud or 
misconduct, increase the health risk to the subject, or confound interpretation of primary  study  
assessment. Important protocol deviat ions will be reviewed at regular intervals by [CONTACT_888094].
14.[ADDRESS_1242825] the si te in advance to arrange an 
auditing visit. The auditor may ask to visit the facilit ies where laboratory  samples are collected, 
where s tudy drug is stored and prepared, and any  other facili ty used during the study . In addi tion, 
there is the possibilit y that thi s study  may be inspected by  [CONTACT_888095], including those of 
foreign governments (eg, the Food and Drug Administration [FDA ], the Uni ted Kingdom  
TAK -831
Study No. TAK -831-2002 Page 91of 111
Protocol Incorporating Amendment No. 04 08 June 2020
CONFIDENTIALMedicines and Healt hcare Products Regulatory  Agency, the Pharmaceut icals and Medical 
Devices Agency o f Japan). If the study  site is contact[CONTACT_4190] a regulatory  body, 
the sponsor should be notified immediately. The inve stigator and study  sites guarantee access for 
qualit y assurance auditors to all study  documents as described in Section  14.1.
15.[ADDRESS_1242826] for the individual participants (ie, subjects) 
according to the protocol, the ethical principles that have their origin in the Declaration o f 
Helsinki, and the ICH Harmonised Tripart ite Guideline for GCP. Each investigator will conduct 
the study  according to applicable local or regional regulatory  requi rements and align his or her 
conduct in accordance with the “Responsibilit ies of the Invest igator” that are listed in 
Appendix B. The principles of Helsinki are addressed through the protocol and through 
appendices containing requirements for informed consent and invest igator responsibilit ies.
15.1 IRB and/or IEC Approval
IRBs and IECs must be constituted according to the applicable state and federal/local 
requi rements of each participating region. The sponsor or designee will require documentation 
noting all names and tit les of members who make up the respect ive IRB or IEC. If any member 
of the IRB or IEC has direct participat ion in this study , written notificat ion regarding his or her 
abstinence fro m voting must also be obtained. Those Americas sites unwilling to provide names 
and tit les of all members due to privacy  and con flict of interest concerns should instead provide a 
Federal Wide Assurance Number or comparable number assigned by [CONTACT_98649] h 
and Human Services.
The sponsor or designee will supply relevant documents for submissio n to the respective IRB or 
IEC for the protocol’s review and approval. This protocol, the Invest igator’s Brochure, a copy o f 
the informed consent form, and, if applicable, subject recruit ment materials and/or 
advert isements and other documents required by [CONTACT_231946], m ust be 
submitted to a central or local IRB or IEC for approval. The IRB’s or IEC’s written approval o f 
the protocol and subject informed consent must be obtained and submitted to the sponsor or 
designee before commencement of the study . The IRB o r IEC approval must refer to the study  
by [CONTACT_45343], number, and versio n date; ident ify versio ns of other documents (eg, 
inform ed consent form ) reviewed; and state the approval date. The sponsor or designee will ship 
drug/notify site once the sp onsor or desi gnee has confirmed the adequacy of site regulatory  
docum entati on.
Study  sites m ust adhere to all requirements st ipulated by [CONTACT_4195]. This may 
include notificat ion to the IRB or IEC regarding protocol amendments, updates to the informed 
consent form, recruit ment materials intended for viewing by  [CONTACT_1766], l ocal safety reporting 
requi rements, reports and updates regarding the ongoing review of the study  at intervals 
specified by [CONTACT_1767], and submissio n of the investigator’s final status report to 
IRB or IEC. All IRB and IEC approvals and relevant documentation for these items must be 
provi ded to the sponsor or designee.
TAK -[ADDRESS_1242827] authorizat ion form (if 
applicable), and subject informat ion sheet (if applicable) describe the planned and permitted 
uses, transfers, and disclo sures of the subject’s personal and personal healt h informat ion for 
purposes of conducting the study. The informed consent form and the subject informat ion sheet 
(if applicable) further explain the nature of the study , its obj ectives, and potential risks and 
benefits, as well as the date informed consent is given. The informed consent form will detail the 
requi rements of the participant and the fact that he or she is free to withdraw at any  time wi thout 
giving a reason and without prejudice to his or her further medical care.
The invest igator is responsible for the preparation, content, and IRB or IEC approval of the 
inform ed consent form  and if applicable, the subject authorization form. The informed consent 
form, subject authori zation form (if applicable), and subject informat ion sheet (if applicable) 
must be approved by [CONTACT_39821].
The informed consent form, subject authorizat ion form  (if applicable), and subject informat ion 
sheet (if applicable) must be written in a language fully comprehensible to the prospective 
subject. It is the responsibilit y of the invest igator to explain the detailed elements of the informed 
consent form, subject authorizat ion form (if applicable), and subject informat ion sheet (if 
applicable) to the subject. Informat ion shoul d be given in both oral and written form whenever 
possible and in the manner deemed appropriate by  [CONTACT_4186]. In the event the subject is not 
capable of rendering adequate written informed consent, then the subject’s l egally  acceptable 
representative may provide such consent for the subject in accordance with applicable laws and 
regul ations.
The subject, or the subject’s legally acceptable representative, must be given ample opportunity  
to: (1) inquire about details of the study  and (2) deci de whether or not to participate in the study . 
If the subject, or the subject’s legally acceptable representative, determines he or she will 
participate in the study , then the informed consent form and subject authorizat ion form (if 
applicable) must be signed and dated by  [CONTACT_423], or the subject’s legally  acceptable 
representative, at the time of consent and prior to the subject entering into the study . The subject 
or the subject’s legally acceptable representative should be instr ucted to sign using their legal 
names, not nicknames, using blue or black ballpo int ink. The invest igator must also sign and date 
the informed consent form and subject authorizat ion (if applicable) at the time of consent and 
prior to subject entering into the study; however, the sponsor may allow a designee o f the 
investigator to sign to the extent permitted by  [CONTACT_1289].
Once signed, the original informed consent form, subject authorization form (if applicable), and 
subject informat ion sheet (if appli cable) will  be stored in the invest igator’s site file. The 
investigator must document the date the subject signs the informed consent in the subject’s 
TAK -[ADDRESS_1242828] authorizat ion 
form (if app licable), and subject informat ion sheet (if applicable) shall be given to the subject.
All revised informed consent forms must be reviewed and signed by [CONTACT_39822]’s legally  acceptable representative in the same manner as the original informed 
consent. The date the revised consent was ob tained shoul d be recorded in the subject’s medical 
record, and the subject should receive a copy  of the revised informed consent form.
 
Investigator 
will n otify  sponsor of consent wi thdrawal .
15.[ADDRESS_1242829]’s right to protection 
against invasio n of privacy. Throughout this study , a subject’s source data will only be linked to 
the sponsor’s clinical trial database or documentation via a subject ID number. As permitted by 
[CONTACT_231946], limited subject attributes, such as sex, age, or date of birth, 
and subject init ials may be used to verify the subject and accuracy  of the subject’s unique ID 
number.
To com ply with ICH Gui delines for GCP and to verify compliance with this protoco l, the 
sponsor requires the investigator to permit the monitor or the sponsor’s designee, representatives 
from any regulatory  authori ty (eg, FDA, Medicines and Healt hcare products Regulatory  Agency, 
Pharmaceut icals and Medical Devices Agency), the sponsor’ s designated auditors, and the 
appropriate IRBs and IECs to review the subject’s original medical records (source data or 
docum ents), including, but not limited to, laboratory  test resul t reports, ECG reports, admissio n 
and discharge summaries for hospi[INVESTIGATOR_45291] a subject’s study  
participat ion, and autopsy  reports. Access to a subject’s original medical records requires the 
specific authorizat ion of the subject as part of the informed consent process (see Section 15.2).
Copi [INVESTIGATOR_39757] (ie, subject name, address, an d other i dentifier fields 
not collected on the subject’s eCRF).
15.[ADDRESS_1242830] igators or to regulatory  agencies, except as required by  
[CONTACT_4201]. Except as otherwise allowable in the study  site agreement, any  public 
disclosure (including publicly accessible websites) related to the protocol or study  resul ts, other 
than study  recrui tment m aterials and/or advertisements, is the sole responsibilit y of the sponsor.

TAK -831
Study No. TAK -831-2002 Page 94of 111
Protocol Incorporating Amendment No. 04 08 June 2020
CONFIDENTIALThe sponsor may publish any  data and informat ion fro m the study  (including data and 
inform ation generated by  [CONTACT_3170]) without the consent of the invest igator. Manuscript 
authorship for any  peer -reviewed publication will appropriately  reflect contribut ions to the 
producti on and review of the document. All publications and presentations must be prepared in 
accordance with this sect ion and the study  site agreem ent. In the event of any discrepancy 
between the protocol and the study  site agreement, the study  site agreement will prev ail. 
The invest igator needs to obtain a prior written approval from the sponsor to publish any 
inform ation from the study  externally such as to a professio nal associ ation. 
15.4.2 Clinical Trial Registration
In order to ensure that informat ion on clinical trials reaches the public in a timely manner and to 
comply with applicable laws, regulat ions and guidance, [COMPANY_005] will, at a minimum register all 
intervent ional clinical trials it sponsors anywhere in the world on ClinicalTrials.gov and/or other 
publicly  accessi ble websites before start of study , as defined in [COMPANY_005] Policy/Standard. [COMPANY_005] 
contact [CONTACT_4203], along wi th invest igator’s cit y, state (for Americas investigators), country , 
and recruit ing status will be registered and available for public viewing.
For some registries, [COMPANY_005] will assist callers in lo cating study  sites cl osest to thei r homes by 
[CONTACT_39824], address, and phone number to the callers request ing trial 
inform ation. Once subjects receive invest igator contact [CONTACT_4203], they may call  the si te 
requesting enrollment into the trial. The invest igative sites are encouraged to handle the trial 
inquiries according to their established subject screening process. If the caller asks addit ional 
questions bey ond the topic of trial en rollment, they should be referred to the sponsor. 
Any invest igator who objects to the sponsor providing this informat ion to callers must provide 
the sponsor with a written notice request ing that their informat ion not be listed on the registry  
site. 
15.4.[ADDRESS_1242831] the results of clinical trials on ClinicalTrials.gov and/or other publicly 
accessible websites, as required by [CONTACT_39825]/Standard, applicable laws, and/or regulat ions.
15.[ADDRESS_1242832] the risk o f injury to study  subjects. Refer to 
the study  site agreement regarding the sponsor’s policy  on subject com pensat ion and treatment 
for injury . If the invest igator has quest ions regarding this policy, he or she should contact [CONTACT_11154].
TAK -831
Study No. TAK -831-2002 Page 95of 111
Protocol Incorporating Amendment No. 04 08 June 2020
CONFIDENTIAL16.0 REFERE NCES
1. Verrall L, Burnet PW, Betts JF, Harrison PJ. The neurobio logy of D-amino acid oxidase 
and its invo lvement in schizophrenia. Mol Psychiatry  2010;15(2):122 -37.
2. Kakegawa W, Miyoshi Y, Hamase K, Matsuda S, Matsuda K, Kohda K, et al . D-serine 
regul ates cerebellar LTD and motor coordination through the delta2 glutamate receptor. 
Nat Neurosci 2011;14(5):603 -11.
3. Duffy S, Labrie V, Roder JC. D -serine augments NMDA -NR2B receptor -dependent 
hippocampal lo ng-term depressio n and spat ial reversal  learning. 
Neuropsychopharmaco logy 2008;33(5):1004-18.
4. Balu DT, Takagi  S, Puhl  MD, Benneyworth MA, Coyle JT. D- serine and serine racemase 
are locali zed to neurons in the adult mouse and human forebrain. Cell Mo l Neurobi ol 
2014;34(3):419 -35.
5. Sham PC, Gottesman, II, MacLean CJ, Kendler KS. Schizophrenia: sex and familial 
morbidity. Psychiatry  Res 1994;52(2):125 -34.
6. Cardno AG, Marshall EJ, Coid B, Macdonald AM, Ribchester TR, Davies NJ, et al. 
Heritabili ty estimates for psy choti c disorders: the Maudsley twin psychosis series. Arch 
Gen Psychiatry  1999;56(2):[ADDRESS_1242833]. Psy choses and cluster A 
personalit y disorders in offspring of schizophrenic parents at 23 y ears of foll ow-up. Arch 
Gen Psychiatry  1995;52(10):857-65.
8. van Os J, Kapur S. Schizophrenia. Lancet 2009;374(9690): 635-45.
9. Poels EM, Kegeles LS, Kantrowitz JT, Slifstein M, Javitt DC, Lieberman JA, et al. 
Imaging gl utam ate in schizophrenia: review of findings and implicat ions for drug 
discovery . Mol  Psychiatry  2014;19(1):20 -9.
10. Fervaha G, Foussias G, Agid O, Remi ngton G. Motivat ional deficits in early schizophrenia: 
prevalent, persistent, and key  determinants of functi onal outcom e. Schizophr Res 
2015;166(1 -3):9-16.
11. Strassnig MT, Ray kov T, O'Gorm an C, Bowie CR, Sabbag S, Durand D, et al. 
Determinants of differe nt aspects of everyday  outcom e in schizophrenia: The roles of 
negat ive symptoms, cognit ion, and funct ional capacit y. Schizophr Res 2015;165(1):76 -82.
12. Krystal JH, D'Souza DC, Mathalon D, Perry  E, Belger A, Hoffman R. NMDA receptor 
antagonist effects, co rtical gl utamatergi c funct ion, and schizophrenia: toward a paradigm 
shift in medicat ion development. Psychopharmacology  (Berl ) 2003;169(3- 4):215 -33.
13. Calcia MA, Madeira C, Alheira FV, Silva TC, Tannos FM, Vargas -Lopes C, et al. Plasma 
levels o f D-serine in Brazilian individuals wit h schizophrenia. Schizophr Res 2012;142(1 -
3):83 -7.
TAK -831
Study No. TAK -831-2002 Page 96of 111
Protocol Incorporating Amendment No. 04 08 June 2020
CONFIDENTIAL14. Ohnuma T, Sakai Y, Maeshima H, Hatano T, Hanzawa R, Abe S, et al. Changes in plasma 
glycine, L -serine, and D -serine levels in patients wit h schizophrenia as their clinical 
symptoms improve: results from the Juntendo Universit y Schizophrenia Projects (JUSP). 
Prog Neuropsychopharmacol Bio l Psychiatry  2008;32(8):1905-12.
15. Hashimoto K, Fukushima T, Shimizu E, Komatsu N, Watanabe H, Shinoda N, et al. 
Decreased serum levels of D -serine in pat ients with schizophrenia: evidence in support of 
the N-methyl-D- aspartate receptor hy pofunction hypothesis of schizophrenia. Arch Gen 
Psychiatry  2003;60(6):572 -6.
16. Hashimoto K, Engberg G, Shimizu E, Nordin C, Lindstrom LH, Iy o M. Reduced D -serine 
to total serine ratio in the cerebrospi[INVESTIGATOR_888045]. Prog 
Neuropsychopharmaco l Biol Psychiatry  2005;29(5):7 67-9.
17. Schizophrenia Working Group of the Psy chiatri c Geno mics Consortium. Bio logical 
insights from 108 schizophrenia -associ ated genet ic loci. Nature 2014;511(7510):421- 7.
18. Lane HY, Lin CH, Green MF, Hellemann G, Huang CC, Chen PW, et al. Add -on trea tment 
of benzoate for schizophrenia: a randomized, double- blind, placebo -controlled trial of D -
amino acid oxidase inhibitor. JAMA Psychiatry  2013;70(12):1267 -75.
19. Radi ZA, Stewart ZS, Grzemski FA, Bobrowski WF. Renal pathophysio logic rol e of 
cortical tubular inclusio n bodies. Toxico l Pathol  2013;41(1):32-7.
20. Lehman AF, Lieberman JA, Dixon LB, McGlashan TH, Miller AL, Perkins DO, et al. 
Treatment Recommendat ions for Pati ents Wi th Schizophrenia. In: Practi ce Gui deline for 
the Treatm ent of Patients With Schizophrenia. 2nd ed. Washington, DC: American 
Psychiatri c Associ ation; 2004; Part A, p. 3 -35.
21. Note for guidance on the clinical investigation of medicinal products in the treatment of 
schizophrenia. European Medicines Agency, Co mmittee for Medicinal Products for Hum an 
Use. Publication No. CPMP/EWP/5595/95.
22. Marder SR, Davis JM, Chouinard G. The effects of risperidone on the five dimensio ns of 
schizophrenia derived by  [CONTACT_293598]: co mbined results of the North American trials. J 
Clin Psychiatry  1997;58(12):538 -46.
23. Haro JM, Kamath SA, Ochoa S, Novick D, Rele K, Fargas A, et al. The Clinical Glo bal 
Impressio n-Schizophrenia scale: a simple instrument to measure the diversit y of symptoms 
present in schizophrenia. Acta Psy chiatr Scand Suppl  2003(4 16):16 -23.
24. Guy W. Clinical Glo bal Impressio n (CGI), ECDEU Version. In: ECDEU Assessment 
Manual for Psy chopharm acology. Revised ed. Rockville, MD: U.S. Dept. of Healt h, 
Educati on, and Welfare; 1976; DHEW publication no. (ADM) 76- 338, p. [ADDRESS_1242834] 
2007;50:s7 -14.
26. Kirkpatrick B, Strauss GP, Nguy en L, Fischer BA, Daniel DG, Cienfuegos A, et al. The 
brief negat ive symptom scale: psycho metric properti es. Schizophr Bull 2011;37(2):300 -5.
TAK -831
Study No. TAK -831-2002 Page 97of 111
Protocol Incorporating Amendment No. 04 08 June 2020
CONFIDENTIAL27. Strauss GP, Hong LE, Gold JM, Buchanan RW, McMahon RP, Keller WR, et al. Factor 
structure of the Brief Negat ive Symptom Scale. Schizophr Res 2012;142(1 -3):96 -8.
28. Keefe RS, Goldberg TE, Harvey  PD, Gol d JM, Poe MP, Coughenour L. The Brief 
Assessment of Cognit ion in Schizophrenia: reliabilit y, sensi tivity, and co mpar ison wit h a 
standard neurocognit ive battery. Schizophr Res 2004;68(2 -3):283 -97.
29. Keefe RS, Poe M, Walker TM, Kang JW, Harvey PD. The Schizophrenia Cognit ion Rating 
Scale: an interview- based assessment and its relat ionship to cognit ion, real -world 
funct ioning, and funct ional capacit y. Am J Psychiatry  2006;163(3):426-32.
30. Green MF, Nuechterlein KH, Kern RS, Baade LE, Fenton WS, Gold JM, et al. Funct ional 
co-primary meas ures f or clinical tri als in schizophrenia: results from the MATRICS 
Psychometric and Standardizat ion Study . Am J Psychiatry  2008;165(2):221-8.
31. Garay  RP, Ci trom e L, Sam alin L, Li u CC, Thom sen MS, Correll CU, et al . Therapeutic 
improvements expected in the near future for schizophrenia and schizoaffective disorder: 
an appraisal of phase III clinical trials of schizophrenia -targeted therapi[INVESTIGATOR_888046]. Expert Opin Phar macother 2016;17(7):921 -36.
32. Posner K, Brown GK, Stanley B, Brent DA, Yershova KV, Oquendo MA, et al. The 
Columbia -Suicide Severit y Rating Scale: init ial validit y and internal  consistency findings 
from three m ultisite studi es wi th adolescents and adults . Am  J Psychiatry  
2011;168(12):1266 -77.
33. Lecrubier Y, Sheehan DV, Weiller E, Amorim P, Bonora I, Sheehan KH, et al. The Mini -
International Neuropsy chiatri c Interview (MINI). A short diagnostic structured interview: 
reliabilit y and validit y according to the CIDI. European Psychiat 1997(12):224- 31.
34. Sheehan DV, Lecrubier Y, Sheehan KH, Janavs J, Weiller E, Keskiner A, et al. The 
validit y of the Mini Internat ional Neuropsy chiatri c Intervi ew (MINI) according to the 
SCID -P and its reliabilit y. Eur Psy chiat ry 1997;12:232 -41.
35. Sheehan DV, Lecrubier Y, Sheehan KH, Amorim P, Janavs J, Weiller E, et al. The Mini-
International Neuropsy chiatri c Interview (M.I.N.I.): the development and validat ion of a 
structured diagnost ic psychiatric interview for DSM -IV and I CD-10. J Clin Psychiatry  
1998;[ADDRESS_1242835] 20:22 -33;quiz 4 -57.
36. Addington D, Addington J, Maticka -Tyndale E. Assessing depressio n in schizophrenia: the 
Calgary Depressi on Scal e. Br J Psy chiatry  Suppl  1993(22):[ADDRESS_1242836] igated by [CONTACT_888096]. Neurosci Lett 2007;413(1):82 -7.
38. Ho BC, Mol a C, Andreasen NC. Cerebellar dy sfuncti on in neurol eptic naive schizophrenia 
patients: clinical, cognit ive, and neuroanatomic correlates of cerebellar neurologic signs. 
Biol Psychiatry  2004;55(12):1146-53.
TAK -[ADDRESS_1242837]-epi[INVESTIGATOR_34923]: State- and trait -related relat ionships to 
psychopathol ogy, cogni tion and ant ipsychotic medicat ion effects. Schizophr Res 2017.
40. Mulhern B, Mukuria C, Barkham M, Knapp M, By[CONTACT_193563] S, Soeteman D, et al. Using generic 
preferenc e-based measures in mental health: psychometric validit y of the EQ -5D and SF -
6D. Br J Psy chiatry  2014;205(3):236-43.
41. Isitt JJ, Nadi pelli VR, Kouassi A, Fava M, Heidbreder C. Health -related quali ty of life in 
acute schizophrenia pat ients treated wi th RBP-7000 once monthly risperidone: An 8 -week, 
rando mized, double -blind, placebo -controlled, multicenter phase 3 study . Schizophr Res 
2016;174(1 -3):[ADDRESS_1242838] 19 70;212:11 -9.
43. Moore TJ, Furberg CD. The harms o f antipsychotic drugs: Evidence fro m key studi es. 
Drug Saf 2017;40(1):3-14.
TAK -831
Study No. TAK -831-2002 Page 99of 111
Protocol Incorporating Amendment No. 04 08 June 2020
CONFIDENTIALAppendix ASchedule of Study Procedures
Study DayScreeningPlacebo
Run-in 12-Week Double -Blind Treatment PeriodSafety
Follow -
up
Days -42
to -15 aDay -14Day 
1 bDay 
7 qDay 
14qDay 
28qDay 
42 qDay 
56 qDay 
70 qDay 
84/
ET 
b, cDays 94 -
98
(10-[ADDRESS_1242839] 
dose)
Visit Number 1 2 3 4 5 6 7 8 9 10 11
Visit Window (Days) d+7 e±2 ±2 ±1 ±2 ±2 ±2 ±2 ±5 ±[ADDRESS_1242840] eligibility 
assessmentX X
Inclusion/exclusion criteria X X X
Demographics, medical 
history, substance useX
Medication history X
Concurrent medical conditions X
Physical examination X X
Vital signs gX X X X X X X X X X X
Height, BMI, weight hX X
Concomitant medications X X X X X X X X X X X
Clinical laboratory tests iX X X X X
HBsAg, anti-HCV X
FSH X
HbA1c X
Pregnancy test (hCG)jX X X X X X X
Urine drug screen kX X X X X X
12-lead ECG X X X
C-SSRS X X X X X X X X X X X
CDSS X
Modified SAS X
PANSS X X X X X X
BNSS X X X X X X
CGI-SCH -I X X X
CGI-SCH -S X X X X X X
BACSlX X X X

TAK -831
Study No. TAK -831-2002 Page 100of 111
Protocol Incorporating Amendment No. 04 08 June 2020
CONFIDENTIALStudy DayScreeningPlacebo
Run-in 12-Week Double -Blind Treatment PeriodSafety
Follow -
up
Days -42
to -15 aDay -14Day 
1 bDay 
7 qDay 
14qDay 
28qDay 
42 qDay 
56 qDay 
70 qDay 
84/
ET 
b, cDays 94 -
98
(10-[ADDRESS_1242841] 
dose)
Visit Number 1 2 3 4 5 6 7 8 9 10 11
Visit Window (Days) d+7 e±2 ±2 ±1 ±2 ±2 ±2 ±2 ±5 ±2
SCoRS X X
Plasma sample for TAK -831 
PK n X X X X X
Plasma sample for PD ( D-and 
L-serine) n X X X X X X
Plasma sample for 
antipsy chotic medicationsX X X X
PTE/AE assessment X X X X X X X X X X X
Call IRT for subject 
ID/medication IDX X X X X X X X X
Digital compliance technology 
trainingX
Randomization X
Dispense study drug pX X X X X X X X
Study  drug 
return/accountability/complian
ceX X X X X X X X
In-clinic study drug dosing X X X
AE: adverse event; anti -HCV: antibody to hepatitis C virus; BACS: Brief Assessment of Cognition in 
Schizophrenia; BMI: body mass index; BNSS: Brief Negative Symptom Scale; CDSS: Calgary Depression Scale 
Score; CGI -SCH -I: Clinical Global Impression -Schizoph renia -Improvement; CGI -SCH -S: Clinical Global 
Impression -Schizophrenia -Severity; COVID -19: coronavirus disease 2019 ; C-SSRS: Columbia -Suicide Severity 
Rating Scale; ECG: electrocardiogram; eCRF: electronic case report form; 
; ET: early termination; FSH: follicle -stimulating hormone; HbA1c: glycosylated hemoglobin; HBsAg: 
hepatitis B surface antigen; hCG: human chorionic gonadotropin; ID: identification; IRT: interactive response 
technology; MINI: Mini International Neu ropsychiatric Interview; ; PANSS: 
Positive and Negative Syndrome Scale; PD: pharmacodynamic(s); ; PK: 
pharmacokinetic(s); PTE: pretreatment event: QD: once daily; SAS: Simpson Angus S0ocale; SCoRS: 
Schizophrenia Cognition Rating Scale.
aMedical Evaluation Form must be reviewed by [CONTACT_36613], and a third -party independent expert 
clinician review of selected assessments included in the study Entry Criteria must be completed, prior to subje ct 
entry  into the placebo run -in period.

TAK -831
Study No. TAK -831-2002 Page 101of 111
Protocol Incorporating Amendment No. 04 08 June 2020
CONFIDENTIALbRandomization is performed at Day 1 (Visit 3). If courier -related delays of laboratory test results occur (eg, due to 
COVID -19 related factors), Visit [ADDRESS_1242842] dose of study drug will be administered in the 
clinic at the end of the Day 1 visit (or as the last procedure if the Day 1 visit is split over 2 days). Subjects will then 
take study drug QD in the mor ning f rom Day  [ADDRESS_1242843] during the double -blind treatment period. 
Study procedures for the Day 84/ET (Visit 10) may be conducted over [ADDRESS_1242844]’s comfort and 
assessment feasibility. The final visit (Day 84/ET) should be performed in pe rson. Alternative methods for 
administering study assessments may be considered when it is not possible for the subject to come to the study site 
or for the site staff or designated clinical personnel to go to the subject’s residence for the final visit (D ay 84/ET) in 
cases where unavoidable circumstance such as the COVID -[ADDRESS_1242845] circumstances (Section 9.1.1).
cFor subjects who prematurely discontinue the study, the PANSS, BNSS, BACS, SCoRS, CGI -
SCH -I, CGI -SCH -S, 
and assessments should be performed only in subjects who received at least [ADDRESS_1242846] dose of study drug; all other ET procedures should be performed for subjects who 
are assessed >[ADDRESS_1242847] visit does not conform to the study plan, the timing of the subsequent visits should be 
planned to maintain the visit schedule relative to randomization.
eIn cases where antipsychotic serum levels are not available within the expected 7 days window, additional 
screening window may be granted in these cases with sponsor or designee approval.
fMay be obtained at screening (Visit 1) or placebo run -in (Visit 2) or at the informant’s location. The initial 
discussion with the informant may include an oral informed consent.
gSupi[INVESTIGATOR_888047] (Visit 1), Day 1 (Visit 3), Day 42 (Visit 7), and Day 
84/ET (Visit 10); sitting blood pressure and pulse will be measured at all other scheduled time points.
hHeight and BMI will be collected at screening (Visit 1) only.
iHematology, serum chemistry, and urinalysis. Clinical laboratory blood samples will be collected after a [ADDRESS_1242848], with the exception of screening (Visit 1) when fasting is not required. Antipsychotic serum blood levels may be 
retested at investigator’s request.
jWomen of childbearing potential only. Serum hCG test will be performed at screening (Visit 1) and safety follow -
up (Visit 11). Urine hCG tests will be performed at all other scheduled time points. The hCG test can be repeated at 
any time at the investigator’s discretion.
kMay be repeated at any time at the investigator’s discretion.
lEfforts should be made to perform the BACS assessment at approximately the same time of day throughout the 
study (postbaseline assessments must be administered ±2 hours from the time of baseline assessment 
administration).
 
nOn Day -14 (Visit 2), 1 PD sample will be collected. On Day 1 (Visit 3), 1 PK blood sample and 1 PD blood 
sample will be collected predose. On Day 28 (Visit 6), subjects will take study drug at the site after predose P K and 
PD blood samples have been collected, and repeat PK and PD blood samples will be collected at the end of the visit. 
On Day  42 (Visit 7), Day 56 (Visit 8), and Day 84/ET (Visit 10), 1 PK blood sample and 1 PD blood sample will be 
collected at each vis it; the subject will take study drug at the usual time in the morning before each of these 3 visits. 
For Day s 42 and 56, it is recommended that sites schedule the clinic visit at different times of the day: [ADDRESS_1242849] meal will be recorded on the source 
document and eCRF.

TAK -831
Study No. TAK -831-2002 Page 102of 111
Protocol Incorporating Amendment No. 04 08 June 2020
CONFIDENTIAL 
pStudy subjects will be instructed to take their study drug QD in the morning with water or milk; subjects should 
avoid drinking juices [ADDRESS_1242850] present at the site. However, in certain 
unavoidable circumstances (such as the COVID -19 pandemic), alternative methods for conducting subject visits (eg, 
video conferencing, telephone visits, or in -home study visits conducted by [CONTACT_888097]) may be used per approval by [CONTACT_36613]. It may be necessary to perform some of the visit 
procedures remotely or at subjects’ residence contingent upon local regulations. Sites should contact [CONTACT_98634] (eg, contract research organization contact) to discuss individual subject and site circumstances. Approval 
may be granted for remote assessments, alternative methods to delivering investigational medicinal product or for 
study site personnel or designate d clinical personnel to visit the subject at their residence. Additionally, approval 
may be granted to omit collection of certain study assessments and visit windows may be extended. There will be no 
interval longer than [ADDRESS_1242851] (Section  9.1.1). 

TAK -[ADDRESS_1242852] igators by  [CONTACT_45348] “Statement of Invest igator” (Form FDA 1572), whi ch must be com pleted and 
signed before the invest igator may participate in this study .
The invest igator agrees to assume the fo llowing responsibilit ies [by [CONTACT_2960] a Form FDA 1572:
1.Conduct the study  in accordance wit h the protocol.
2.Personally conduct or supervise the staff who will assist in the protocol.
3.Ensure that study  related procedures, including study  specific (nonrouti ne/nonstandard panel) 
screening assessments are NOT performed on potent ial subjects, prior to the receipt of 
written approval  from relevant governing bodies/authorities.
4.Ensure that all co lleagues and emplo yees assist ing in the conduct of the stud y are inform ed 
of these obligat ions.
5.Secure prior approval of the study  and any  changes by  [CONTACT_82309]/IEC that conform 
to 21 Code of Federal Regulat ions (CFR) Part 56, ICH, and local regulatory  requi rements.
6.Ensure that the IRB/IEC will be responsi ble for initi al review, continuing review, and 
approval  of the protocol . Prom ptly report to the IRB/IEC all changes in research act ivity and 
all anticipated ri sks to subj ects. Make at l east y early  reports on the progress of the study  to 
the IRB/IEC, and is sue a final report within [ADDRESS_1242853]’s medical chart. Valid informed consent is the most current 
versio n approved by [CONTACT_1201]/IEC. Each informed consent form should contain a subject 
authori zation sect ion that describes the uses and disclosures of a sub ject’s personal 
inform ation (including personal healt h informat ion) that will take place in connection wit h 
the study . If an informed consent form does not include such a subject authorization, then the 
investigator must obtain a separate subject authoriza tion form from each subject or the 
subject’s legally acceptable representative.
9.Prepare and maintain adequate case histories of all persons entered into the study , incl uding 
eCRFs, hospi[INVESTIGATOR_1097], laboratory  resul ts, etc, and maintain these data for a mi nimum  of 
2years fo llowing notificat ion by [CONTACT_45349]. The invest igator should 
contact [CONTACT_4182] m the sponsor bef ore di sposing o f any such 
docum ents.
10.Allow possible inspection and copying by [CONTACT_4216] -specified essent ial 
docum ents.
TAK -[ADDRESS_1242854] igator/institution retains the services of any individual or party to perform trial -
related duties and funct ions, the invest igator/inst itution shoul d ensure that this individual or 
party  is qualified to perform those trial -related duties and functions and should implement 
procedures to ensure the integrit y of the tri al-related duti es and fu nctions performed and any 
data generated.
TAK -[ADDRESS_1242855]:
1.A statement that the study  involves research.
2.An explanat ion of the purposes of the research.
3.The expected duration of the subject’s participat ion.
4.A descript ion of the procedures to be fo llowed, including invasive procedures.
5.The i dentificat ion of any  procedures that are experimental.
6.The e stimated number of subjects invo lved in the study .
7.A descript ion of the subject’s responsibilit ies.
8.A descript ion of the conduct of the study .
9.A statement describing the treatment(s) and the probabilit y for random  assignment to each 
treatm ent.
10.A descript ion of the possible side effects of the treatment that the subject may receive.
11.A descript ion of any  reasonably  foreseeable ri sks or di scomf orts to the subject and, when 
applicable, to an embry o, fetus, or nursing infant.
12.A descript ion of any  benefi ts to the subject or to others that reasonably may be expected fro m 
the research. When there is no intended clinical benefit to the subject, the subject should be 
made aware of this.
13.Disclosures of appropri ate al ternat ive procedures or courses of treatment, if any, that might 
be advantageous to the subject and their important potential risks and benefits.
14.A statement describing the extent to which confident iality of records i dentifying the subject 
will be maintained, and a note of the possibilit y that regulatory  agencies, auditor(s), 
IRB/IEC, and the monitor may inspect the records. By  [CONTACT_2960] a written informed consent 
form, the subject or the subject’s legally  acceptable representative is authorizing such access.
15.For research invo lving more than minimal risk, an ex planat ion as to whether any  
compensat ion and an explanat ion as to whether any medical treatments are available if injury 
occurs and, if so, what they  consist of or where further informat ion may be obtained.
16.The ant icipated prorated payment(s), if any, to t he subject for participat ing in the study.
17.The ant icipated expenses, if any , to the subject for parti cipat ing in the study.
18.An explanat ion of whom to contact [CONTACT_39831] 
(invest igator), subject’s rights, and IRB/IE C and who m to contact i n the event of a research -
related injury  to the subject.
19.A statement that participat ion is vo luntary, that refusal to participate will invo lve no penalt y 
or loss of benefit s to whi ch the subject otherwise is entit led, and that the su bject or the 
TAK -[ADDRESS_1242856]’s legally acceptable representative may discontinue participation at any  time without 
penalt y or l oss of benefits to which the subject is otherwise ent itled.
20.The consequences of a subject’s decisio n to wi thdraw from  the research and pr ocedures for 
orderly terminat ion of part icipation by [CONTACT_423].
21.A statement that the subject or the subject’s legally acceptable representative will be 
inform ed in a t imely manner if informat ion beco mes available that may be relevant to the 
subject’s wil lingness to continue participat ion in the study .
22.  
23.The foreseeable circumstances or reasons under which the subject’s partic ipation in the study  
may be terminated.
24.A wri tten subject authori zation (either contained wit hin the informed consent form or 
provi ded as a separate document) describing to the subject the contemplated and permissible 
uses and disclosures o f the subject’s personal informat ion (including personal health 
inform ation) for purposes of conducting the study . The subject authorizat ion must contain the 
following statements regarding the uses and disclo sures of the subject’s personal 
inform ation:
a)that personal infor mation (including personal healt h informat ion) may be processed by  [CONTACT_45351] y reporti ng 
purposes, including, without limitat ion, to the fo llowing: (1) [COMPANY_005], its affiliates, and 
licensing partners; (2) business partners assist ing [COMPANY_005], its affiliates, and licensing 
partners; (3) regulatory  agencies and other healt h authorities; and (4) IRBs/IECs;
b)it is possible that personal informat ion (including personal healt h informat ion) may be
processed and transferred to countries that do not have data protection laws that offer 
subjects the same level o f protecti on as the data protection laws wit hin this country; 
however, [COMPANY_005] will make every  effort to keep y our personal  information confide ntial, 
and y our name [CONTACT_39846] [CONTACT_2371];
c)that personal information (including personal healt h informat ion) may be added to 
[COMPANY_005]’s research databases for purposes of developi[INVESTIGATOR_007] a better understanding of the 
safet y and effect iveness o f the study  drug(s), studying other therapi[INVESTIGATOR_39759], 
developi[INVESTIGATOR_007] a better understanding of disease, and improving the efficiency of future 
clinical studies;
d)that subjects agree not to restrict the use and disclo sure of their personal informat ion 
(including personal healt h informat ion) upon withdrawal fro m the study  to the extent that 
the restricted use or disclosure of such informat ion may  impact the scient ific integrity of 
the research; and
e)that the subject’s ident ity will r emain confident ial in the event that study  resul ts are 
published.

TAK -831
Study No. TAK -831-2002 Page 107of 111
Protocol Incorporating Amendment No. 04 08 June 2020
CONFIDENTIAL25.Female subjects of childbearing potential (eg, nonsterilized, premenopausal female subjects) 
who are sexually  active m ust use acceptable effect ive contraception (as defined in the 
inform ed consent) from  screening throughout the duration of the study , and for [ADDRESS_1242857] igator’s personal 
inform ation may be transferred to other parties located in countries throughout the world (eg, the 
[LOCATION_008], [LOCATION_002], and Japan), including the following:
[COMPANY_005], its affiliates, and licensing partners.
Business partners assist ing [COMPANY_005], its affiliates, and licensing partners.
Regulatory  agencies and other health authorit ies.
IRBs and IECs.
Invest igator’s persona l informat ion may be retained, processed, and transferred by  [CONTACT_39833]:
Assessment of the suitabilit y of invest igator for the study  and/or other clinical studies.
Management, monitoring, in spect ion, and audit of the study .
Analysis, review, and verificat ion of the study  results.
Safety reporti ng and pharmacovigilance relat ing to the study .
Preparati on and submissio n of regulatory  filings, correspondence, and communicat ions to 
regul atory  agen cies rel ating to the study .
Preparati on and submissio n of regulatory  filings, correspondence, and communicat ions to 
regul atory  agencies rel ating to other medications used in other clinical studies that may 
contain the same chemical compound present in the study  drug.
Inspect ions and invest igations by [CONTACT_4218].
Self-inspect ion and internal audit within [COMPANY_005], its affiliates, and licensing partners.
Archiving and audit of study  records.
Posting invest igator site contact [CONTACT_82753], study details and results on publicly accessible 
clinical trial registries, databases, and websites.
Invest igator’s personal informat ion may be transferred to other countries that do not have data 
protecti on laws that offer the same level of pro tection as data protection laws in investigator’s 
own country .
Invest igator acknowledges and consents to the use of his or her personal information by [CONTACT_47407].
TAK -831
Study No. TAK -831-2002 Page 109of 111
Protocol Incorporating Amendment No. 04 08 June 2020
CONFIDENTIALAppendix EHistory of Protocol Amendments 01 through 03
Amendment History: 
Date Amendment Number Amendment Type Region
30 October 2017 Initial Protocol Not applicable Global
26 June 2018 Amendment 01 Substantial Global
19 July  2018 Amendment 02 Substantial Local (Czech Republic)
[ADDRESS_1242858] ion describes the changes in reference to the protocol incorporating Amendment No. 01. 
The primary  reason for thi s amendment was to revise elements of the study  design.
In addit ion, inclusio n/excl usion criteria, randomizati on cri teria, excluded medicat ions, cri teria 
for discont inuat ion or wi thdrawal  of a subject to include deterioration of the underlying illness, 
companion medicat ions, m onitoring of  plasma l evels of ant ipsychoti c medicati on, contracepti on 
procedures, poststudy  care, cl arificat ion of study  procedures, and updating acceptable 
contraception options were revised for clarificat ion or optimization of the prio r protocol  content. 
The number of subje ctsand statistical methods were revised for optimizing the study  efficacy 
analysis based on re- evaluat ion of the relevant scient ific cont ingencies.
Minor grammat ical, editorial, formatting, and administrative changes not affect ing the conduct of 
the study  were included for cl arificat ion and administrative purposes only.
Changes in Amendment No. [ADDRESS_1242859] oratory  objectives , safet y endpo ints, and exploratory  endpo ints.
3.Revisio n of inclusio n/exclusio n criteria.
4.Clarificat ion on randomization criteria.
5.Revisio n of excluded medication and dietary  products.
6.Revisio n of criteria for discont inuation or withdrawal of a subject.
7.Revisio n of storage condit ions for drug supplies.
8.Moni toring of anti psychoti c plasma levels.
9.Clarificat ion on contraception and pregnancy avo idance procedure.
10.Clarificat ion on poststudy  care.
11.Revisio n of statist ical methods.
12.Revisio n of bene fit risk profile.
TAK -831
Study No. TAK -831-2002 Page 110of 111
Protocol Incorporating Amendment No. 04 08 June 2020
CONFIDENTIAL13.Updating treatment c ompliance .
Protocol Amendment No. 02 (Local Czech Republic)
The Czech Republic country -specific amendment was based on feedback from the Czech 
Republic regulatory  authori ty in their review o f the original  protocol .
Protocol Amendment No. [ADDRESS_1242860] and site 
burden, r eviseinclusio n/exclusion criteria to provide appropriate flexibilit y to the subject and 
site,revise conco mitant m edicat ion requirements, and to update recommendat ions for the 
management of pregnancy and lactation based on the relevant TAK -831 nonclinical studies. In 
addition, additional clarificat ions were provi ded in study  design, inclusio n/exclusio n criteria, 
rando mizat ion criteria, excluded medicat ions, cri teria for discontinuat ion or wi thdrawal  of a 
subject, video monitoring for assessments, monitoring of plasma levels of ant ipsychotic 
medicat ion, and rater monitoring. 
Minor grammat ical, editorial, formatting, and administrative changes not affect ingthe conduct of 
the study  are included for clarificat ion and administrative purposes only.
Changes in Amendment No. [ADDRESS_1242861] inform ation.
2.Removed Q -LES-Q 18 assessment from the study .
3.Revised study  design to increase the number of clinical sites , clarify management of run -in 
medicat ion, clarify  informed consent procedures for informants, and allow for flexibilit y in 
scheduling the Day  2 visit.
4.Revised inclusio n and exclusio n criteria based on updates made to excluded medications and 
new reco mmendat ions for the m anagement of pregnancy and lactation; provided addit ional 
clarificati on of  excl usionary characteristi cs for subjects wi th diabetes; added an except ion for 
inclusio n of subjects with Gilbert syndro me; and added criteria to e xclude subjects who may 
be less likely to respond to treatment; addit ional changes were made for clarit y and 
consistency.
5.Updated study  drug com pliance cri teria and instructi ons for subject randomizat ion approval. 
6.Removed ant iconvulsants and uridine 5 ′-diphospho -glucuronosyltransferase (UGT) enzyme 
inhibitors from excluded medicat ions list and provided addit ional clarificati on on comm only 
prescribed conco mitant m edicati ons permi tted during the conduct of the study .
7.Revised study  drug com pliance threshold i n criteria for discont inuat ion and added text for 
consistency wit h revisio ns to randomizat ion criteria.
8.Clarified use of nonbenzodiazepi[INVESTIGATOR_82490].
TAK -831
Study No. TAK -831-2002 Page 111of 111
Protocol Incorporating Amendment No. 04 08 June 2020
CONFIDENTIAL9.Modified rescue medicat ions to include benzodiazepi[INVESTIGATOR_888048].
10.Added text to allow for flexibilit y with morning dosing.
11.Corrected i nstructi ons for the destruction of sponsor -supplied drugs.
12.Added text to allow for infra -axillary  temperature measurement.
13.Added text to allow for individual except ions for video rec ording of clinical interviews.
14.Revised order of psy chiatri c/neurol ogical  scales/assessments.
16.Added text to clarify the management and interpretation of ant ipsychotic plasma level assays.
17. U pdated contraceptive and pregnancy avo idance procedures.
18. Updated pregnancy procedures.
19.Revised SAE co llection procedures to include instructions for electronic data capture.
20.Revised CDSS and modified SAS assessments in Schedule of Study  Procedures.
21.Revised Schedule of Study  Procedures footnotes for consistency and clarificat ion.

    
 
  
 
  
 
ELECTRONIC SIGNATURES  
Signed by [CONTACT_4232] 
(dd-MMM-yyyy HH:mm ‘UTC’) 
 
 
 
 
 
 
 
   
 
   
   
 
   
   
 
   
   
 
   
   
 
   
   
 
   
   
 
   
   
 
   
   
 
   
   
 
   
   
 
   
   
 
   
   
 
   
   
 
   
   
 
   
   
 
   
 
090101d680db5728Amendment 04 to A Phase 2, 12-Week, Randomized, Double-Blind, Placebo-Controlled, Parallel Study to
Evaluate Efficacy, Safety, Tolerability, and Pharmacokinetics of 3 Dose Levels of TAK-831 in Adjunctive
Treatment of Adult Subjects With Negative Symptoms of Schizophrenia
08-Jun-2020 12:54 UTC
08-Jun-2020 14:14 UTC
08-Jun-2020 16:23 UTC
08-Jun-2020 16:54 UTC
